



# Particle Based Model for Airborne Disease Transmission

Michael B Dillon  
Charles F Dillon

April 2020

LLNL-TR-808973

Lawrence Livermore National Laboratory is operated by Lawrence Livermore National Security, LLC, for the U.S. Department of Energy, National Nuclear Security Administration under Contract DE-AC52-07NA27344.



## **Auspices and Disclaimer**

This work was performed under the auspices of the U.S. Department of Energy by Lawrence Livermore National Laboratory under Contract DE-AC52-07NA27344.

This document was prepared as an account of work sponsored by an agency of the United States government. Neither the United States government nor Lawrence Livermore National Security, LLC, nor any of their employees makes any warranty, expressed or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States government or Lawrence Livermore National Security, LLC. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States government or Lawrence Livermore National Security, LLC, and shall not be used for advertising or product endorsement purposes.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

1 Particle Based Model for Airborne Disease  
2 Transmission

3

4 **Authors**

5 Michael B Dillon,<sup>a,\*</sup> [dillon7@llnl.gov](mailto:dillon7@llnl.gov)

6 Charles F Dillon

7

8 <sup>a</sup> Lawrence Livermore National Laboratory

9 \* Corresponding author

10

## 11 Executive Summary

12 Prior literature documents cases of airborne infectious disease transmission at distances  
13 ranging from  $\geq 2$  m to inter-continental in scale. Physics- and biology- based models describe  
14 the key aspects of these airborne disease transmission events, but important gaps remain. This  
15 report extends current approaches by developing a new, single-particle based theory that (a)  
16 assesses the likelihood of rare airborne infections (where individuals inhale either one or no  
17 infectious particles) and (b) explicitly accounts for the variability in airborne exposures and  
18 population susceptibilities within a geographic region of interest. For these hazards, airborne  
19 particle fate and transport is independent of particulate concentration, and so results for  
20 complex releases can be determined from the results of many single-particle releases.

21 This work is intended to provide context for both (a) the initial stages of a disease outbreak and  
22 (b) larger scale ( $\geq 2$  m) disease spread, including distant disease “sparks” (low probability,  
23 unexpected disease transmission events that infect remote, susceptible populations). The  
24 physics of airborne particulate dispersion inherently constrains airborne disease transmission.  
25 As such, this work suggests results that, *a priori*, may be applicable to many airborne diseases.

### 27 Model Predictions:

- 28 i. Modeling predictions of the single-particle transmission kernel suggest that outdoor  
29 airborne disease transmission events may occur episodically as the infection  
30 probabilities can vary over many orders of magnitude depending on the distance  
31 downwind; specific virus, prion, or microorganism; and meteorological conditions.
- 32 ii. Model results suggest that, under the right conditions, an indoor infected person  
33 could spread disease to a similar, or greater, number of people downwind than in  
34 the building they occupy. However, the downwind, per-person infection probability  
35 is predicted to be lower than the within-building, per-person infection probability.  
36 This finding is limited to airborne transmission considerations.
- 37 iii. This work suggests a new relative disease probability metric for airborne transmitted  
38 diseases. This metric, which is distinct from the traditional relative risk metric, is  
39 applicable when the rate at which the infectious agent loses infectivity in the  
40 atmosphere is  $\lesssim 1 \text{ h}^{-1}$ .

41

## 42 Table of Contents

43	<b>Executive Summary</b> .....	<b>2</b>
44	<b>Table of Contents</b> .....	<b>3</b>
45	<b>1. Introduction</b> .....	<b>5</b>
46	<b>2. Physics- and Biology- Based Airborne Transmission Modeling</b> .....	<b>7</b>
47	<b>2.1. Dilute Particle Considerations</b> .....	<b>9</b>
48	<b>2.2. Advantages of Spatial and Temporal Averaging</b> .....	<b>9</b>
49	<b>2.3. Discrete Nature of Airborne Infection</b> .....	<b>10</b>
50	<b>2.4. Building Protection</b> .....	<b>11</b>
51	<b>3. Theory</b> .....	<b>14</b>
52	<b>3.1. Absolute (Mean) Infection Probabilities for Geographic Regions</b> .....	<b>14</b>
53	<b>3.2. Relative Infection and Disease Probability</b> .....	<b>16</b>
54	<b>3.3. Indoor Airborne Particle Dynamics</b> .....	<b>18</b>
55	<b>4. Results</b> .....	<b>20</b>
56	<b>4.1. Upper Bound on Absolute Infection Probability vs. Distance</b> .....	<b>22</b>
57	<b>4.2. Relative Infection and Disease Probability vs. Distance</b> .....	<b>26</b>
58	<b>4.3. Model Prediction – Outbreak Data Comparison</b> .....	<b>29</b>
59	<b>4.4. Relative Magnitude of Within Building and Downwind Infections</b> .....	<b>33</b>
60	<b>5. Discussion</b> .....	<b>34</b>
61	<b>5.1. Characterizing Airborne Disease Spread</b> .....	<b>34</b>
62	<b>5.2. Background Disease Incidence</b> .....	<b>35</b>
63	<b>5.3. Key Infectious Agent/Disease Characteristics</b> .....	<b>36</b>
64	5.3.1. Number of Infectious Particles Emitted: <i>Total Particles Released</i> .....	<b>36</b>
65	5.3.2. Single Particle Infectivity: [Single Particle Infection Probability] .....	<b>37</b>
66	5.3.4. Loss of Particle Infectivity While Airborne: Affects [Normalized TSIAC].....	<b>38</b>
67	<b>5.4. Potential Future Efforts</b> .....	<b>40</b>
68	<b>6. Acknowledgements</b> .....	<b>42</b>
69	<b>7. Attestations</b> .....	<b>43</b>
70	<b>8. References</b> .....	<b>44</b>
71		

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

72	<b>Supplemental Material A: Airborne Disease Transmission Literature Review.....</b>	<b>66</b>
73	Near Range (< 5 m) .....	66
74	Short Range (5 m to 50 m).....	67
75	Medium Range (50 m to 500 m).....	68
76	Long Range (500 m to 500 km).....	69
77	Continental and Global Range (> 500 km) .....	71
78	<b>Supplemental Material B: Key Atmospheric Transport and Dispersion Modeling Concepts .....</b>	<b>73</b>
79	Mean Air Flow in the Atmosphere.....	73
80	Atmospheric Turbulence .....	74
81	Atmospheric Dispersion Physics .....	75
82	Atmospheric Dispersion Models .....	77
83	<b>Supplemental Material C: General Theory.....</b>	<b>80</b>
84	Section Variables Definitions .....	81
85	Conceptual Model .....	86
86	Rare Exposures .....	86
87	Subgroups .....	87
88	Groups.....	88
89	Absolute Infection Probability for Geographic Regions.....	90
90	Relative Infection Probability for Geographic Regions .....	91
91	Extrapolating Regional Infection Probabilities .....	91
92	Relationship to Disease and Other Metrics .....	94
93	<b>Supplemental Material D: Indoor Particle Dynamics .....</b>	<b>95</b>
94	Section Variables Definitions .....	96
95	Building Protection Against Outdoor-Origin Particles.....	98
96	Normalized Indoor Exposures .....	102
97	Fraction of Indoor Airborne Particles Released to the Outdoors .....	104
98	<b>Supplemental Material E: Outdoor Normalized Time and Space Integrated Air Concentrations.....</b>	<b>106</b>
99	<b>Supplemental Material F: Outbreak Model-Measurement Comparison .....</b>	<b>130</b>
100	<b>Supplemental Material G: Infection Estimates.....</b>	<b>131</b>
101	Section Variables Definitions .....	131
102	Key Equation.....	132
103	Downwind Infections .....	133
104	Within Building Assumptions .....	134
105	<b>Supplemental Material H: U.S. Coxiella burnetti Infection and Disease Estimates .....</b>	<b>135</b>
106	Background .....	135
107	Human Infection and Disease Characteristics .....	136
108	Human Infection and Disease Prevalence .....	137
109	Acute Q Fever .....	138
110	Comparison to Prior Work .....	140
111		

## 112 **1. Introduction**

113 Particles of all types are routinely transported in the atmosphere, including infectious disease  
114 particles. The physics of the local airborne person-to-person inhalation pathway of infectious  
115 disease transmission was investigated by early Public Health investigators who were focused on  
116 human Tuberculosis and Measles outbreaks [1]–[3]. As documented in the **Supplemental**  
117 **Material A: Airborne Disease Transmission Literature Review**, airborne human, veterinary, and  
118 plant disease transmission and other bioaerosol transmission events naturally occur across a  
119 wide range of distance scales, from two meters up to and including inter-continental  
120 transmission. These multiscale transmission events include bacteria, viruses, and fungi.

121 The population disease burden caused by infectious agents that are transmitted through the air  
122 remains substantial as lower respiratory infections and Tuberculosis are the fourth and tenth,  
123 respectively, leading causes of death world-wide [4], [5]. We adopt here the classic definition of  
124 the airborne disease transmission pathway as the inhalation of  $\leq 5 \mu\text{m}$  aerodynamic diameter  
125 (AD) infectious particles that have traveled airborne a distance of two or more meters.<sup>1</sup> We  
126 note that the airborne pathway can be the primary means of disease transmission or a  
127 secondary pathway when more than one disease transmission pathway is active, including the  
128 droplet ( $> 5 \mu\text{m}$  AD particles) or contact pathways, e.g., [6], [7].

129 Physics- and biology- based atmospheric transport and dispersion models have been developed  
130 to predict airborne infectious disease transmissions, exposures, and the subsequent infection  
131 or disease incidence to various degrees of accuracy, e.g., [8]. However, important scientific gaps  
132 remain (discussed below). The aim of physics- and biology- based models is to determine (a) the  
133 extent of airborne disease spread (including identification of disease sources) and (b) disease  
134 outbreak control strategies. These remain key areas of research and this report extends  
135 current, physics- and biology- based modeling approaches. Specifically, we develop a new  
136 theory that provides methods and metrics to assess rare, but finite airborne infection incidence  
137 (single particle airborne disease transmission: dilute atmospheric exposures where an  
138 individual inhales either one infectious particle<sup>2</sup> or none at all).

139

---

<sup>1</sup> For readability, much of the focus of this paper is on  $\leq 5 \mu\text{m}$  AD infectious particles. However, we note that the research presented in this paper is also relevant to larger particles.

<sup>2</sup> The infectious particle can, in theory, carry one or more infectious pathogens and be physically larger than the pathogen itself, see the 5.3.2. *Single Particle Infectivity* section.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

140 In this report, we highlight implications for two distinct categories of diseases. In the first case,  
141 the disease does not have significant individual to individual transmission ( $R_0 < 1$ ).<sup>3</sup> One  
142 example is Q Fever in humans in which the source of infectious particles is outdoors (i.e.,  
143 infected livestock and/or contaminated soil) and infections are not typically passed from one  
144 human to another. In the second case, the disease has notable individual to individual  
145 transmission ( $R_0 > 1$ ) and so there may be the potential for rapid disease spread. We note that  
146 both disease cases may have multiple disease transmission pathways, including direct contact,  
147 indirect contact, or ingestion.  
148

---

<sup>3</sup>  $R_0$  is the basic reproduction number and is defined as the expected number of secondary cases produced by a single (typical) infection in a totally susceptible population (dimensionless). If  $R_0 < 1$ , then an exposed person can become ill but typically does not infect others. If  $R_0 > 1$ , then further person-to-person infection spread may occur.



M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

## 149 2. Physics- and Biology- Based Airborne Transmission Modeling

150 Airborne transmission of infectious disease from an infected host to a susceptible individual  
151 occurs in three phases: (a) the release of infectious particles into the air; (b) particle transport  
152 to, and the exposure of, downwind individuals; and (c) the infection of susceptible exposed  
153 individuals (receptors), see **Figure 1**. Physics and biology based models mathematically describe  
154 each of these three phases. They estimate the number and/or distribution of subsequent  
155 infections using previously determined principles combined with key particle, environmental,  
156 infectious organism, and receptor properties, see **Table 1**. This paper focuses on improvements  
157 for modeling the second and third phases.

158


159 **Figure 1. Conceptual model of the airborne transmission pathway**

160

**Release Phase**  
Release determines  
infectious agent,  
particle properties  
and numbers

**Fate, Transport, and Exposure Phase**  
Exposures are determined by particle,  
infectious agent, environmental,  
and receptor (host) properties

**Infection Phase**  
Infections are determined by  
particle, infectious agent,  
and receptor (host) properties



161

162

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

163 **Table 1. Key properties affecting the airborne disease transmission pathway**

164

<b>Particle Physical Properties</b>	Particle number Particle size (aerodynamic diameter) and infectivity* as a function of (a) time, (b) the infectious agent and (c) environmental conditions (e.g., temperature, humidity, solar radiation)
<b>Environmental Properties</b>	Wind speed, Turbulence, Precipitation, Temperature, Humidity, Solar radiation, Terrain/Land Use, and Built Environment (for indoor exposures)
<b>Infectious Agent Properties</b>	Infectivity* as a function of (a) time and (b) particle, environmental, and receptor properties Pathogenicity (ability to cause disease)
<b>Receptor (Host) Properties</b>	Breathing rate as a function of the receptor and environmental properties (e.g., activity, temperature) Number of receptors (population) Factors affecting infection probability* Age, Gender, Nutrition, Health Status, Immune status

165 \* The probability that an inhaled particle causes infection for a given receptor is affected by  
166 parameters in several columns. Specifically, it depends on a combination of particle,  
167 infectious agent, and receptor properties - each of which depends, in part, upon  
168 environmental properties.

169

## 170 **2.1. Dilute Particle Considerations**

171 If airborne particles are added to a small mass of air, the resulting particle concentration is, in  
172 many cases, dilute and the material's presence will not significantly affect the local  
173 atmosphere.<sup>4</sup> Therefore the downwind transport and dilution (dispersion) of such material can  
174 be determined from environmental (meteorological + surface) considerations alone. Also, as a  
175 practical matter, dilute particles can be assumed to behave *independently* in the atmosphere,  
176 i.e., there is essentially no particle-to-particle interaction. Therefore, the downwind exposure  
177 associated with any release of dilute material is mathematically identical to the sum of the  
178 exposures associated with many independent "point" releases that occur at specific points in  
179 time and space. Thus, insights and model results derived for single particles released at a  
180 specific location and time can be combined to characterize the more complex cases, such as  
181 complex particle aerodynamic diameter distributions and/or time varying locations and release  
182 quantities.

183

## 184 **2.2. Advantages of Spatial and Temporal Averaging**

185 Physics-based models of atmospheric transport and dispersion simulate the effects of the  
186 physical processes which determine the air concentrations of infectious particles downwind of  
187 a release. All practical dispersion models resolve only a portion of the atmospheric motions and  
188 physical processes, typically the regional winds that transport particles downwind. The effects  
189 of the unresolved processes, such as turbulent eddies that dilute the airborne particulate cloud,  
190 are parameterized, often using empirical data. An important consequence is that model  
191 predictions can be much more accurate with predicting metrics that are spatially and/or  
192 temporally integrated (or averaged), see **Supplemental Material B: Key Atmospheric Transport  
193 and Dispersion Modeling Concepts**. This study uses the exposure integrated over a (a) a disc  
194 (circular area) and (b) along a circle arc both centered at the release point, see **Figure 2**. These  
195 exposure metrics also eliminate sensitivity to wind direction uncertainty, although we note that  
196 other uncertainties, such as wind speed, remain.<sup>5</sup>

197

---

<sup>4</sup> The number of particles required to change the behavior of the local atmosphere depends on the (a) atmospheric volume of interest, (b) particle size and density, (c) release duration, and (d) ambient wind speed [9]. For context, assuming a light wind ( $1 \text{ m s}^{-1}$ ) and monodisperse particles as dense as water ( $1000 \text{ kg m}^{-3}$ ); a  $1 \text{ m}^3$  release volume can contain at least  $10^{16}$   $0.1 \text{ }\mu\text{m}$  diameter particles,  $10^{13}$   $1 \text{ }\mu\text{m}$  diameter particles, or  $10^{10}$   $10 \text{ }\mu\text{m}$  diameter particles without violating this assumption.


<sup>5</sup> Standard wind measurements are typically only accurate to within 5 degrees [10]–[14]. Thus plume predictions based on such a single measurement may be offset by as much as a 1 km by the time the plume is 10 km downwind.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

198 **Figure 2. Illustration of airborne exposure (plume) integrated over a (left) a disc and (right)**  
199 **along a circle arc, both centered at the release point.**

200



201

202

203

### 204 2.3. Discrete Nature of Airborne Infection

205 The research community understands that airborne, infectious agents are carried as or within  
206 discrete particles, either as individual viruses, prions, or microorganisms or as part of a larger  
207 particle which could contain more than one infectious agent. However, there has been limited  
208 attention, within the context of risk assessment, as to how the discrete, quantal nature of  
209 airborne particulate exposures affect downwind infection probabilities. This scientific gap is  
210 particularly notable for rare exposures - defined for the purposes of this paper as exposures  
211 where a typical individual inhales either one infectious particle or none at all, see **Supplemental**  
212 **Material C: General Theory.**

213 Historically, rare exposure infection probabilities have been estimated by (a) extrapolating  
214 population-mean dose-response models to “less-than-one” infectious agent exposures<sup>6</sup> or (b)  
215 using “single hit” models. Population-mean dose-response models are often based on data  
216 from toxicology experiments that use multiple infectious agent exposures to extrapolate to  
217 single particle exposures. Single hit models assume that (a) the number of infectious agents  
218 inhaled by a given individual is a random number whose expected value equals the predicted  
219 exposure and (b) the likelihood of an individual inhaling an infectious organism is independent  
220 of the total number of infectious agents inhaled. Effectively each infectious agent inhaled is  
221 assumed to cause infection independently, although the overall infection probability can

---

<sup>6</sup> “Less than one” exposures occur when in a mathematical model the expectation value of the individual exposure is less than one infectious agent.

222 depend on other factors, including exposure to other viruses or microorganisms [3], [15]–[19].  
223 Recent work has extended single hit models to consider infectious agents randomly aggregating  
224 while in the environment, see [20], [21] and refs therein. However with the exception of a  
225 single theoretical treatment of a complex exposure distribution [19], we did not identify a prior  
226 approach that explicitly addresses a real-world situation in which (a) a distribution of infectious  
227 particles types is aerosolized, (b) the number of infectious agents present in each particle may  
228 scale with particle volume (i.e., is not random), and (c) environmental fate (and hence  
229 downwind exposures) vary by particle type (again is not random).

230 Separately, we note that the current physics-based airborne exposure models have been  
231 validated against measurements of high concentrations of airborne particulates (and gases). As  
232 such they do not explicitly consider the quantal nature of exposures inherent to rare exposures  
233 to particulate matter, i.e., the downwind individuals are exposed to either one or no particles.  
234 The theory developed later in the paper addresses this historical gap, see the **3. Theory** section.

235

## 236 **2.4. Building Protection**

237 Ideally, airborne infectious particle risks would be assessed at the location where the exposure  
238 takes place. It is generally acknowledged that buildings afford protection from outdoor airborne  
239 infection. However most current assessments of downwind exposures to airborne infectious  
240 particles only consider outdoor exposures and typically do not consider the degree to which  
241 buildings protect their occupants from such hazards. For example, in a recent review of existing  
242 pathogenic, bio-aerosol dispersion modeling literature; only two studies were included that  
243 consider the degree to which indoor exposures may differ from outdoor exposures and no  
244 general theory was discussed [8]. This gap is notable as (a) individuals spend about 85% of a  
245 typical day indoors [22]; (b) outdoor airborne biological particles have been proven to infiltrate  
246 indoors and be inhaled by building occupants, e.g., [23], [24]; and (c) the scientific and public  
247 health communities have long recognized the importance of the contribution of indoor  
248 exposures during disease outbreaks involving outdoor, airborne plumes of infectious particles.  
249 For example, outdoor-origin fungal pathogens such as *Aspergillus*, including *fumigatus* and  
250 *flavus*, and *Histoplasma capsulatum* are known pose a particularly severe hazard to indoor,  
251 immune compromised individuals and hospital facilities are engineered to minimize such  
252 concerns [25]–[29].

253 The degree to which building occupants are protected from outdoor, airborne, infectious  
254 particles is determined by (a) the building air change rate (the rate at which outdoor air passes  
255 through air handling systems, open windows and doors, and/or cracks in the building envelope)  
256 and (b) indoor particle dynamics (e.g., deposition, resuspension and rate at which infectious

M Dillon and  
C Dillon


Particle Model for  
Airborne Disease Transmission

257 agents lose infectivity), see **Supplemental Material D: Indoor Particle Dynamics**. We, and  
258 collaborators, have recently developed a proof-of-concept method, Regional Shelter Analysis  
259 (RSA), to (a) estimate the degree of protection US buildings provide against outdoor airborne  
260 particulate hazards and (b) estimate total population exposures [30], [31]. **Figure 3** illustrates  
261 the RSA method for calculating building protection-adjusted population impacts resulting from  
262 an estimate of the outdoor hazard. The example shown is for an external gamma radiation  
263 hazard. The process for inhalation exposures is similar. US building protection against  
264 particulate hazards varies strongly, i.e., by orders of magnitude, with particle size and building  
265 use (occupancy). For context, being inside a typical US residence is expected to reduce outdoor  
266 exposures by a factor of 5 for 1  $\mu\text{m}$  AD particles, a size typical of many individual bacteria [30].  
267

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

268 **Figure 3. Regional Shelter Analysis illustrative calculation (top panel) and summary (bottom**  
 269 **pane). This schematic illustration uses an outdoor (external) radiation exposure and shelter**  
 270 **quality (building protection) estimates. Potential applications and uses are listed.**



271

## Regional Shelter Analysis summary

- Incorporates shelter quality into existing assessment methods
- Applicable to
  - Nuclear, radiological, chemical, and biological acute and chronic hazards (e.g., outdoor particle air pollution, wildfire smoke)
  - External radiation and inhalation exposure (rad and non-rad) pathways
  - Spatial scales ranging from individual buildings to census tracts to entire countries
  - Capable of using multiple data sources
- Elements being integrated into operational models
  - US Department of Energy, NARAC
  - US Department of Defense, HPAC

### Illustrative fallout protection



[https://figshare.com/authors/Michael\\_Dillon/4116202](https://figshare.com/authors/Michael_Dillon/4116202)

272

273



### 274 **3. Theory**

275 Theoretically, the total number of infections in a disease outbreak could be calculated by  
276 considering every exposed person. Computationally this approach is challenging to implement,  
277 due in part to the need to acquire high resolution input data such as individual exposures and  
278 responses to each exposure. To provide an alternative approach, we develop here infection  
279 probability prediction equations for (a) the number of airborne infections (and the absolute  
280 airborne infection probability) expected in a specific geographic region for both the general and  
281 the rare exposure cases (**Equations 1 and 2**) and (b) an equation that relates the relative  
282 probability of airborne infection across two regions (**Equation 3**). Note that these, and  
283 subsequent, equations can also be used directly without modification to estimate disease  
284 probability and other probabilities of interest. These equations are based on the atmospheric  
285 physics assumptions and considerations presented in the *2. Physics-and Biology- Based*  
286 *Airborne Transmission Modeling* section. **Supplemental Material C: General Theory** formally  
287 derives these equations and provides more detail, including theory that considers multiple  
288 particle types that have varying infectivity and environmental fates. **Supplemental Material D:**  
289 **Indoor Particle Dynamics** provides more detail on **Equations 5 to 7** which predict the degree to  
290 which buildings protect their occupants from outdoor airborne hazards; expected numbers of  
291 infections in the indoor environment from an indoor release; and the fraction of indoor,  
292 airborne, infectious particles that may exit a given building into the outdoor atmosphere.

293

#### 294 **3.1. Absolute (Mean) Infection Probabilities for Geographic Regions**

295 Geographic regions, e.g., zip codes and census tracts, are often used when reporting  
296 epidemiological data and defining outbreak response zones, e.g., for quarantine and/or  
297 vaccination. In general, people within these geographic regions may have varying exposures  
298 and/or responses to a given exposure, e.g., individuals inside a building may receive a smaller  
299 exposure than those outside; immune compromised individuals may be more sensitive than a  
300 healthy person. To account for these considerations, we extend the previously developed  
301 Regional Shelter Analysis methodology [30], [31]. Specifically, we assign each group of people  
302 within a geographic region a linear scaling factor, termed *adjustment factor*, to account for  
303 both exposure and response variability.

304 For a given release, the total number of airborne infections in a region can be determined by  
305 **Equation 1. Equation 2** can be used when the (a) population density and adjustment factor are  
306 constant within a region, e.g., the geographic entity is a residential area, and (b) exposures are  
307 rare.



M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

308 (Equation 1)

$$\begin{aligned}
 309 \quad & [Airborne\ Infections](r_{source}, r) \\
 310 \quad & = [Absolute\ Airborne\ Infection\ Probability](r_{source}, r) \\
 311 \quad & \cdot [Population\ Density](r) \cdot [Area](r)
 \end{aligned}$$

312 (Equation 2)

$$\begin{aligned}
 313 \quad & [Absolute\ Airborne\ Infection\ Probability](r_{source}, r) \approx \\
 314 \quad & \left( \frac{[Total\ Particles\ Released] \cdot [Normalized\ TSIAC](r_{source}, r)}{[Single\ Particle\ Infection\ Probability]_{ref} \cdot [Infection\ Adjustment\ Factor](r)} \right) \\
 & \quad \quad \quad [Area](r)
 \end{aligned}$$

315

316 where

317  $r$  = a specific geographic region (dimensionless),

318  $[Absolute\ Airborne\ Infection\ Probability](r_{source}, r)$  = mean probability that a random individual in  
319 region  $r$  becomes infected by inhaling an airborne particle emitted from region  $r_{source}$ .  
320 (dimensionless),

321  $[Airborne\ Infections](r_{source}, r)$  = total number of people who become infected in region  $r$  by inhaling  
322 infectious airborne particles emitted from region  $r_{source}$ . (people),

323  $[Area](r)$  = area of region  $r$  ( $m^2$ ),

324  $[Infection\ Adjustment\ Factor](r)$  = linear scaling factor for region  $r$  that accounts for the deviation of  
325 exposure and infection response from the reference exposure and infection response  
326 (dimensionless),

327  $[Normalized\ TSIAC](r_{source}, r)$  = particle air concentration integrated over region  $r$  and the passage of the  
328 airborne infectious plume assuming that a single particle has been released to the air from source  
329 region  $r_{source}$ . TSIAC = time and space integrated air concentration. ( $s\ m^{-1}$ ),

330  $[Population\ Density](r)$  = population density in region  $r$  (people  $m^{-2}$ ),

331  $[Single\ Particle\ Infection\ Probability]_{ref}$  = reference probability that an individual will become infected  
332 after being exposed to a single particle. This term includes the individual's breathing rate. ( $m^3\ s^{-1}$   
333  $particle^{-1}$ ), and

334  $[Total\ Particles\ Released]$  = total number of particles released into the atmosphere (particles).

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

### 3.2. Relative Infection and Disease Probability

Although disease outbreak assessments are often based on absolute risks, key outbreak response parameters may not be known. In this setting, relative infection probability metrics can be useful. **Equation 3** can also be used to model either relative probabilities of infection or disease. When the source of airborne particles and, separately, the impacted regions are similar (e.g.,  $r$  and  $r_{ref}$  are both residential areas and  $r_{new\ source}$  and  $r_{ref\ source}$  are both office areas), **Equation 3** provides the theoretically expected ratio of regional infection probabilities. *Note that Equation 3 does not require any information on the release amount per person, the infectivity of individual particles, or the adjustment factor (variation of exposure and population sensitivity).* When there is a single source region (i.e.,  $r_{new\ source} = r_{ref\ source}$ ), **Equation 3** allows the infection probability of different downwind regions to be compared. When a clear case of region-to-region airborne disease transmission has been identified, **Equation 3** could be used to estimate the infection (or disease) rates for new sources and receptor regions. *We note that this relative infection/disease probability metric is distinct in form from the traditional “relative risk” metric which is defined as the ratio of infection (or disease) incidence between exposed and baseline (ideally non-exposed) populations.*

(Equation 3)

$$\begin{aligned}
 [Relative\ Infection\ Probability](r) &= [Relative\ Disease\ Probability](r) \\
 &= \frac{[Absolute\ Airborne\ Infection\ Probability](r_{new\ source}, r)}{[Absolute\ Airborne\ Infection\ Probability](r_{ref\ source}, r_{ref})} \\
 &= \left( \frac{[Normalized\ TSIAC](r_{new\ source}, r)}{[Normalized\ TSIAC](r_{ref\ source}, r_{ref})} \right) \cdot \left( \frac{[Area](r_{ref})}{[Area](r)} \right) \\
 &\quad \cdot \left( \frac{[Infectious\ People](r_{new\ source})}{[Infectious\ People](r_{ref\ source})} \right)
 \end{aligned}$$

where

$[Infectious\ People](r_{source})$  = number of people emitting infectious particles in source region  $r_{source}$ .  
(people),

$[Relative\ Disease\ Probability](r)$  = ratio of the region  $r$  disease probability to reference region  $r_{ref}$  disease probability. (dimensionless), and

$[Relative\ Infection\ Probability](r)$  = ratio of the region  $r$  infection probability to reference region  $r_{ref}$  infection probability. (dimensionless).

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

363 The equations presented in the prior sections and derived in **Supplemental Material C: General**  
364 **Theory** focus on infection probability. However, not all infections result in disease. In addition,  
365 other metrics, such as the probability of needing medical resources or economic impact, may  
366 also be of interest. It is straightforward to adapt the prior equations to any metric in which the  
367 probability of an individual's response to a single particle exposure can be calculated by  
368 multiplying (a) a reference response probability by (b) a linear scaling factor (i.e., a metric  
369 specific adjustment factor). While the scaling factor may take any value and may vary by  
370 individual, the value for a specific individual cannot change. The adjustment factors can vary by  
371 metric. When these conditions are met, the relative incidence, i.e., **Equation 3**, of multiple  
372 metrics of interest, such as infection and disease, are the same. The **Equation 3** disease spread  
373 estimates could also be used to assess importance of other disease transmission pathways for  
374 the new receptor region, see **Equations 1** and **4**.

375 **(Equation 4)**

$$376 \quad [NonAirborne\ Infections](r) = [Total\ Infections](r) - [Airborne\ Infections](r)$$

377

378 where

379  $[NonAirborne\ Infections](r)$  = number of infected individuals in region  $r$  that were infected by the  
380 transmission pathways OTHER than airborne. (people), and

381  $[Total\ Infections](r)$  = number of infected individuals in region  $r$ . (people).

382

### 383 3.3. Indoor Airborne Particle Dynamics

384 Infectious airborne particles can be emitted within a building. Once airborne, these particles  
385 have the potential, among other fates, to (a) be inhaled and infect people within the building or  
386 (b) exit the building, enter the outdoor atmosphere, and be transported downwind. To provide  
387 context for later discussion, we have extended prior work [30] and derived **Equations 5 to 7**,  
388 which estimate key parameters.<sup>7</sup> **Supplemental Material D: Indoor Particle Dynamics** derives  
389 these, and other, equations. These equations do not assume, but are compatible with, rare  
390 (single particle) exposures.

391 (Equation 5)

392 
$$[Building\ Protection\ Factor] = \frac{(\lambda_{out} + \lambda_{internal})}{\lambda_{in}}$$

393 (Equation 6)

394 
$$[Normalized\ TSIAC]_{indoor} = \frac{1}{[Room\ Height] \cdot (\lambda_{out} + \lambda_{internal})}$$

395 (Equation 7)

396 
$$[Building\ Exit\ Fraction] = \frac{\lambda_{out} \cdot L_{out}}{(\lambda_{out} + \lambda_{internal})}$$

397

398

---

<sup>7</sup> These equations assume that the air within the building is well mixed. As the mixing process takes time and depends on the room/building/population details, exposures (and infection probability) may be higher in the room occupied by an infected individual. We note that within room spread is an area of active research, e.g., [32], but the well-mixed assumption has also been often, but not always, been employed by prior modeling studies that examined indoor bioaerosol dynamics and disease transmission, e.g., [6], [7], [33], [34], and references therein. For context, the mixing time constants for both buoyant and mechanical flow conditions in laboratory studies of room mixing are of order 10 min to < 1 h [35], [36].

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

399 where

400

401  $\lambda_{in}$  = the rate at which outdoor airborne particles enter the building – typically via infiltration or ventilation.  
402 Includes losses that occur during transport from outdoor to indoor. ( $h^{-1}$ ),

403  $\lambda_{internal}$  = the rate at which indoor particles are lost within the building. This term includes both physical  
404 losses, such as deposition to indoor surfaces, and infectivity losses while the particle is airborne ( $h^{-1}$ ),

405  $\lambda_{out}$  = the rate at which indoor particles exit the building. ( $h^{-1}$ ),

406 [*Building Exit Fraction*] = fraction of material released within a building that exits the building and enters  
407 the outdoor atmosphere. (no units),

408 [*Building Protection Factor*] = ratio of the outdoor to indoor exposure. Similar to sunscreen and personal  
409 protective respirator rating systems, higher protection factor values indicate lower exposures and  
410 thus increased protection. (protection factor),

411  $L_{out}(particle\ size)$  = the fraction of indoor particles lost while exiting the building. (dimensionless),

412 [*Normalized TSIAC*]<sub>indoor</sub> = indoor time and space integrated air concentration assuming a single particle  
413 is released. ( $s\ m^{-1}$ ), and

414 [*Room Height*] = height of building living space. (m).

415

## 416 **4. Results**

417 This section applies the previously derived theory to estimate regional-level metric values. First,  
418 upper bound estimates are provided for both individual person level and regional level  
419 infection probabilities for locations downwind. These results assume that infectious particles  
420 are emitted from a single, non-moving source.<sup>8</sup> Second, the relative infection and disease  
421 probabilities as a function of downwind distances are provided. The modeling examples  
422 provided here (a) assume 1  $\mu\text{m}$  AD particles and no airborne loss of infectivity and (b) consider  
423 a wide range of common weather conditions.<sup>9</sup> Other scenarios, including those with varying  
424 particle and environmental parameters, are briefly discussed for context. Third, the relative  
425 importance of within building and downwind (both indoors and outdoors) infections is  
426 illustrated.

427 In this section we also compare the modeled predictions for relative infection probabilities  
428 (**Equation 3**), with existing observational data from disease outbreaks which have a major  
429 airborne transmission pathway. This is not a formal theory validation but is a useful initial  
430 assessment of theory predictions compared to data from real-world events. As the primary data  
431 collected by the investigators were not available, existing data were abstracted from journal  
432 article tables and figures, see **Supplemental Material F: Outbreak Model-Measurement**  
433 **Comparison**. The scope and detail of the published observational data varied between studies  
434 which limited the comparisons. In general, the outbreak disease case ascertainment method  
435 was notified clinical cases (passive surveillance) and so a fraction of diagnosed cases and any  
436 undiagnosed cases were missed. Detailed sub-regional population demographics were not  
437 presented, and so adjusted age-specific disease incidence rates could not be estimated. Disc-  
438 specific disease incidence rates were not available in some studies. Also, true background  
439 disease incidence rates were not reported. Multiple transmission pathways are common in  
440 infectious diseases. Most of these studies evaluated that possibility, but one study did not [37].

441 All studies showed a clear pattern of high disease incidence rates close to an exposure source  
442 with a rapid decrease in disease incidence with increasing distance thereafter. **Figure 4**  
443 demonstrates this behavior using the Q Fever data. This attack rates shown in **Figure 4** likely  
444 underestimate the actual values, see the *5.2. Background Disease Incidence* section below.

---


<sup>8</sup> This is an assumption used to simplify the analysis presented in this report. Methodology exists for modeling mobile populations that is compatible with RSA analysis, see the *5.4 Potential Future Efforts* section and reference [31].

<sup>9</sup> 1  $\mu\text{m}$  AD particles are chosen here for theoretical modeling purposes. However, this particle size is characteristic of many infectious bacterial cells. Furthermore, infectious agents, including viruses, may be carried on, or in, larger particles comprised of other material such as respiratory fluids, see the *5.3.2. Single Particle Infectivity* section.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

445 **Figure 4. Observed Q Fever attack rate as a function of distance as published in airborne**  
446 **infectious disease outbreak studies. The distance downwind corresponds to the radial**  
447 **distance from the source to the center of a circular band (torus) centered on the source. The**  
448 **band width varies with each point and ranges from 50 m to 5 km. The legend shows the study**  
449 **location, outbreak year, and infectious agent (Q = Q Fever (*Coxiella burnetii*)).**



450  
451

#### 452 **4.1. Upper Bound on Absolute Infection Probability vs. Distance**

453 The top panels in **Figure 5(a-b)** show the predicted upper bound on the absolute airborne  
454 infection probability for each particle released to the outdoor atmosphere as integrated (a)  
455 over a series of discs and (b) along a series of circle arcs (see **Figure 2**) at distances between 50  
456 m and 20 km from the release point. The bottom panels show the corresponding number of  
457 infections in an urban area (assuming 0.01 people m<sup>-2</sup>) for each airborne particle released. For  
458 context, about 30% of the New York State, US 2000 Census Tracts have population densities ≥  
459 0.01 people m<sup>-2</sup>.

460 The results shown in **Figure 5** were derived from **Equations 1 and 2** and **Table E2** from  
461 **Supplemental Material E: Outdoor Normalized Time and Space Integrated Air Concentrations**.  
462 We present here the results for one important class of possible weather scenarios, where  
463 constant light, moderate, and strong winds (1, 4.5, and 10 m s<sup>-1</sup>, respectively) would transport  
464 an airborne particle 1 km downwind in about 17, 4, and 2 min, respectively.<sup>10</sup> Thus these results  
465 are reasonable when losses are not significant on the timescale of minutes to hours.<sup>11</sup>

466 The absolute infection probability varies over several orders of magnitude and decreases  
467 rapidly with distance. Broadly speaking, the infection probability increases with (i) decreasing  
468 wind speed and (ii) increasing atmospheric stability (increasing stability corresponds to  
469 decreasing rates at which material dilutes within the broader atmosphere). The actual infection  
470 probability will be smaller if not all inhaled particles cause infections and/or the individual is  
471 indoors or otherwise protected. In the latter case, downwind infection probability estimates  
472 can be determined by dividing the values shown in **Figure 5** by a building protection factor, e.g.,  
473 [30]. We note that the expected number of infections linearly scales with both the total number  
474 of particles released and the population density.

475 When the airborne loss rate is significant on the timescale of minutes, e.g., 10 h<sup>-1</sup>, the modeled  
476 relative infection incidence increases with wind speed at distances greater than 1 km, see  
477 **Figure 6**.

---


<sup>10</sup> This transport timescale calculation is intended for illustrative purposes as it does not consider the effects of atmospheric turbulence (e.g., plume dispersion) nor the known increase of wind speed with height above the earth's surface.

<sup>11</sup> For context, respirable size (1 to 5 μm AD) particle deposition losses are often limited (approximately 0.1 h<sup>-1</sup> or less) on these scales. Deposition rates depends on particle size, atmospheric conditions, and surface characteristics. For this illustrative calculation, we have assumed (a) a 1 cm s<sup>-1</sup> deposition velocity (the speed at which the particle travels to a surface and is lost) [38], (b) a 300 m boundary layer height (the height of the air near the surface that is well mixed – this value corresponds to stable, nighttime conditions), and (c) that the atmospheric boundary layer is a well-mixed system and so the deposition loss rate = deposition velocity / boundary layer height [39].



478 **Figure 5. Predicted infection probabilities and infections by distance, wind speed and**  
479 **atmospheric stability for a single airborne particle with no airborne loss of infectivity. Legend**  
480 **box indicates Pasquill-Gifford-Turner atmospheric stability class (A to F) and the 10 m agl**  
481 **wind speed. Individual person infection probability (top panels) is dimensionless. Urban area**  
482 **infections (bottom panels) assume a uniform population density of 0.01 people m<sup>-2</sup> and has**  
483 **dimensions of people (disc) or people m<sup>-1</sup> (arc).**


**Figure 5a. Infection Probabilities and Urban Infections Within a Disc Centered on the Release**



484

485

**Figure 5b. Infection Probabilities and Urban Infections  
Along an Arc Centered on the Release**




486

487

488 **Figure 6. Predicted infection probabilities and infections by distance, wind speed and**  
489 **atmospheric stability for a single airborne particle with a  $10 \text{ h}^{-1}$  airborne loss of infectivity.**  
490 **Legend box indicates Pasquill-Gifford-Turner atmospheric stability class (A to F) and the 10 m**  
491 **agl wind speed. Individual person infection probability (top panels) is dimensionless. Urban**  
492 **area infections (bottom panels) assume a uniform population density of  $0.01 \text{ people m}^{-2}$  and**  
493 **has dimensions of people (disc) or people  $\text{m}^{-1}$  (arc).**

**Figure 6. Infection Probabilities and Urban Infections  
Along an Arc Centered on the Release**



494

## 495 **4.2. Relative Infection and Disease Probability vs. Distance**

496 **Figure 7a** shows the corresponding relative infection (and disease) probabilities as calculated by  
497 **Equation 3** and the upper bound absolute infection probability curves shown in **Figure 5** as  
498 integrated over (top panel) a disc and (bottom panel) along a circle arc, both being centered at  
499 the common release point ( $r_{new\ source} = r_{ref\ source}$ ). While the relative infection (and disease)  
500 probabilities again decrease rapidly with distance, there is minimal variation with wind speed or  
501 atmospheric stability over the range of atmospheric conditions considered.<sup>12</sup> Hence the relative  
502 infection probability metric may be particularly valuable when there is incomplete or entirely  
503 lacking information on meteorological conditions, but (a) atmospheric conditions are known to  
504 not be materially changing during the time it takes for the infectious particles to travel from the  
505 source to the receptor and (b) the particle infectivity is not lost rapidly in the atmosphere. *This*  
506 *relationship is expected to hold even when the exposed population has varying sensitivity to the*  
507 *infecting particle and/or are located inside buildings affording different degrees of protection as*  
508 *long as the distributions of both the infection sensitivity and building protection are similar in*  
509 *both exposure regions.*

510 When the airborne loss rate is significant on the timescale of minutes, e.g.,  $10\ h^{-1}$ , the modeled  
511 relative infection incidence for circle arcs increases with wind speed, see **Figure 7b**. Notably,  
512 the slope of  $\log_{10}(\text{distance from source})$  vs.  $\log_{10}(\text{relative infection rate})$  is smaller than the no (0  
513  $h^{-1}$ ) airborne loss rate case. Due to the rapid decrease in airborne infection probability with  
514 distance, the corresponding plots for relative infection incidence for a disc are nearly identical  
515 to that shown in **Figure 7a**.

516

---


<sup>12</sup> The equations shown in **Figure 7** are based on the mean of the individual slope and intercept for each weather case ( $r^2 > 0.99$  for all cases). The individual values varied less than 15% from the mean values provided.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

517 **Figure 7. Predicted relative infection probabilities by distance, wind speed and atmospheric**  
 518 **stability for a single airborne particle with (a) 0 h<sup>-1</sup> and (b) 10 h<sup>-1</sup> airborne infectivity loss rates.**  
 519 **Legend box indicates Pasquill-Gifford-Turner atmospheric stability class (A to F) and the 10 m**  
 520 **agl wind speed. Relative infection probability is dimensionless.**

**Figure 7a. Relative Infection Probabilities  
as a Function of Distance from Release**




521

522

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

**Figure 7b. Relative Infection Probabilities  
as a Function of Distance from Release**



523

524

### 525 **4.3. Model Prediction – Outbreak Data Comparison**

526 In this section, we compare previously published, major airborne outbreak data against relative  
527 probability values calculated using **Equation 3**. First we use data from Q Fever (*Coxiella*  
528 *burnetti*) [37], [40]–[42], Legionnaire’s disease (*Legionella pneumophila*) [43], [44], and Valley  
529 Fever (*Coccidioides immitis*) [45], [46] outbreaks. We note that these human pathogens have  
530 reproductive number ( $R_0$ ) values less than 1 (Case 1 diseases) and so they have little or no  
531 potential for person-to-person transmission, simplifying the airborne disease modeling.<sup>13</sup>  
532 Subsequently we use results derived from veterinary disease outbreak studies of Highly  
533 Pathogenic Avian influenza (HPAI) [47]–[49], Foot and Mouth Disease (FMD) [50], [51], and  
534 Classical Swine Fever (CSF) [52]. These diseases have reproductive numbers ( $R_0$ ) greater than 1  
535 (Case 2 diseases) and so have the potential for secondary epidemic spread (they also are known  
536 to have multiple disease transmission pathways). The modeled values were determined using  
537 **Equation 3** and the neutral (D) stability, moderate wind ( $4.5 \text{ m s}^{-1}$  at 10 m agl) modeling results  
538 presented in **Supplemental Material E: Outdoor Normalized Time and Space Integrated Air**  
539 **Concentrations**. Other than the source location, definition of the base and reference areas, and  
540 the assumption of a single source ( $r_{new\ source} = r_{ref\ source}$ ), no disease or outbreak specific  
541 information was used in the modelling.

542 **Figure 8** compares the predicted model relative disease probabilities to the observed relative  
543 incidence of clinical disease reported for Q Fever, Legionnaire’s disease, and Valley Fever  
544 outbreaks. The modeled and measured values are reasonably well correlated,  $r^2 = 0.86$ , and  
545 close to the 1:1 line.<sup>14</sup> The base and reference areas vary by comparison point and are specified  
546 in **Supplemental Material F: Outbreak Model-Measurement Comparison**. Some data points  
547 from these studies were not used either due to (a) the low number of observed disease cases<sup>15</sup>  
548 or (b) because they were adjacent to the source and did not exhibit the expected decrease in  
549 disease rate with distance. The specific data points used and omitted are indicated in the  
550 **Supplemental Material F: Outbreak Model-Measurement Comparison**.

---

<sup>13</sup> This case is also applicable to initial stage of epidemic that is later propagated by secondary transmission.

<sup>14</sup> A linear regression (not shown) of the data presented in **Figure 8** yields  $\log_{10}(\text{Modeled Relative Disease Probability}) = 1.05 (\pm 0.08) * \log_{10}(\text{Observed Relative Disease Incidence}) - 0.10 (\pm 0.05)$ . A linear regression with all available data reduces the correlation,  $r^2 = 0.53$ , but yields a similar line,  $\log_{10}(\text{Modeled Relative Disease Probability}) = 0.85 (\pm 0.13) * \log_{10}(\text{Observed Relative Disease Incidence}) - 0.02 (\pm 0.09)$ . The provided parameter uncertainties are  $\pm 1\sigma$ .

<sup>15</sup> As a practical matter, the population within the region of interest may be low and so the corresponding disease incidence rates may be unreliable.




M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

551 **Figure 8. Modeled Relative Disease Probability Compared to Observed Relative Disease**  
552 **Incidence as published in airborne infectious disease outbreak studies. The dashed line is the**  
553 **1:1 line which indicates perfect agreement. The legend box shows the study location,**  
554 **outbreak year, and infectious agent (Q = Q Fever (*Coxiella burnetti*); L = Legionnaire's Disease**  
555 **(*Legionella*); C = Valley Fever (*Coccidioidomycosis*)).**

556





M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

558 **Table 2** demonstrates that our prediction<sup>16</sup> of the slope of  $\log_{10}(\text{distance from source})$  vs.  
559  $\log_{10}(\text{relative infection rate}) \leq -2$  is consistent with both (a) the previously discussed studies and  
560 (b) as previously reported for Highly Pathogenic Avian influenza and Foot and Mouth Disease  
561 outbreaks. We note that Classical Swine Fever and Valley Fever do not have sufficient data to  
562 formally assess this statement, but the reported values are  $\pm 25\%$  of the predicted values.

563 For the HPAI, FMD, and CSF cases, the infection rate as a function of distance was determined  
564 by the original authors from a set of base equations whose parameter values were determined  
565 from the timing of the discovery of each specific disease case, the locations of known infected  
566 farms, assumptions about disease incubation periods, the time from infection until detection,  
567 certain farm attributes, and (for some studies) varying sensitivity to a given infectious exposure.  
568 In contrast to the current analysis, the analyses presented in those studies did not model the  
569 physics of disease transmission mechanisms, nor do they assume airborne transmission. In  
570 these outbreaks, the infection probability (transmission kernel) was demonstrated to be  
571 relatively constant over an initial, short-range geographic extent and then decrease with  
572 distance. The latter decrease in infection probability (disease incidence rate) with distance is  
573 equivalent to the slope in equation shown in lower panels of both **Figure 7(a-b)**.<sup>17</sup>

574 The observed FMD disease rate decreases notably faster than that demonstrated in our  
575 baseline results, which assume no atmospheric loss of infectivity. The FMD results are,  
576 however, more consistent with modeling that includes infectivity losses that are significant on  
577 the timescale of the plume transport and we note that FMD virus is in fact known to lose  
578 infectivity in the atmosphere [53].

579

---

<sup>16</sup> We speculate, but have not proven, that this result is related to the well-known fact that away from the source, airborne plume dispersion is proportional to  $(\text{distance})^{1/2}$ , see **Supplemental Material B: Key Atmospheric Transport and Dispersion Modeling Concepts**. If true, then we would expect that the slope of  $\log_{10}(\text{distance from source})$  vs.  $\log_{10}(\text{relative infection rate})$  would be closer to -1 for impacts that take place close to the source, where dispersion eddies are well-correlated and the airborne plume dispersion is proportional to distance.

<sup>17</sup> (a) This statement is true in the mathematical limit that the “base” and “reference” distance in the prior study equations are large relative to the constant infectivity distance, (b) The modeling presented in this study is limited to less than 20 km from the source.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

580 **Table 2. Summary of decrease in relative infectivity (or disease) with distance for selected**  
581 **studies.**

Outbreak	Decrease in Relative Infectivity (or Disease) Incidence with Distance	Uncertainty / Variability	Reference
<b>model prediction for 1 <math>\mu\text{m}</math> aerodynamic diameter particles and no atmospheric losses</b>			
n/a	-1.9	-1.7 to -1.9 <sup>a</sup>	(this study)
<b>analysis of prior studies shown in Figure 8<sup>b</sup></b>			
<i>Q Fever (Coxiella burnetti)</i>			
Netherlands 2008	-2.2	-1.8 to -2.5 <sup>c</sup>	[40]
W. Midlands 1989	-1.5	-0.9 to -2.0 <sup>c</sup>	[42]
Germany 2005	-1.4	-0.17 to -2.7 <sup>c</sup>	[37]
<i>Legionnaire's Disease (Legionella)</i>			
Norway 2005	-1.5	-1.3 to -1.8 <sup>c</sup>	[43]
France 2003	-0.7	n/a	[44]
<i>Valley Fever (Coccidioidomycosis)</i>			
Simi Valley 1994	-1.4	n/a	[45], [46]
<b>other prior studies<sup>d</sup></b>			
<i>Highly Pathogenic Avian Influenza (HPAI)</i>			
Netherlands 2003	-2.1	-1.8 to -2.4 <sup>c</sup>	[47]
Minnesota 2015 (first wave)	-2.4	-1.7 to -3.7 <sup>c</sup>	[48]
Italy 2000	-2.1	-1.9 to -2.3 <sup>c</sup>	[49] (reported in [48])
<i>Foot and Mouth Disease (FMD)</i>			
Japan 2010	-2.5	n/a	[50]
Great Britain 2001 (conditioned on Feb 23 data)	-2.7	-2.6 to -2.8 <sup>c</sup>	[51]
<i>Classical Swine Fever (CSF)</i>			
Netherlands 1997/1998	-2.2	n/a	[52]

582

583 <sup>a</sup> range modeled

584 <sup>b</sup> slope of  $\log_{10}(\text{distance in m})$  vs.  $\log_{10}(\text{relative disease rate})$  calculated for this study

585 <sup>c</sup> 95% Confidence Interval

586 <sup>d</sup> as reported in referenced study

587

#### 588 4.4. Relative Magnitude of Within Building and Downwind Infections

589 Physical science considerations suggest that some fraction of airborne indoor particles will exit  
590 buildings. For example, we predict that, on average, about 35% of the airborne,  $0 \text{ hr}^{-1}$  infectivity  
591 loss rate,  $1 \mu\text{m}$  particles in US single family homes will be released to the outdoor atmosphere,  
592 see **Supplemental Material D: Indoor Particle Dynamics** and [30].<sup>18</sup> Indeed under some  
593 conditions, infections due to airborne transmission could result in similar numbers of people  
594 being infected downwind than in the same house as an infected individual – see the example  
595 provided in **Supplemental Material G: Infection Estimates**. When the regional population  
596 density is notably greater than  $0.01 \text{ people m}^{-2}$ , more people may be infected downwind than  
597 within the source building. We note that (a) not all diseases are capable of longer-distance  
598 downwind transmission, see 5.3. *Key Infectious Agent/Disease Characteristics* section, (b) other  
599 disease transmission pathways may substantially increase the probability of being infected  
600 while sharing the same house as an infected individual, (c) downwind individuals may be  
601 indoors, and (d) even for the airborne transmission pathway, the “per-person” infection  
602 probability is higher within a given building than it is downwind.

603 Building operation changes could alter the absolute and relative probability of source building  
604 and downwind infections. For example, actions that increase the indoor/outdoor air change  
605 rates ( $\lambda_{out}, \lambda_{in}$ ), such as increasing the ventilation, would (a) decrease indoor exposures within  
606 the source building, (b) increase the number of infectious particles emitted to the greater  
607 atmosphere, and (c) decrease the protection downwind buildings provide their occupants. In  
608 contrast, actions that increase the within building loss rates ( $\lambda_{internal}$ ), potentially including  
609 replacement of existing furnace filters with higher efficiency filters, have the potential to  
610 reduce exposures in both the source and downwind buildings.

611

---

<sup>18</sup> This fraction is expected to vary with particle size, airborne infectivity loss rate, and building type.

## 612 **5. Discussion**

### 613 **5.1. Characterizing Airborne Disease Spread**

614 In a disease outbreak situation, it may be necessary to establish whether airborne disease  
615 transmission is occurring. Laboratory studies to identify the suspect pathogen and the known  
616 pathogen characteristics (see the *5.3. Key Infectious Agent/Disease Characteristics* section  
617 above) are valuable in this regard. Epidemiological factors may indicate a spatio-temporal signal  
618 consistent with airborne transmission, specifically (a) new infections that have no contact with  
619 a known infectious individual, (b) correlation between new infections and key weather  
620 conditions, and (c) the presence of disease “sparks” outside the regions of known infection. This  
621 work suggests an additional method, where the geographic distribution of observed disease  
622 cases agrees with that predicted by **Equation 3**, i.e.,  $\log_{10}(\text{distance from source})$  vs.  
623  $\log_{10}(\text{disease rate})$  is linear with a slope  $\leq -2$ . Comparison to prior outbreak data suggests that  
624 this airborne transmission signal may be readily apparent, especially in cases where there is a  
625 single emission source. However, we note that it could be (a) mimicked by other infection  
626 transmission pathways if they are also correlated with distance from the source, (b) obscured  
627 by other disease transmission pathways, and (c) challenging to identify when there are  
628 multiple, geographically separate emission source regions. However, other disease transmission  
629 pathway(s) should be considered when the **Equation 3** predicted signal is absent.

630 The theory and modeling presented in this paper define the single particle airborne disease  
631 transmission kernel. This kernel corresponds to the set of lower probability, longer-distance  
632 airborne transmission events. These could contribute to large scale disease spread by  
633 “sparking” unexpected disease outbreaks distant from an emission source. The impacts of these  
634 longer-distance transmissions can be high for diseases that can cause many secondary  
635 infections (i.e., Case 2 diseases). In the plant biology and biosafety literature, it is well  
636 understood that these low probability, long distance (100’s of km) spread events do occur and  
637 are a primary mechanism of long-term species colonization of new environments and plant  
638 pathogen spread [54]–[57]. Indeed, unexpected long-distance disease sparks are a particularly  
639 well-documented problem in Foot and Mouth Disease of ruminants, where prior investigators  
640 have noted “Airborne spread is the most important mechanism of uncontrollable [disease]  
641 spread and although this is not a common event, when it occurs the speed and extent of spread  
642 can be spectacular” [58].

643

## 644 **5.2. Background Disease Incidence**

645 Due to the predicted finite, but characteristically low, individual-person infection probability  
646 rates in the general population, airborne diseases that present similarly to other common, non-  
647 airborne diseases may be prone to being under diagnosed and under reported. While an  
648 individual event may not affect many people, the cumulative impact of routine, small-scale  
649 events could pose a significant health burden. More accurately defining the airborne disease  
650 burden may be important since with appropriately targeted programs, there is a potential to  
651 reduce the currently existing US population airborne disease burden.

652 As an illustration, Q Fever is a disease with a well-established airborne transmission pathway  
653 and disease control measures exist [59]. Q Fever is often considered a rare disease; however, it  
654 is known that Q Fever cases are significantly underreported even though it is a US nationally  
655 notifiable disease with mandatory reporting in most states [60], [61]. US nationally  
656 representative data from 2003 to 2004 suggest that the overall adult population prevalence of  
657 acute, recent, and chronic Coxiella infections is 6 million people, 3% of the general US  
658 population [62]. Further analysis of this data indicates the prevalence of Acute Q Fever (Coxiella  
659 burnetti) infections may be approximately 2 million people, see **Supplemental Material H: U.S.  
660 Coxiella burnetti Infection and Disease Estimates**.<sup>19</sup> For comparison, during this time period  
661 there were 70 Q Fever cases in the national reporting system [64], [65] and in 2017 there were  
662 153 acute and 40 chronic Q Fever cases reported in the US [66]. Disease underreporting rates  
663 are similar for other major airborne disease mentioned here. For example, among US  
664 hospitalized persons with pneumonia, Legionnaire's Disease is ten times more common than  
665 currently being diagnosed [67].

666 Accurately estimating background disease rates is also an important step in investigating  
667 epidemic outbreaks as these are needed to produce accurate absolute outbreak incidence  
668 estimates and relative risks. We note that true population-based background incidence and  
669 prevalence rates are unavailable for most diseases.<sup>20</sup> This literature gap is a practical matter as  
670 analysts often arbitrarily choose the lowest observed incidence rates at a location adjacent to  
671 the main body of outbreak cases as a background reference rate. However, as seen above,  
672 infections at these distances might be due to long-distance airborne transmission as this work  
673 suggests that once an infectious particle is airborne, there is a non-zero probability of infections  
674 downwind. Misclassification of background disease rates could result in inaccurate (a)

---

<sup>19</sup> Direct contact and vectors (ticks) are also known to transmit Coxiella infections and so these estimates may not be solely due to airborne transmission [61], [63].

<sup>20</sup> A notable exception is focused vaccine safety studies which perform population-based assessments of background prevalence of rare diseases as a baseline to compare against rare adverse vaccine events, e.g., [68].

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

675 estimation of the true spatial extent of an outbreak and (b) dose-response modeling [69]. There  
676 is also risk of undiagnosed cases and secondary disease spread.

677

### 678 **5.3. Key Infectious Agent/Disease Characteristics**

679 Only select infectious agents can transmit disease via inhalation of a single particle, particularly  
680 over longer (>5 m) distances. Based on **Equation 2**, the key infectious agent/disease  
681 characteristics that determine the likelihood of airborne transmission are (a) the number of  
682 infectious particles emitted, (b) the degree of infectivity of individual particles, and (c) the loss  
683 of particle infectivity while airborne. **Table 3** summarizes these characteristics.

684

**Table 3. Summary of Factors Relevant to Single Particle Airborne Disease Transmission**

---

The number of infectious airborne particles emitted must be comparable to, or larger than, the number required to expose a downwind individual.

A single particle must carry sufficient infectious material to cause disease when inhaled.

Airborne transport must occur rapidly enough so that enough infectious particles are present downwind. This can happen in one of two ways.

- (1) Airborne infectivity losses could be negligible.
- (2) Infectious particles are transported fast enough so that airborne losses are limited.

685

#### 686 **5.3.1. Number of Infectious Particles Emitted: [*Total Particles Released*]**

687 With respect to Case 2 ( $R_0 > 1$ ) human diseases, human-origin particles can comprise a  
688 significant fraction of indoor airborne particles, e.g., [70], [71], and ill individuals are known to  
689 emit infectious particles through coughing, sneezing, breathing, and/or shedding of infected  
690 skin or mucosal cells [71]–[74]. While it is challenging to develop reliable estimates of the  
691 number of infectious particles emitted by an ill individual, working estimates of total human  
692 respirable (1 to 5  $\mu\text{m}$  AD) particle emissions are available from published studies. For context,  
693 up to  $10^6$  airborne particles can be emitted per sneeze (although there is some debate on the  
694 fraction of these particles that are respirable) [75], [76];  $10^3$  to  $10^5$  respirable diameter particles  
695 are emitted both in a cough and for short (15 to 30 minute) periods of breathing and talking  
696 [33], [73], [77]–[80]; and  $10^7$  skin cells are shed per day (of which a fraction become airborne  
697 respirable particles) [53], [81]. We note that sick individuals may emit more particles than  
698 healthy individuals and some individuals can emit an order of magnitude or more particles than

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

699 the average person, e.g., super-spreaders [77], [82]. For context, we estimate  $10^4$  to  $10^6$   
700 environmentally stable infectious particles emitted indoors are required to infect one  
701 downwind person in an urban area ( $0.01 \text{ people m}^{-2}$ ).<sup>21</sup>

702

### 703 **5.3.2. Single Particle Infectivity: [Single Particle Infection Probability]**

704 Individual particles need to carry enough infectious material to cause disease. For some  
705 disease-causing infectious agents, this is a given as they possess a very low infectious inhalation  
706 dose. One example is *Coxiella burnetii*, which causes Q Fever, where a single bacterium can  
707 potentially cause infection in humans [15], [83].<sup>22</sup> For other infectious agents, multiple  
708 individual agents are required for infection. Theoretically, the required number of infectious  
709 agents may be transported on the surface of, or within, larger carrier particles.<sup>23</sup> From physical  
710 considerations alone, approximately 100  $1 \mu\text{m AD}$  infectious agents (a common bacteria size)  
711 could fit within a single  $5 \mu\text{m AD}$  particle.<sup>24</sup> For smaller agents, such as viruses, the number of  
712 agents in a carrier particle could be much larger.

713

714

---

<sup>21</sup> **Figure 5a** suggests that the outdoor release of  $10^3$  to  $10^5$  particles would infect a downwind outdoor individual. A factor of 10x reduction is added to account for both (a) the fraction of particles released indoors that exit the building and enter the outdoor atmosphere and (b) protection that downwind buildings protect their occupancy, see **Supplemental Material G: Infection Estimates**.

<sup>22</sup> The dose required to infect 50% of the human subjects is 1.18 bacteria (95% CI: 0.76 to 40.2).

<sup>23</sup> Bacteria have the capacity to bind to a wide variety of surfaces and particles and depending on the vehicle, multiple bacteria can become airborne, including on the surface of human skin cells, e.g., [84]. Furthermore, viruses and bacteria such as Tuberculosis, *Coxiella burnetii*, *Legionella Pneumophila*, *Chlamydia pneumoniae* and others are intracellular pathogens, i.e., they infect host hosts by penetrating within cells where they reside and multiply [85]. Thus, there is the potential for multiple pathogens to be present in a single particle when the infected cells are exhaled (or exfoliated) as airborne particles [86]. We are unaware of a field experiment demonstrating multiple infectious agents present on a single airborne particle, no doubt due to the technical challenges involved [87]. However, this characteristic has been demonstrated in the laboratory, e.g., [88].

<sup>24</sup> (1) This 0<sup>th</sup> order estimate is based on volume considerations and assumes a spherical geometry. (2) the number of agents actually present in a particle will also depend on other factors and can be much smaller.



#### 715 **5.3.4. Loss of Particle Infectivity While Airborne: Affects [Normalized TSIAC]**

716 Some infectious agents – including important human pathogens and economically important  
717 plant disease pathogens – are environmentally hardy and are known to readily transmit disease  
718 over long distances - causing significant disease outbreaks [57], [89]–[95]. However, other  
719 agents, including many human and veterinary pathogens, are more fragile and their potential  
720 for long-distance airborne disease transmission is more controversial. For some of these  
721 pathogens, the rate at which infectivity is lost in the atmosphere can be high and depends, in  
722 part, on the specific virus or microorganism and strain, microbial state (e.g., vegetative cell vs.  
723 spore), environmental conditions (e.g., temperature, humidity, insolation), and particle  
724 composition [96]–[98]. For context, reported airborne loss rates for a collection of pathogens  
725 (Category A select agents) range from undetectable to up to about  $5 \text{ h}^{-1}$  when expressed as a  
726 first order (base e) loss rate [98]. Observed loss rates are not always first order, as it is common  
727 to observe an initial “die-off” followed by a slower loss rate for a relatively hardy  
728 subpopulation, and so an alternate metric is also informative. These same studies reported that  
729 time required for 90% of the original material to be lost is at least 15 min [98].

730 The mere existence of notable atmospheric infectivity loss rates may not, in and of itself,  
731 prevent agents from transmitting disease via the atmosphere. Indeed, many of the examples  
732 provided in the medium and long range subsections of the **Supplemental Material A: Airborne  
733 Disease Transmission Literature Review** are known to have significant airborne loss rates.  
734 However, our modeling results indicate that even when infectivity is lost rapidly,  $10 \text{ h}^{-1}$ ,  
735 infection probabilities are minimally impacted several hundred meters downwind, see **Figure  
736 7b**. Longer distance airborne transmission of infectious agents with notable atmospheric loss  
737 rates is also facilitated by the following:

738 First, environmental conditions (e.g., insolation, temperature and humidity) are not  
739 fixed and so airborne disease transmission may simply be limited to when conditions are  
740 favorable for agent atmospheric survival. As one example, viruses or microorganisms  
741 that are sensitive to solar (UV) radiation would not be affected at night.<sup>25</sup> Similarly, UV  
742 exposure varies significantly by latitude, season, time of day, cloud cover, air pollution,  
743 airborne dust, indoors vs. outdoors, etc. . Similar considerations hold true for other  
744 common environmental variables including humidity and temperature.

---

<sup>25</sup> Also, bacteria have the ability to repair injuries induced by environmental damage. With regard to UV radiation, [99] reviews the effects of UV on viruses and makes the point that much of the existing published literature relates to the more potent UV (UV-C) radiation spectrum used in commercial UV germicidal irradiation devices. As UV-C does not reach the earth’s surface; natural ground-level solar UV wavelengths fall in the less viricidal UV-A and B spectrum above 290 nm.



745 Second, even if there is a significant airborne infectivity loss rate, disease transmission  
746 might occur if the outdoor atmospheric transport is rapid relative to the loss rate. For  
747 many common weather conditions, downwind transport of airborne particles may  
748 indeed be rapid - with kilometer scale transport occurring in 15 minutes or less.<sup>26</sup>  
749 When airborne infectivity loss rates are significant, infection rates are predicted to be  
750 higher at higher wind speeds, see **Figure 6**. For context when airborne infectivity loss  
751 rates are negligible, infection rates are predicted to be higher during the night (stable  
752 atmospheric conditions) and at lower wind speeds, see **Figure 5**.

---

<sup>26</sup> As an illustrative example, moderate winds,  $4.5 \text{ m s}^{-1}$ , would transport an outdoor airborne particle 1 km downwind in about 4 min. This example is intended for illustrative purposes as it does not consider the effects of atmospheric turbulence (e.g., plume dispersion) nor the known increase of wind speed with height above the earth's surface. Furthermore, this calculation focuses on outdoor emissions and exposures. Particles emitted indoors will take time to move outdoors and, similarly, outdoor particles will take additional time to travel indoors to expose indoor people.

#### 753 **5.4. Potential Future Efforts**

754 This paper develops new theory for airborne disease transmission; models potential physical  
755 exposures; provides a selective literature review of airborne disease transmission; and provides  
756 an initial model comparison to published epidemiological data of the predicted relative  
757 infection/disease prevalence as a function of downwind distance for a single source region.  
758 However, the key variables and modeling parameters presented here are necessarily general  
759 and/or limited to archetypical cases.

760 More detailed analyses could provide more accurate predictions for specific scenarios and –  
761 coupled with laboratory, epidemiological, and/or field measurements – could also be used to  
762 validate the work presented in this paper. These detailed analyses could consider:

- 763 (a) specific agents, particle properties, environmental conditions, and population  
764 demographics;<sup>27</sup>
- 765 (b) mobile populations;
- 766 (c) particle distributions (including sizes greater than 5  $\mu\text{m}$  AD);
- 767 (d) improved exposure modeling particularly for (i) outdoor exposures < 50 m and > 20 km  
768 from the source and (ii) indoor exposures where which the indoor air is not well mixed,  
769 e.g., < few meters from the source; and
- 770 (e) other disease transmission pathways, such as droplets, fomites, and direct/indirect  
771 contact including the case in which outdoor airborne particles travel indoors, deposit on  
772 indoor surfaces, and pose an on-going contact or resuspension hazard.

773 We note that special, at-risk, populations, such as (a) children < 5 years of age, (b) the elderly,  
774 or (c) immune compromised persons, may have higher infection disease risks relative to the  
775 general population, e.g., the examples of influenza risks or Aspergillus infections in immune  
776 compromised people.

777 After appropriate scientific peer review and validation, applications of this research may help  
778 enhance airborne disease outbreak management and chronically occurring airborne exposure  
779 management. Potential future research areas are briefly highlighted here, although we note  
780 that such work should be conducted with due consideration of (a) the potential impact on, or  
781 interaction with, other disease transmission pathways<sup>28</sup> and (b) other factors, such as food,

---

<sup>27</sup> We note that the effects of known variations in the building stock, population demographic distributions, and daily population mobility patterns could be assessed prior to the outbreak event and used to in real time to provide higher fidelity quantitative results [30], [31].

<sup>28</sup> Many viruses and microorganisms are opportunistic and so may have multiple, simultaneous disease transmission pathways.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

782 water, medical needs, resource limitations, communication capabilities, expected population  
783 compliance, and impending hazards (e.g. fire).

784 The theory developed here could inform future updates to remediation clearance and  
785 biosafety criteria, i.e., how clean is clean enough. As one example, the interim B.  
786 anthracis clearance strategy suggests a best-practice clearance goal of no detectable  
787 viable spores on any environmental sample [100]. This goal was selected, in part,  
788 because the dose (exposure) response (infectivity or disease) relationship for B.  
789 anthracis is not sufficiently understood to adequately assess disease risk. The theory  
790 presented in this paper, coupled with estimates of how much surface contamination  
791 could become airborne, could bound the downwind risk – even in the absence of any  
792 data on a dose-response relationship.

793 Suspectable populations could be protected when high-risk environmental conditions  
794 are forecasted [101]–[103]. This response paradigm is in common use for other airborne  
795 hazards where evacuation<sup>29</sup> and shelter (see next paragraph) are routinely used  
796 protective actions [31].

797 Sheltering has the potential to reduce airborne disease spread, both within a single  
798 building as well as further downwind. Sheltering actions may include changes to  
799 population locations (e.g., shelter in place) as well as changes to building stock and  
800 operations (e.g., weatherization programs to reduce indoor/outdoor air change rates;  
801 improved particulate filtration). The use of mass (“cleaner-air”) shelters, such as those  
802 currently used to reduce population level outdoor wildfire smoke (air quality)  
803 exposures, should be carefully considered in infectious disease settings as some  
804 diseases can rapidly spread when many people are in close quarters.

805

---

<sup>29</sup> The airborne infection probability is predicted to be directly proportional to population density and so reducing the number of people at risk in high density regions, such as through zoning changes or preventative evacuation, could reduce the overall disease spread rate.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

## 806 **6. Acknowledgements**

807 The authors are grateful to their family for their support and enduring patience. The authors  
808 also thank Ron Baskett and John Nasstrom of the Lawrence Livermore National Laboratory for  
809 their considerable assistance in developing the Supplemental Material B: Key Atmospheric  
810 Transport and Dispersion Modeling Concepts section. Furthermore, the authors acknowledge  
811 the assistance of Brooke Buddemeier, Steve Homann, Brenda Pobanz, Ellen Raber, Antoun  
812 Tarabay, and Ken Turteltaub of the Lawrence Livermore National Laboratory; Richard Sextro of  
813 Lawrence Berkeley National Laboratory; David Brown of Argonne National Laboratory; Dev Jani  
814 of the US Department of Homeland Security, Countering Weapons of Mass Destruction Office;  
815 Frederick Miller of the National Institute of Health; William Rhodes of Mele Associates, Inc.;  
816 Benjamin Arnold of the University of California, San Francisco; Joseph Chang of the RAND  
817 Corporation; Michael Mastrangelo of the University of Texas Medical Branch; and Mark Nicas  
818 of the University of California, Berkeley during the development of this manuscript. Financial  
819 support was provided by the US Department of Homeland Security for related early efforts and  
820 the Lawrence Livermore National Laboratory for facilitating the review of this material. Finally,  
821 the authors would like to thank Freepik for the icons, designed by Freepik from Flaticon  
822 ([www.flaticon.com](http://www.flaticon.com)), used, in part, in the development of Figures 1 and D1.

823 This document was prepared as an account of work sponsored by an agency of the United  
824 States government. Neither the United States government nor Lawrence Livermore National  
825 Security, LLC, nor any of their employees makes any warranty, expressed or implied, or assumes  
826 any legal liability or responsibility for the accuracy, completeness, or usefulness of any  
827 information, apparatus, product, or process disclosed, or represents that its use would not  
828 infringe privately owned rights. Reference herein to any specific commercial product, process,  
829 or service by trade name, trademark, manufacturer, or otherwise does not necessarily  
830 constitute or imply its endorsement, recommendation, or favoring by the United States  
831 government or Lawrence Livermore National Security, LLC. The views and opinions of authors  
832 expressed herein do not necessarily state or reflect those of the United States government or  
833 Lawrence Livermore National Security, LLC, and shall not be used for advertising or product  
834 endorsement purposes.

835 Lawrence Livermore National Laboratory is operated by Lawrence Livermore National Security,  
836 LLC, for the U.S. Department of Energy, National Nuclear Security Administration under  
837 Contract DE-AC52-07NA27344.

838

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

## 839 **7. Attestations**

840

### 841 **Ethics statement**

842 No humans or animals were used this in work

843

### 844 **Data accessibility**

845 No primary data were used in this analysis. The referenced supplemental materials have been  
846 provided.

847

### 848 **Competing interests**

849 The authors have no competing interests for the material provided in this manuscript beyond  
850 (a) being and/or previously employed at our respective organizations and (b) receiving funding  
851 from the acknowledged sources.

852

### 853 **Author's contributions**

854

855 Michael Dillon (MBD) was responsible for the study concept and design, theory development,  
856 modeling, and data analysis.

857

858 Charles Dillon (CFD) was responsible for the epidemiologic content (including identification of  
859 previously reported outbreak data) and, jointly with MBD, developed the Supplemental  
860 Material A: Airborne Disease Transmission Literature Review Discussion and Supplemental  
861 Material H: U.S. Coxiella burnetti Infection and Disease Estimates sections.

862

863 Ron Baskett (RB) and MBD developed the Supplemental Material B: Key Atmospheric Transport  
864 and Dispersion Modeling Concepts (i.e., RB was a co-author on this section). John Nasstrom  
865 provided significant feedback and suggestions.

866

867 MBD and CFD both participated in literature searches, manuscript drafting, and revision  
868 through its many versions.

869

870 All authors give approval for release.

871

### 872 **Funding statement**

873

874 MBD was supported, in part, by the US Department of Homeland Security for early efforts.

875

876 CFD was self-supported.

877 **8. References**

- 878 [1] R. L. Riley *et al.*, “Aerial dissemination of pulmonary tuberculosis. A two-year study of  
879 contagion in a tuberculosis ward. 1959,” *Am. J. Epidemiol.*, vol. 142, no. 1, pp. 3–14, Jul.  
880 1995.
- 881 [2] A. D. Langmuir, “Airborne Infection: How Important for Public Health?: I. A Historical  
882 Review,” *Am. J. Public Health Nations Health*, vol. 54, no. 10, pp. 1666–1668, Oct. 1964,  
883 doi: 10.2105/AJPH.54.10.1666.
- 884 [3] W. F. Wells, *Airborne Contagion and Air Hygiene: An Ecological Study of Droplet Infections*.  
885 Cambridge, Massachusetts: Harvard University Press, 1955.
- 886 [4] C. Troeger *et al.*, “Estimates of the global, regional, and national morbidity, mortality, and  
887 aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic  
888 analysis for the Global Burden of Disease Study 2016,” *Lancet Infect. Dis.*, vol. 18, no. 11,  
889 pp. 1191–1210, Nov. 2018, doi: 10.1016/S1473-3099(18)30310-4.
- 890 [5] “The top 10 causes of death.” [https://www.who.int/news-room/fact-sheets/detail/the-](https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death)  
891 [top-10-causes-of-death](https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death) (accessed Jan. 23, 2020).
- 892 [6] B. Killingley and J. Nguyen-Van-Tam, “Routes of influenza transmission,” *Influenza Other*  
893 *Respir. Viruses*, vol. 7, pp. 42–51, Sep. 2013, doi: 10.1111/irv.12080.
- 894 [7] J. S. Kutter, M. I. Spronken, P. L. Fraaij, R. A. Fouchier, and S. Herfst, “Transmission routes  
895 of respiratory viruses among humans,” *Curr. Opin. Virol.*, vol. 28, pp. 142–151, Feb. 2018,  
896 doi: 10.1016/j.coviro.2018.01.001.
- 897 [8] J. P. G. Van Leuken, A. N. Swart, A. H. Havelaar, A. Van Pul, W. Van der Hoek, and D.  
898 Heederik, “Atmospheric dispersion modelling of bioaerosols that are pathogenic to  
899 humans and livestock – A review to inform risk assessment studies,” *Microb. Risk Anal.*,  
900 vol. 1, pp. 19–39, Jan. 2016, doi: 10.1016/j.mran.2015.07.002.
- 901 [9] R. E. Britter, “Atmospheric dispersion of dense gases,” *Annu. Rev. Fluid Mech.*, vol. 21, no.  
902 1, pp. 317–344, 1989.
- 903 [10] US Environmental Protection Agency, Office of Air Quality Planning and Standards,  
904 “Quality Assurance Handbook for Air Pollution Measurement Systems Volume IV  
905 Meteorological Measurements, Version 2.0 (Final),” US Environmental Protection Agency,  
906 Research Triangle Park, NC, EPA-454-B-08-002, Mar. 2008.
- 907 [11] US National Weather Service, “Automated Surface Observing System (ASOS) User’s  
908 Guide,” US National Oceanic and Atmospheric Administration, US Department of Defense,  
909 US Federal Aviation Administration, and US Navy, Silver Spring, MD, Mar. 1998. [Online].  
910 Available: <https://www.weather.gov/media/asos/aum-toc.pdf>.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

- 911 [12] US Department of Energy, “Environmental Radiological Effluent Monitoring and  
912 Environmental Surveillance,” US Department of Energy, Washington DC, DOE Handbook,  
913 DOE-HDBK- -2015 1216. [Online]. Available: [https://www.id.energy.gov/ESER/DOC/DOE-](https://www.id.energy.gov/ESER/DOC/DOE-HDBK-1216-2015v2.pdf)  
914 HDBK-1216-2015v2.pdf.
- 915 [13] World Meteorological Organization, *Guide to meteorological instruments and methods of*  
916 *observation*. Geneva, Switzerland: World Meteorological Organization, 2008.
- 917 [14] US Nuclear Regulatory Commission, “Regulatory Guide 1.23 - Meteorological Monitoring  
918 Programs for Nuclear Power Plants (Revision 1),” US Nuclear Regulatory Commission,  
919 Office of Nuclear Regulatory Research, Washington DC, Mar. 2007. [Online]. Available:  
920 <https://www.nrc.gov/docs/ML0703/ML070350028.pdf>.
- 921 [15] R. J. Brooke, M. E. Kretzschmar, N. T. Mutters, and P. F. Teunis, “Human dose response  
922 relation for airborne exposure to *Coxiella burnetii*,” *BMC Infect. Dis.*, vol. 13, no. 1, p. 488,  
923 2013, doi: 10.1186/1471-2334-13-488.
- 924 [16] D. J. A. Toth *et al.*, “Quantitative Models of the Dose-Response and Time Course of  
925 Inhalational Anthrax in Humans,” *PLoS Pathog.*, vol. 9, no. 8, p. e1003555, Aug. 2013, doi:  
926 10.1371/journal.ppat.1003555.
- 927 [17] R. Hardy, K. Schilling, J. Fromm, X. Dai, and M. Cook, “Technical Background Document:  
928 Microbial Risk Assessment and Fate and Transport Modeling of Aerosolized  
929 Microorganisms at Wastewater Land Application Facilities in Idaho,” Idaho Department of  
930 Environmental Quality, Feb. 2006. [Online]. Available:  
931 [https://www.deq.idaho.gov/media/529643-microbial\\_risk\\_assessment.pdf](https://www.deq.idaho.gov/media/529643-microbial_risk_assessment.pdf).
- 932 [18] V. Nilsen and J. Wyller, “QMRA for Drinking Water: 1. Revisiting the Mathematical  
933 Structure of Single-Hit Dose-Response Models: QMRA: Structure of Single-Hit Dose-  
934 Response Models,” *Risk Anal.*, vol. 36, no. 1, pp. 145–162, Jan. 2016, doi:  
935 10.1111/risa.12389.
- 936 [19] C. N. Haas, “Conditional Dose-Response Relationships for Microorganisms: Development  
937 and Application,” *Risk Anal.*, vol. 22, no. 3, pp. 455–463, Jun. 2002, doi: 10.1111/0272-  
938 4332.00035.
- 939 [20] P. F. M. Teunis *et al.*, “Norwalk virus: How infectious is it?,” *J. Med. Virol.*, vol. 80, no. 8,  
940 pp. 1468–1476, Aug. 2008, doi: 10.1002/jmv.21237.
- 941 [21] N. Van Abel, M. E. Schoen, J. C. Kissel, and J. S. Meschke, “Comparison of Risk Predicted by  
942 Multiple Norovirus Dose-Response Models and Implications for Quantitative Microbial  
943 Risk Assessment: Comparison of Risk Predicted by Multiple Norovirus Dose-Response  
944 Models,” *Risk Anal.*, Jun. 2016, doi: 10.1111/risa.12616.
- 945 [22] N. E. Klepeis *et al.*, “The National Human Activity Pattern Survey (NHAPS): a resource for  
946 assessing exposure to environmental pollutants,” *J. Expo. Anal. Environ. Epidemiol.*, vol.  
947 11, no. 3, pp. 231–252, Jun. 2001, doi: 10.1038/sj.jea.7500165.



M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

- 948 [23] K. Teschke, Y. Chow, K. Bartlett, A. Ross, and C. van Netten, "Spatial and temporal  
949 distribution of airborne *Bacillus thuringiensis* var. *kurstaki* during an aerial spray program  
950 for gypsy moth eradication," *Environ. Health Perspect.*, vol. 109, no. 1, pp. 47–54, 2001.
- 951 [24] B. G. Shelton, K. H. Kirkland, W. D. Flanders, and G. K. Morris, "Profiles of Airborne Fungi in  
952 Buildings and Outdoor Environments in the United States," *Appl. Environ. Microbiol.*, vol.  
953 68, no. 4, pp. 1743–1753, Apr. 2002, doi: 10.1128/AEM.68.4.1743-1753.2002.
- 954 [25] R.-P. Vonberg and P. Gastmeier, "Nosocomial aspergillosis in outbreak settings," *J. Hosp.*  
955 *Infect.*, vol. 63, no. 3, pp. 246–254, Jul. 2006, doi: 10.1016/j.jhin.2006.02.014.
- 956 [26] J. R. Lentino, M. A. Rosenkranz, J. A. Michaels, V. P. Kurup, H. D. Rose, and M. W. Rytel,  
957 "Nosocomial aspergillosis: a retrospective review of airborne disease secondary to road  
958 construction and contaminated air conditioners," *Am. J. Epidemiol.*, vol. 116, no. 3, pp.  
959 430–437, Sep. 1982.
- 960 [27] J. P. Luby, P. M. Southern, C. E. Haley, K. L. Vahle, R. S. Munford, and R. W. Haley,  
961 "Recurrent exposure to *Histoplasma capsulatum* in modern air-conditioned buildings,"  
962 *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.*, vol. 41, no. 2, pp. 170–176, Jul. 2005, doi:  
963 10.1086/430907.
- 964 [28] S. Chamany *et al.*, "A large histoplasmosis outbreak among high school students in  
965 Indiana, 2001," *Pediatr. Infect. Dis. J.*, vol. 23, no. 10, pp. 909–914, Oct. 2004.
- 966 [29] K. Benedict and R. K. Mody, "Epidemiology of Histoplasmosis Outbreaks, United States,  
967 1938–2013," *Emerg. Infect. Dis.*, vol. 22, no. 3, Mar. 2016, doi: 10.3201/eid2203.151117.
- 968 [30] M. B. Dillon, R. G. Sextro, and W. W. Delp, "Regional Shelter Analysis - Inhalation Exposure  
969 Application (Particles)," Lawrence Livermore National Laboratory, Livermore, CA, LLNL-TR-  
970 786237, Aug. 2019.
- 971 [31] M. B. Dillon and C. F. Dillon, "Regional Shelter Analysis - Inhalation Exposure  
972 Methodology," Lawrence Livermore National Laboratory, Livermore, CA, LLNL-TR-786042,  
973 Aug. 2019.
- 974 [32] Z. T. Ai and A. K. Melikov, "Airborne spread of expiratory droplet nuclei between the  
975 occupants of indoor environments: A review," *Indoor Air*, vol. 28, no. 4, pp. 500–524, Jul.  
976 2018, doi: 10.1111/ina.12465.
- 977 [33] M. Nicas, W. W. Nazaroff, and A. Hubbard, "Toward Understanding the Risk of Secondary  
978 Airborne Infection: Emission of Respirable Pathogens," *J. Occup. Environ. Hyg.*, vol. 2, no.  
979 3, pp. 143–154, Mar. 2005, doi: 10.1080/15459620590918466.
- 980 [34] W. W. Nazaroff, "Indoor bioaerosol dynamics," *Indoor Air*, vol. 26, no. 1, pp. 61–78, Feb.  
981 2016, doi: 10.1111/ina.12174.
- 982 [35] D. Rim and A. Novoselac, "Transient Simulation of Airflow and Pollutant Dispersion Under  
983 Mixing Flow and Buoyancy Driven Flow Regimes in Residential Buildings," *ASHRAE Trans.*,  
984 vol. 114, Part 2, pp. 130–142, 2008.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

- 985 [36] W. W. Nazaroff, "Indoor particle dynamics," *Indoor Air*, vol. 14, no. s7, pp. 175–183, Aug.  
986 2004, doi: 10.1111/j.1600-0668.2004.00286.x.
- 987 [37] A. Gilsdorf, C. Kroh, S. Grimm, E. Jensen, C. Wagner-Wiening, and K. Alpers, "Large Q fever  
988 outbreak due to sheep farming near residential areas, Germany, 2005," *Epidemiol. Infect.*,  
989 vol. 136, no. 08, Aug. 2008, doi: 10.1017/S0950268807009533.
- 990 [38] A. Petroff and L. Zhang, "Development and validation of a size-resolved particle dry  
991 deposition scheme for application in aerosol transport models," *Geosci. Model Dev.*, vol. 3,  
992 no. 2, pp. 753–769, Dec. 2010, doi: 10.5194/gmd-3-753-2010.
- 993 [39] W. C. Hinds, *Aerosol technology: properties, behavior, and measurement of airborne*  
994 *particles*, 2. ed. New York: Wiley, 1999.
- 995 [40] B. Schimmer *et al.*, "The use of a geographic information system to identify a dairy goat  
996 farm as the most likely source of an urban Q-fever outbreak," *BMC Infect. Dis.*, vol. 10, no.  
997 1, p. 69, Dec. 2010, doi: 10.1186/1471-2334-10-69.
- 998 [41] J. P. van Leuken *et al.*, "Improved correlation of human Q fever incidence to modelled C.  
999 burnetii concentrations by means of an atmospheric dispersion model," *Int. J. Health*  
1000 *Geogr.*, vol. 14, no. 1, p. 14, Dec. 2015, doi: 10.1186/s12942-015-0003-y.
- 1001 [42] J. I. Hawker *et al.*, "A large outbreak of Q fever in the West Midlands: windborne spread  
1002 into a metropolitan area?," *Commun. Dis. Public Health PHLIS*, vol. 1, no. 3, pp. 180–187,  
1003 Sep. 1998.
- 1004 [43] K. Nygard *et al.*, "An Outbreak of Legionnaires Disease Caused by Long-Distance Spread  
1005 from an Industrial Air Scrubber in Sarpsborg, Norway," *Clin. Infect. Dis.*, vol. 46, no. 1, pp.  
1006 61–69, Jan. 2008, doi: 10.1086/524016.
- 1007 [44] T. M. Nhu Nguyen *et al.*, "A Community-Wide Outbreak of Legionnaires Disease Linked to  
1008 Industrial Cooling Towers—How Far Can Contaminated Aerosols Spread?," *J. Infect. Dis.*,  
1009 vol. 193, no. 1, pp. 102–111, Jan. 2006, doi: 10.1086/498575.
- 1010 [45] E. Schneider, "A Coccidioidomycosis Outbreak Following the Northridge, Calif,  
1011 Earthquake," *JAMA J. Am. Med. Assoc.*, vol. 277, no. 11, p. 904, Mar. 1997, doi:  
1012 10.1001/jama.1997.03540350054033.
- 1013 [46] R. W. Jibson, "A Public Health Issue Related to Collateral Seismic Hazards: The Valley Fever  
1014 Outbreak Triggered by the 1994 Northridge, California Earthquake," *Surv. Geophys.*, vol.  
1015 23, pp. 511–528, 2002.
- 1016 [47] G. J. Boender *et al.*, "Risk Maps for the Spread of Highly Pathogenic Avian Influenza in  
1017 Poultry," *PLoS Comput. Biol.*, vol. 3, no. 4, p. e71, 2007, doi: 10.1371/journal.pcbi.0030071.
- 1018 [48] P. J. Bonney *et al.*, "Spatial transmission of H5N2 highly pathogenic avian influenza  
1019 between Minnesota poultry premises during the 2015 outbreak," *PLOS ONE*, vol. 13, no. 9,  
1020 p. e0204262, Sep. 2018, doi: 10.1371/journal.pone.0204262.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

- 1021 [49] I. Dorigatti, P. Mulatti, R. Rosà, A. Pugliese, and L. Busani, “Modelling the spatial spread of  
1022 H7N1 avian influenza virus among poultry farms in Italy,” *Epidemics*, vol. 2, no. 1, pp. 29–  
1023 35, Mar. 2010, doi: 10.1016/j.epidem.2010.01.002.
- 1024 [50] Y. Hayama, T. Yamamoto, S. Kobayashi, N. Muroga, and T. Tsutsui, “Mathematical model  
1025 of the 2010 foot-and-mouth disease epidemic in Japan and evaluation of control  
1026 measures,” *Prev. Vet. Med.*, vol. 112, no. 3–4, pp. 183–193, Nov. 2013, doi:  
1027 10.1016/j.prevetmed.2013.08.010.
- 1028 [51] I. Chis Ster and N. M. Ferguson, “Transmission Parameters of the 2001 Foot and Mouth  
1029 Epidemic in Great Britain,” *PLoS ONE*, vol. 2, no. 6, p. e502, Jun. 2007, doi:  
1030 10.1371/journal.pone.0000502.
- 1031 [52] J. A. Backer, T. J. Hagenaars, H. J. W. van Roermund, and M. C. M. de Jong, “Modelling the  
1032 effectiveness and risks of vaccination strategies to control classical swine fever  
1033 epidemics,” *J. R. Soc. Interface*, vol. 6, no. 39, pp. 849–861, Oct. 2009, doi:  
1034 10.1098/rsif.2008.0408.
- 1035 [53] M. B. Dillon, “Skin as a potential source of infectious foot and mouth disease aerosols,”  
1036 *Proc. R. Soc. B Biol. Sci.*, vol. 278, no. 1713, pp. 1761–1769, Jun. 2011, doi:  
1037 10.1098/rspb.2010.2430.
- 1038 [54] J. K. M. Brown, “Aerial Dispersal of Pathogens on the Global and Continental Scales and Its  
1039 Impact on Plant Disease,” *Science*, vol. 297, no. 5581, pp. 537–541, Jul. 2002, doi:  
1040 10.1126/science.1072678.
- 1041 [55] D. J. Smith *et al.*, “Intercontinental Dispersal of Bacteria and Archaea by Transpacific  
1042 Winds,” *Appl. Environ. Microbiol.*, vol. 79, no. 4, pp. 1134–1139, Feb. 2013, doi:  
1043 10.1128/AEM.03029-12.
- 1044 [56] D. J. Smith *et al.*, “Free Tropospheric Transport of Microorganisms from Asia to North  
1045 America,” *Microb. Ecol.*, vol. 64, no. 4, pp. 973–985, Nov. 2012, doi: 10.1007/s00248-012-  
1046 0088-9.
- 1047 [57] M. Meyer *et al.*, “Quantifying airborne dispersal routes of pathogens over continents to  
1048 safeguard global wheat supply,” *Nat. Plants*, vol. 3, no. 10, pp. 780–786, Oct. 2017, doi:  
1049 10.1038/s41477-017-0017-5.
- 1050 [58] A. I. Donaldson and S. Alexandersen, “Predicting the spread of foot and mouth disease by  
1051 airborne virus,” *Rev. Sci. Tech. Int. Off. Epizoot.*, vol. 21, no. 3, pp. 569–575, Dec. 2002.
- 1052 [59] N. J. Clark and R. J. Soares Magalhães, “Airborne geographical dispersal of Q fever from  
1053 livestock holdings to human communities: a systematic review and critical appraisal of  
1054 evidence,” *BMC Infect. Dis.*, vol. 18, no. 1, p. 218, Dec. 2018, doi: 10.1186/s12879-018-  
1055 3135-4.
- 1056 [60] “Q Fever | Summary | NNDSS.” <https://wwwn.cdc.gov/nndss/conditions/q-fever/>  
1057 (accessed Feb. 11, 2020).

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

- 1058 [61] A. Anderson *et al.*, "Diagnosis and management of Q fever--United States, 2013:  
1059 recommendations from CDC and the Q Fever Working Group [see also Errata in MMWR  
1060 Recomm Rep 2013 62(35):730]," *MMWR Recomm. Rep. Morb. Mortal. Wkly. Rep.*  
1061 *Recomm. Rep. Cent. Dis. Control*, vol. 62, no. RR-03, pp. 1–30, Mar. 2013.
- 1062 [62] A. D. Anderson *et al.*, "Seroprevalence of Q Fever in the United States, 2003-2004," *Am. J.*  
1063 *Trop. Med. Hyg.*, vol. 81, no. 4, pp. 691–694, Oct. 2009, doi: 10.4269/ajtmh.2009.09-0168.
- 1064 [63] T. O. Berge and E. H. Lennette, "World distribution of Q fever: human, animal and  
1065 arthropod infection," *Am. J. Hyg.*, vol. 57, no. 2, pp. 125–143, Mar. 1953.
- 1066 [64] R. S. Hopkins *et al.*, "Summary of Notifiable Diseases --- United States, 2003," *Morb.*  
1067 *Mortal. Wkly. Rep.*, vol. 52, no. 54, pp. 1–85, Apr. 2005.
- 1068 [65] R. A. Jajosky *et al.*, "Summary of Notifiable Diseases --- United States, 2004," *Morb.*  
1069 *Mortal. Wkly. Rep.*, vol. 53, no. 53, pp. 1–79, Jun. 2006.
- 1070 [66] "Epidemiology and Statistics | Q Fever | CDC," Sep. 16, 2019.  
1071 <https://www.cdc.gov/qfever/stats/index.html> (accessed Feb. 06, 2020).
- 1072 [67] K. Cassell, P. Gacek, T. Rabatsky-Ehr, S. Petit, M. Cartter, and D. M. Weinberger,  
1073 "Estimating the True Burden of Legionnaires' Disease," *Am. J. Epidemiol.*, vol. 188, no. 9,  
1074 pp. 1686–1694, Sep. 2019, doi: 10.1093/aje/kwz142.
- 1075 [68] T. A. Rasmussen *et al.*, "Use of population based background rates of disease to assess  
1076 vaccine safety in childhood and mass immunisation in Denmark: nationwide population  
1077 based cohort study," *BMJ*, vol. 345, no. sep17 1, pp. e5823–e5823, Sep. 2012, doi:  
1078 10.1136/bmj.e5823.
- 1079 [69] V. H. Hackert *et al.*, "Q Fever: Evidence of a Massive Yet Undetected Cross-Border  
1080 Outbreak, With Ongoing Risk of Extra Mortality, in a Dutch-German Border Region,"  
1081 *Transbound. Emerg. Dis.*, p. tbed.13505, Feb. 2020, doi: 10.1111/tbed.13505.
- 1082 [70] J. Qian, D. Hospodsky, N. Yamamoto, W. W. Nazaroff, and J. Peccia, "Size-resolved  
1083 emission rates of airborne bacteria and fungi in an occupied classroom: Size-resolved  
1084 bioaerosol emission rates," *Indoor Air*, vol. 22, no. 4, pp. 339–351, Aug. 2012, doi:  
1085 10.1111/j.1600-0668.2012.00769.x.
- 1086 [71] D. Hospodsky *et al.*, "Human Occupancy as a Source of Indoor Airborne Bacteria," *PLoS*  
1087 *ONE*, vol. 7, no. 4, p. e34867, Apr. 2012, doi: 10.1371/journal.pone.0034867.
- 1088 [72] M. Ludlow *et al.*, "Infection of lymphoid tissues in the macaque upper respiratory tract  
1089 contributes to the emergence of transmissible measles virus," *J. Gen. Virol.*, vol. 94, no.  
1090 Pt\_9, pp. 1933–1944, Sep. 2013, doi: 10.1099/vir.0.054650-0.
- 1091 [73] J. Yan *et al.*, "Infectious virus in exhaled breath of symptomatic seasonal influenza cases  
1092 from a college community," *Proc. Natl. Acad. Sci.*, vol. 115, no. 5, pp. 1081–1086, Jan.  
1093 2018, doi: 10.1073/pnas.1716561115.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

- 1094 [74] W. G. Lindsley *et al.*, “Viable influenza A virus in airborne particles expelled during coughs  
1095 versus exhalations,” *Influenza Other Respir. Viruses*, vol. 10, no. 5, pp. 404–413, Sep. 2016,  
1096 doi: 10.1111/irv.12390.
- 1097 [75] Z. Y. Han, W. G. Weng, and Q. Y. Huang, “Characterizations of particle size distribution of  
1098 the droplets exhaled by sneeze,” *J. R. Soc. Interface*, vol. 10, no. 88, p. 20130560, Nov.  
1099 2013, doi: 10.1098/rsif.2013.0560.
- 1100 [76] J. P. Duguid, “The size and the duration of air-carriage of respiratory droplets and droplet-  
1101 nuclei,” *Epidemiol. Infect.*, vol. 44, no. 6, pp. 471–479, Sep. 1946, doi:  
1102 10.1017/S0022172400019288.
- 1103 [77] J. Lee *et al.*, “Quantity, Size Distribution, and Characteristics of Cough-generated Aerosol  
1104 Produced by Patients with an Upper Respiratory Tract Infection,” *Aerosol Air Qual. Res.*,  
1105 vol. 19, no. 4, pp. 840–853, 2019, doi: 10.4209/aaqr.2018.01.0031.
- 1106 [78] W. Yang and L. C. Marr, “Dynamics of Airborne Influenza A Viruses Indoors and  
1107 Dependence on Humidity,” *PLoS ONE*, vol. 6, no. 6, p. e21481, Jun. 2011, doi:  
1108 10.1371/journal.pone.0021481.
- 1109 [79] R. M. Jones, “Critical Review and Uncertainty Analysis of Factors Influencing Influenza  
1110 Transmission: Factors Influencing Influenza Transmission,” *Risk Anal.*, vol. 31, no. 8, pp.  
1111 1226–1242, Aug. 2011, doi: 10.1111/j.1539-6924.2011.01598.x.
- 1112 [80] S. Asadi, A. S. Wexler, C. D. Cappa, S. Barreda, N. M. Bouvier, and W. D. Ristenpart,  
1113 “Aerosol emission and superemission during human speech increase with voice loudness,”  
1114 *Sci. Rep.*, vol. 9, no. 1, p. 2348, Dec. 2019, doi: 10.1038/s41598-019-38808-z.
- 1115 [81] W. C. Noble, “Dispersal of skin microorganisms\*,” *Br. J. Dermatol.*, vol. 93, no. 4, pp. 477–  
1116 485, Oct. 1975, doi: 10.1111/j.1365-2133.1975.tb06527.x.
- 1117 [82] D. A. Edwards *et al.*, “Inhaling to mitigate exhaled bioaerosols,” *Proc. Natl. Acad. Sci.*, vol.  
1118 101, no. 50, pp. 17383–17388, Dec. 2004, doi: 10.1073/pnas.0408159101.
- 1119 [83] R. J. Brooke, N. T. Mutters, O. Péter, M. E. E. Kretzschmar, and P. F. M. Teunis, “Exposure  
1120 to low doses of *Coxiella burnetii* caused high illness attack rates: Insights from combining  
1121 human challenge and outbreak data,” *Epidemics*, vol. 11, pp. 1–6, Jun. 2015, doi:  
1122 10.1016/j.epidem.2014.12.004.
- 1123 [84] T. E. P. Kimkes and M. Heinemann, “How bacteria recognise and respond to surface  
1124 contact,” *FEMS Microbiol. Rev.*, vol. 44, no. 1, pp. 106–122, Jan. 2020, doi:  
1125 10.1093/femsre/fuz029.
- 1126 [85] M. T. Silva, “Classical labeling of bacterial pathogens according to their lifestyle in the host:  
1127 inconsistencies and alternatives,” *Front. Microbiol.*, vol. 3, p. 71, 2012, doi:  
1128 10.3389/fmicb.2012.00071.
- 1129 [86] R. P. Clark and M. L. de Calcina-Goff, “Some aspects of the airborne transmission of  
1130 infection,” *J. R. Soc. Interface*, vol. 6, no. Suppl\_6, pp. S767–S782, Dec. 2009, doi:  
1131 10.1098/rsif.2009.0236.focus.



M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

- 1132 [87] T. Šantl-Temkiv *et al.*, “Bioaerosol field measurements: Challenges and perspectives in  
1133 outdoor studies,” *Aerosol Sci. Technol.*, vol. 54, no. 5, pp. 520–546, May 2020, doi:  
1134 10.1080/02786826.2019.1676395.
- 1135 [88] B. Lighthart, B. T. Shaffer, B. Marthi, and L. M. Ganio, “Artificial wind-gust liberation of  
1136 microbial bioaerosols previously deposited on plants,” *Aerobiologia*, vol. 9, no. 2–3, pp.  
1137 189–196, Dec. 1993, doi: 10.1007/BF02066261.
- 1138 [89] S. A. Isard, S. H. Gage, P. Comtois, and J. M. Russo, “Principles of the Atmospheric Pathway  
1139 for Invasive Species Applied to Soybean Rust,” *BioScience*, vol. 55, no. 10, p. 851, 2005,  
1140 doi: 10.1641/0006-3568(2005)055[0851:POTAPF]2.0.CO;2.
- 1141 [90] S. A. Isard and S. H. Gage, *Flow of life in the atmosphere: an airscape approach to*  
1142 *understanding invasive organisms*. East Lansing: Michigan State University Press, 2001.
- 1143 [91] A. Rieux *et al.*, “Long-Distance Wind-Dispersal of Spores in a Fungal Plant Pathogen:  
1144 Estimation of Anisotropic Dispersal Kernels from an Extensive Field Experiment,” *PLoS*  
1145 *ONE*, vol. 9, no. 8, p. e103225, Aug. 2014, doi: 10.1371/journal.pone.0103225.
- 1146 [92] S. A. Isard, J. M. Russo, and A. Ariatti, “The Integrated Aerobiology Modeling System  
1147 applied to the spread of soybean rust into the Ohio River valley during September 2006,”  
1148 *Aerobiologia*, vol. 23, no. 4, pp. 271–282, Dec. 2007, doi: 10.1007/s10453-007-9073-z.
- 1149 [93] P. Skelsey, G. J. T. Kessel, A. A. M. Holtslag, A. F. Moene, and W. van der Werf, “Regional  
1150 spore dispersal as a factor in disease risk warnings for potato late blight: A proof of  
1151 concept,” *Agric. For. Meteorol.*, vol. 149, no. 3–4, pp. 419–430, Mar. 2009, doi:  
1152 10.1016/j.agrformet.2008.09.005.
- 1153 [94] M. Meyer, L. Burgin, M. C. Hort, D. P. Hodson, and C. A. Gilligan, “Large-Scale Atmospheric  
1154 Dispersal Simulations Identify Likely Airborne Incursion Routes of Wheat Stem Rust Into  
1155 Ethiopia,” *Phytopathology*, p. PHYTO-01-17-003, Aug. 2017, doi: 10.1094/PHYTO-01-17-  
1156 0035-FI.
- 1157 [95] B. A. Walther and P. W. Ewald, “Pathogen survival in the external environment and the  
1158 evolution of virulence,” *Biol. Rev.*, vol. 79, no. 4, pp. 849–869, Nov. 2004, doi:  
1159 10.1017/S1464793104006475.
- 1160 [96] W. D. Griffiths and G. A. L. DeCosemo, “The assessment of bioaerosols: A critical review,”  
1161 *J. Aerosol Sci.*, vol. 25, no. 8, pp. 1425–1458, Dec. 1994, doi: 10.1016/0021-  
1162 8502(94)90218-6.
- 1163 [97] J. W. Tang, “The effect of environmental parameters on the survival of airborne infectious  
1164 agents,” *J. R. Soc. Interface*, vol. 6, no. Suppl\_6, pp. S737–S746, Dec. 2009, doi:  
1165 10.1098/rsif.2009.0227.focus.
- 1166 [98] R. Sinclair, S. A. Boone, D. Greenberg, P. Keim, and C. P. Gerba, “Persistence of Category A  
1167 Select Agents in the Environment,” *Appl. Environ. Microbiol.*, vol. 74, no. 3, pp. 555–563,  
1168 Feb. 2008, doi: 10.1128/AEM.02167-07.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

- 1169 [99] C. D. Lytle and J.-L. Sagripanti, "Predicted Inactivation of Viruses of Relevance to  
1170 Biodefense by Solar Radiation," *J. Virol.*, vol. 79, no. 22, pp. 14244–14252, Nov. 2005, doi:  
1171 10.1128/JVI.79.22.14244-14252.2005.
- 1172 [100] US Environmental Protection Agency and Centers for Disease Control and Prevention,  
1173 "Interim Clearance Strategy for Environments Contaminated with *Bacillus anthracis*,"  
1174 Washington DC, Jul. 2012. [Online]. Available: [https://www.epa.gov/emergency-](https://www.epa.gov/emergency-response/epacdc-interim-clearance-strategy-environments-contaminated-anthrax)  
1175 [response/epacdc-interim-clearance-strategy-environments-contaminated-anthrax](https://www.epa.gov/emergency-response/epacdc-interim-clearance-strategy-environments-contaminated-anthrax).
- 1176 [101] D. Villanueva and K. Schepanski, "Investigation of atmospheric conditions fostering the  
1177 spreading of legionnaires' disease in outbreaks related to cooling towers," *Int. J.*  
1178 *Biometeorol.*, vol. 63, no. 10, pp. 1347–1356, Oct. 2019, doi: 10.1007/s00484-019-01751-  
1179 9.
- 1180 [102] A. D. Hagerman *et al.*, "Temporal and geographic distribution of weather conditions  
1181 favorable to airborne spread of foot-and-mouth disease in the coterminous United  
1182 States," *Prev. Vet. Med.*, vol. 161, pp. 41–49, Dec. 2018, doi:  
1183 10.1016/j.prevetmed.2018.10.016.
- 1184 [103] A. Russo, C. M. Gouveia, P. M. M. Soares, R. M. Cardoso, M. T. Mendes, and R. M. Trigo,  
1185 "The unprecedented 2014 Legionnaires' disease outbreak in Portugal: atmospheric driving  
1186 mechanisms," *Int. J. Biometeorol.*, vol. 62, no. 7, pp. 1167–1179, Jul. 2018, doi:  
1187 10.1007/s00484-018-1520-8.
- 1188 [104] S. M. Burrows, W. Elbert, M. G. Lawrence, and U. Pöschl, "Bacteria in the global  
1189 atmosphere – Part 1: Review and synthesis of literature data for different ecosystems,"  
1190 *Atmospheric Chem. Phys.*, vol. 9, no. 23, pp. 9263–9280, Dec. 2009, doi: 10.5194/acp-9-  
1191 9263-2009.
- 1192 [105] S. M. Burrows *et al.*, "Bacteria in the global atmosphere – Part 2: Modeling of emissions  
1193 and transport between different ecosystems," *Atmospheric Chem. Phys.*, vol. 9, no. 23, pp.  
1194 9281–9297, Dec. 2009, doi: 10.5194/acp-9-9281-2009.
- 1195 [106] V. R. Després *et al.*, "Primary biological aerosol particles in the atmosphere: a review,"  
1196 *Tellus B*, vol. 64, no. 0, Feb. 2012, doi: 10.3402/tellusb.v64i0.15598.
- 1197 [107] R. M. Bowers, A. P. Sullivan, E. K. Costello, J. L. Collett, R. Knight, and N. Fierer, "Sources  
1198 of Bacteria in Outdoor Air across Cities in the Midwestern United States," *Appl. Environ.*  
1199 *Microbiol.*, vol. 77, no. 18, pp. 6350–6356, Sep. 2011, doi: 10.1128/AEM.05498-11.
- 1200 [108] P. H. Gregory, *Microbiology of the Atmosphere*, 2nd ed. Aylesbury: Leonard Hill Books,  
1201 1973.
- 1202 [109] A. M. Jones and R. M. Harrison, "The effects of meteorological factors on atmospheric  
1203 bioaerosol concentrations—a review," *Sci. Total Environ.*, vol. 326, no. 1–3, pp. 151–180,  
1204 Jun. 2004, doi: 10.1016/j.scitotenv.2003.11.021.



M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

- 1205 [110] Pan-American Aerobiology Association, M. Muilenberg, and H. Burge, Eds., *Aerobiology:*  
1206 *proceedings of the Pan-American Aerobiology Association*. Boca Raton: Lewis Publishers,  
1207 1996.
- 1208 [111] H. Salem, S. A. Katz, and Royal Society of Chemistry (Great Britain), Eds., *Aerobiology:*  
1209 *the toxicology of airborne pathogens and toxins*. Cambridge: Royal Society of Chemistry,  
1210 2016.
- 1211 [112] N. I. Stilianakis and Y. Drossinos, “Dynamics of infectious disease transmission by  
1212 inhalable respiratory droplets,” *J. R. Soc. Interface*, vol. 7, no. 50, pp. 1355–1366, Sep.  
1213 2010, doi: 10.1098/rsif.2010.0026.
- 1214 [113] J. W. Tang, P. Wilson, N. Shetty, and C. J. Noakes, “Aerosol-Transmitted Infections—a  
1215 New Consideration for Public Health and Infection Control Teams,” *Curr. Treat. Options*  
1216 *Infect. Dis.*, vol. 7, no. 3, pp. 176–201, Sep. 2015, doi: 10.1007/s40506-015-0057-1.
- 1217 [114] U.S. Centers for Disease Control and Prevention, “Meningococcal Disease,” in *The Pink*  
1218 *Book: Course Textbook - Epidemiology and Prevention of Vaccine-Preventable Diseases*,  
1219 13th ed., J. Hamborsky, A. Kroger, and S. Wolfe, Eds. Washington DC: Public Health  
1220 Foundation, 2015.
- 1221 [115] J. M. McLaughlin, F. L. Khan, E. A. Thoburn, R. E. Isturiz, and D. L. Swerdlow, “Rates of  
1222 hospitalization for community-acquired pneumonia among US adults: A systematic  
1223 review,” *Vaccine*, vol. 38, no. 4, pp. 741–751, Jan. 2020, doi:  
1224 10.1016/j.vaccine.2019.10.101.
- 1225 [116] Y. Li *et al.*, “Role of ventilation in airborne transmission of infectious agents in the built  
1226 environment - a multidisciplinary systematic review,” *Indoor Air*, vol. 17, no. 1, pp. 2–18,  
1227 Feb. 2007, doi: 10.1111/j.1600-0668.2006.00445.x.
- 1228 [117] I. Eames, J. W. Tang, Y. Li, and P. Wilson, “Airborne transmission of disease in hospitals,”  
1229 *J. R. Soc. Interface*, vol. 6, no. Suppl\_6, pp. S697–S702, Dec. 2009, doi:  
1230 10.1098/rsif.2009.0407.focus.
- 1231 [118] W. Kowalski, *Hospital Airborne Infection Control*. Boca Raton: CRC Press, 2011.
- 1232 [119] J. Alzona, B. L. Cohen, H. Rudolph, H. N. Jow, and J. O. Frohlinger, “Indoor-outdoor  
1233 relationships for airborne particulate matter of outdoor origin,” *Atmospheric Environ.*  
1234 *1967*, vol. 13, no. 1, pp. 55–60, Jan. 1979, doi: 10.1016/0004-6981(79)90244-0.
- 1235 [120] A. G. Arruda *et al.*, “Aerosol Detection and Transmission of Porcine Reproductive and  
1236 Respiratory Syndrome Virus (PRRSV): What Is the Evidence, and What Are the Knowledge  
1237 Gaps?,” *Viruses*, vol. 11, no. 8, p. 712, Aug. 2019, doi: 10.3390/v11080712.
- 1238 [121] B. W. Mitchell and D. J. King, “Effect of negative air ionization on airborne transmission  
1239 of Newcastle disease virus,” *Avian Dis.*, vol. 38, no. 4, pp. 725–732, Dec. 1994.
- 1240 [122] H. Hakim *et al.*, “Aerosol Disinfection Capacity of Slightly Acidic Hypochlorous Acid  
1241 Water Towards Newcastle Disease Virus in the Air: An In Vivo Experiment,” *Avian Dis.*, vol.  
1242 59, no. 4, pp. 486–491, Dec. 2015, doi: 10.1637/11107-042115-Reg.1.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

- 1243 [123] S. Dee, S. Otake, and J. Deen, "Use of a production region model to assess the efficacy of  
1244 various air filtration systems for preventing airborne transmission of porcine reproductive  
1245 and respiratory syndrome virus and *Mycoplasma hyopneumoniae*: Results from a 2-year  
1246 study," *Virus Res.*, vol. 154, no. 1–2, pp. 177–184, Dec. 2010, doi:  
1247 10.1016/j.virusres.2010.07.022.
- 1248 [124] D. D. Ferguson, T. C. Smith, K. J. Donham, and S. J. Hoff, "The Efficiency of Biofilters at  
1249 Mitigating Airborne MRSA from a Swine Nursery," *J. Agric. Saf. Health*, vol. 21, no. 4, pp.  
1250 217–227, Oct. 2015, doi: 10.13031/jash.21.10716.
- 1251 [125] P. J. Hitchcock *et al.*, "Improving performance of HVAC systems to reduce exposure to  
1252 aerosolized infectious agents in buildings; recommendations to reduce risks posed by  
1253 biological attacks," *Biosecurity Bioterrorism Biodefense Strategy Pract. Sci.*, vol. 4, no. 1,  
1254 pp. 41–54, 2006, doi: 10.1089/bsp.2006.4.41.
- 1255 [126] P. V. Nielsen, "Control of airborne infectious diseases in ventilated spaces," *J. R. Soc.*  
1256 *Interface*, vol. 6, no. suppl\_6, Dec. 2009, doi: 10.1098/rsif.2009.0228.focus.
- 1257 [127] F. Memarzadeh, R. N. Olmsted, and J. M. Bartley, "Applications of ultraviolet germicidal  
1258 irradiation disinfection in health care facilities: Effective adjunct, but not stand-alone  
1259 technology," *Am. J. Infect. Control*, vol. 38, no. 5, pp. S13–S24, Jun. 2010, doi:  
1260 10.1016/j.ajic.2010.04.208.
- 1261 [128] D. J. Alexander, "Newcastle disease and other avian paramyxoviruses," *Rev. Sci. Tech.*  
1262 *Int. Off. Epizoot.*, vol. 19, no. 2, pp. 443–462, Aug. 2000.
- 1263 [129] D. J. Alexander, E. W. Aldous, and C. M. Fuller, "The long view: a selective review of 40  
1264 years of Newcastle disease research," *Avian Pathol.*, vol. 41, no. 4, pp. 329–335, Aug.  
1265 2012, doi: 10.1080/03079457.2012.697991.
- 1266 [130] D. E. Swayne, "Avian influenza vaccines and therapies for poultry," *Comp. Immunol.*  
1267 *Microbiol. Infect. Dis.*, vol. 32, no. 4, pp. 351–363, Jul. 2009, doi:  
1268 10.1016/j.cimid.2008.01.006.
- 1269 [131] M. Hugh-Jones, W. H. Allan, F. A. Dark, and G. J. Harper, "The evidence for the airborne  
1270 spread of Newcastle disease," *J. Hyg. (Lond.)*, vol. 71, no. 02, pp. 325–339, Jun. 1973, doi:  
1271 10.1017/S0022172400022786.
- 1272 [132] J. Gloster, "Analysis of two outbreaks of Newcastle disease," *Agric. Meteorol.*, vol. 28,  
1273 no. 2, pp. 177–189, Feb. 1983, doi: 10.1016/0002-1571(83)90006-7.
- 1274 [133] P. Vittoz and R. Engler, "Seed dispersal distances: a typology based on dispersal modes  
1275 and plant traits," *Bot. Helvetica*, vol. 117, no. 2, pp. 109–124, Dec. 2007, doi:  
1276 10.1007/s00035-007-0797-8.
- 1277 [134] S. J. Wright *et al.*, "Understanding strategies for seed dispersal by wind under  
1278 contrasting atmospheric conditions," *Proc. Natl. Acad. Sci.*, vol. 105, no. 49, pp. 19084–  
1279 19089, Dec. 2008, doi: 10.1073/pnas.0802697105.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

- 1280 [135] M. B. Soons, R. Nathan, and G. G. Katul, "Human Effects on Long-Distance Wind  
1281 Dispersal and Colonization by Grassland Plants," *Ecology*, vol. 85, no. 11, pp. 3069–3079,  
1282 Nov. 2004, doi: 10.1890/03-0398.
- 1283 [136] P. M. Seaverns, K. E. Sackett, D. H. Farber, and C. C. Mundt, "Consequences of Long-  
1284 Distance Dispersal for Epidemic Spread: Patterns, Scaling, and Mitigation," *Plant Dis.*, vol.  
1285 103, no. 2, pp. 177–191, Feb. 2019, doi: 10.1094/PDIS-03-18-0505-FE.
- 1286 [137] C. M. Brown *et al.*, "A community outbreak of Legionnaires' disease linked to hospital  
1287 cooling towers: an epidemiological method to calculate dose of exposure," *Int. J.*  
1288 *Epidemiol.*, vol. 28, no. 2, pp. 353–359, Apr. 1999, doi: 10.1093/ije/28.2.353.
- 1289 [138] J. Castilla *et al.*, "A large Legionnaires' disease outbreak in Pamplona, Spain: early  
1290 detection, rapid control and no case fatality," *Epidemiol. Infect.*, vol. 136, no. 06, pp. 823–  
1291 832, Jun. 2008, doi: 10.1017/S0950268807009077.
- 1292 [139] M. Sabria *et al.*, "A community outbreak of Legionnaires' disease: evidence of a cooling  
1293 tower as the source," *Clin. Microbiol. Infect.*, vol. 12, no. 7, pp. 642–647, Jul. 2006, doi:  
1294 10.1111/j.1469-0691.2006.01447.x.
- 1295 [140] C. R. Phares *et al.*, "Legionnaires' disease among residents of a long-term care facility:  
1296 The sentinel event in a community outbreak," *Am. J. Infect. Control*, vol. 35, no. 5, pp.  
1297 319–323, Jun. 2007, doi: 10.1016/j.ajic.2006.09.014.
- 1298 [141] A. García-Fulgueiras *et al.*, "Legionnaires' Disease Outbreak in Murcia, Spain," *Emerg.*  
1299 *Infect. Dis.*, vol. 9, no. 8, pp. 915–921, Aug. 2003, doi: 10.3201/eid0908.030337.
- 1300 [142] L. E. Garrison *et al.*, "Vital Signs: Deficiencies in Environmental Control Identified in  
1301 Outbreaks of Legionnaires' Disease — North America, 2000–2014," *MMWR Morb. Mortal.*  
1302 *Wkly. Rep.*, vol. 65, no. 22, pp. 576–584, Jun. 2016, doi: 10.15585/mmwr.mm6522e1.
- 1303 [143] D. Weiss *et al.*, "A Large Community Outbreak of Legionnaires' Disease Associated With  
1304 a Cooling Tower in New York City, 2015," *Public Health Rep.*, vol. 132, no. 2, pp. 241–250,  
1305 Mar. 2017, doi: 10.1177/0033354916689620.
- 1306 [144] R. Fitzhenry *et al.*, "Legionnaires' Disease Outbreaks and Cooling Towers, New York City,  
1307 New York, USA," *Emerg. Infect. Dis.*, vol. 23, no. 11, Nov. 2017, doi:  
1308 10.3201/eid2311.161584.
- 1309 [145] A. T. Chamberlain, J. D. Lehnert, and R. L. Berkelman, "The 2015 New York City  
1310 Legionnaires' Disease Outbreak: A Case Study on a History-Making Outbreak," *J. Public*  
1311 *Health Manag. Pract.*, vol. 23, no. 4, pp. 410–416, 2017, doi:  
1312 10.1097/PHH.0000000000000558.
- 1313 [146] M.-P. Brenier-Pinchart *et al.*, "Influence of internal and outdoor factors on filamentous  
1314 fungal flora in hematology wards," *Am. J. Infect. Control*, vol. 37, no. 8, pp. 631–637, Oct.  
1315 2009, doi: 10.1016/j.ajic.2009.03.013.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

- 1316 [147] C. C. Chang *et al.*, “Consensus guidelines for implementation of quality processes to  
1317 prevent invasive fungal disease and enhanced surveillance measures during hospital  
1318 building works, 2014: Quality processes in prevention of IFD,” *Intern. Med. J.*, vol. 44, no.  
1319 12b, pp. 1389–1397, Dec. 2014, doi: 10.1111/imj.12601.
- 1320 [148] J. E. Blair, Y.-H. H. Chang, Y. Ruiz, S. Duffy, B. E. Heinrich, and D. F. Lake, “Distance from  
1321 Construction Site and Risk for Coccidioidomycosis, Arizona, USA,” *Emerg. Infect. Dis.*, vol.  
1322 20, no. 9, pp. 1464–1471, Sep. 2014, doi: 10.3201/eid2009.131588.
- 1323 [149] R. S. Dungan, “Estimation of Infectious Risks in Residential Populations Exposed to  
1324 Airborne Pathogens During Center Pivot Irrigation of Dairy Wastewaters,” *Environ. Sci.  
1325 Technol.*, vol. 48, no. 9, pp. 5033–5042, May 2014, doi: 10.1021/es405693v.
- 1326 [150] R. S. Dungan, “BOARD-INVITED REVIEW: Fate and transport of bioaerosols associated  
1327 with livestock operations and manures,” *J. Anim. Sci.*, vol. 88, no. 11, pp. 3693–3706, Nov.  
1328 2010, doi: 10.2527/jas.2010-3094.
- 1329 [151] N. Wery, “Bioaerosols from composting facilities - a review,” *Front. Cell. Infect.  
1330 Microbiol.*, vol. 4, Apr. 2014, doi: 10.3389/fcimb.2014.00042.
- 1331 [152] E. D. Berry *et al.*, “Effect of Proximity to a Cattle Feedlot on Escherichia coli O157:H7  
1332 Contamination of Leafy Greens and Evaluation of the Potential for Airborne Transmission,”  
1333 *Appl. Environ. Microbiol.*, vol. 81, no. 3, pp. 1101–1110, Feb. 2015, doi:  
1334 10.1128/AEM.02998-14.
- 1335 [153] P. Douglas *et al.*, “Use of dispersion modelling for Environmental Impact Assessment of  
1336 biological air pollution from composting: Progress, problems and prospects,” *Waste  
1337 Manag.*, vol. 70, pp. 22–29, Dec. 2017, doi: 10.1016/j.wasman.2017.08.023.
- 1338 [154] P. Douglas *et al.*, “Predicting Aspergillus fumigatus exposure from composting facilities  
1339 using a dispersion model: A conditional calibration and validation,” *Int. J. Hyg. Environ.  
1340 Health*, vol. 220, no. 1, pp. 17–28, Jan. 2017, doi: 10.1016/j.ijheh.2016.09.017.
- 1341 [155] Y. Li, H. Zhang, X. Qiu, Y. Zhang, and H. Wang, “Dispersion and Risk Assessment of  
1342 Bacterial Aerosols Emitted from Rotating-Brush Aerator during Summer in a Wastewater  
1343 Treatment Plant of Xi’an, China,” *Aerosol Air Qual. Res.*, vol. 13, no. 6, pp. 1807–1814,  
1344 2013, doi: 10.4209/aaqr.2012.09.0245.
- 1345 [156] M. L. Cain, B. G. Milligan, and A. E. Strand, “Long-distance seed dispersal in plant  
1346 populations,” *Am. J. Bot.*, vol. 87, no. 9, pp. 1217–1227, Sep. 2000.
- 1347 [157] R. Nathan, “Long-Distance Dispersal of Plants,” *Science*, vol. 313, no. 5788, pp. 786–788,  
1348 Aug. 2006, doi: 10.1126/science.1124975.
- 1349 [158] R. Nathan *et al.*, “Mechanistic models of seed dispersal by wind,” *Theor. Ecol.*, vol. 4, no.  
1350 2, pp. 113–132, May 2011, doi: 10.1007/s12080-011-0115-3.
- 1351 [159] D. E. Aylor, “Spread of Plant Disease on a Continental Scale: Role of Aerial Dispersal of  
1352 Pathogens,” *Ecology*, vol. 84, no. 8, pp. 1989–1997, Aug. 2003, doi: 10.1890/01-0619.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

- 1353 [160] J. Gloster *et al.*, “Airborne spread of foot-and-mouth disease – Model intercomparison,”  
1354 *Vet. J.*, vol. 183, no. 3, pp. 278–286, Mar. 2010, doi: 10.1016/j.tvjl.2008.11.011.
- 1355 [161] J. Gloster, A. Freshwater, R. F. Sellers, and S. Alexandersen, “Re-assessing the likelihood  
1356 of airborne spread of foot-and-mouth disease at the start of the 1967–1968 UK foot-and-  
1357 mouth disease epidemic,” *Epidemiol. Infect.*, vol. 133, no. 05, p. 767, Apr. 2005, doi:  
1358 10.1017/S0950268805004073.
- 1359 [162] J. Gloster, L. Burgin, A. Jones, and R. Sanson, “Atmospheric dispersion models and their  
1360 use in the assessment of disease transmission,” *Rev. Sci. Tech. Int. Off. Epizoot.*, vol. 30,  
1361 no. 2, pp. 457–465, Aug. 2011.
- 1362 [163] H. P. Spijkerboer *et al.*, “Ability of the Gaussian plume model to predict and describe  
1363 spore dispersal over a potato crop,” *Ecol. Model.*, vol. 155, no. 1, pp. 1–18, Sep. 2002, doi:  
1364 10.1016/S0304-3800(01)00475-6.
- 1365 [164] M. C. Fisher *et al.*, “Emerging fungal threats to animal, plant and ecosystem health,”  
1366 *Nature*, vol. 484, no. 7393, pp. 186–194, Apr. 2012, doi: 10.1038/nature10947.
- 1367 [165] D. E. Aylor, G. S. Taylor, and G. S. Raynor, “Long-range transport of tobacco blue mold  
1368 spores,” *Agric. Meteorol.*, vol. 27, no. 3–4, pp. 217–232, Dec. 1982, doi: 10.1016/0002-  
1369 1571(82)90007-3.
- 1370 [166] M. Blanco-Meneses, I. Carbone, and J. B. Ristaino, “Population structure and migration  
1371 of the Tobacco Blue Mold Pathogen, *Peronospora tabacina*, into North America and  
1372 Europe,” *Mol. Ecol.*, vol. 27, no. 3, pp. 737–751, Feb. 2018, doi: 10.1111/mec.14453.
- 1373 [167] V. R. Brown and S. N. Bevins, “A review of virulent Newcastle disease viruses in the  
1374 United States and the role of wild birds in viral persistence and spread,” *Vet. Res.*, vol. 48,  
1375 no. 1, p. 68, Dec. 2017, doi: 10.1186/s13567-017-0475-9.
- 1376 [168] J. Davis, M. G. Garner, and I. J. East, “Analysis of Local Spread of Equine Influenza in the  
1377 Park Ridge Region of Queensland,” *Transbound. Emerg. Dis.*, vol. 56, no. 1–2, pp. 31–38,  
1378 Mar. 2009, doi: 10.1111/j.1865-1682.2008.01060.x.
- 1379 [169] A. Ssematimba, T. J. Hagenaars, and M. C. M. de Jong, “Modelling the Wind-Borne  
1380 Spread of Highly Pathogenic Avian Influenza Virus between Farms,” *PLoS ONE*, vol. 7, no.  
1381 2, p. e31114, Feb. 2012, doi: 10.1371/journal.pone.0031114.
- 1382 [170] R. J. F. Ypma *et al.*, “Genetic Data Provide Evidence for Wind-Mediated Transmission of  
1383 Highly Pathogenic Avian Influenza,” *J. Infect. Dis.*, vol. 207, no. 5, pp. 730–735, Mar. 2013,  
1384 doi: 10.1093/infdis/jis757.
- 1385 [171] J. Gloster, “Risk of airborne spread of foot-and-mouth disease from the continent to  
1386 England,” *Vet. Rec.*, vol. 111, no. 13, pp. 290–295, Sep. 1982.
- 1387 [172] J. Gloster, R. F. Sellers, and A. I. Donaldson, “Long distance transport of foot-and-mouth  
1388 disease virus over the sea,” *Vet. Rec.*, vol. 110, no. 3, pp. 47–52, Jan. 1982.



M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

- 1389 [173] J. Gloster, R. M. Blackall, R. F. Sellers, and A. I. Donaldson, "Forecasting the airborne  
1390 spread of foot-and-mouth disease," *Vet. Rec.*, vol. 108, no. 17, pp. 370–374, Apr. 1981.
- 1391 [174] L. S. Christensen, "Analysis of the epidemiological dynamics during the 1982-1983  
1392 epidemic of foot-and-mouth disease in Denmark based on molecular high-resolution strain  
1393 identification," *J. Gen. Virol.*, vol. 86, no. 9, pp. 2577–2584, Sep. 2005, doi:  
1394 10.1099/vir.0.80878-0.
- 1395 [175] T. Mikkelsen *et al.*, "Investigation of airborne foot-and-mouth disease virus transmission  
1396 during low-wind conditions in the early phase of the UK 2001 epidemic," *Atmospheric  
1397 Chem. Phys.*, vol. 3, no. 6, pp. 2101–2110, Nov. 2003, doi: 10.5194/acp-3-2101-2003.
- 1398 [176] J. H. Sorensen, D. K. J. Mackay, C. O. Jensen, and A. I. Donaldson, "An integrated model  
1399 to predict the atmospheric spread of foot-and-mouth disease virus," *Epidemiol. Infect.*,  
1400 vol. 124, no. 3, pp. 577–590, 2000.
- 1401 [177] H. Tissot-Dupont, M.-A. Amadei, M. Nezri, and D. Raoult, "Wind in November, Q Fever in  
1402 December," *Emerg. Infect. Dis.*, vol. 10, no. 7, pp. 1264–1269, Jul. 2004, doi:  
1403 10.3201/eid1007.030724.
- 1404 [178] H. Tissot-Dupont, S. Torres, M. Nezri, and D. Raoult, "Hyperendemic focus of Q fever  
1405 related to sheep and wind," *Am. J. Epidemiol.*, vol. 150, no. 1, pp. 67–74, Jul. 1999.
- 1406 [179] G. Dupuis, J. Petite, O. Péter, and M. Vouilloz, "An Important Outbreak of Human Q  
1407 Fever in a Swiss Alpine Valley," *Int. J. Epidemiol.*, vol. 16, no. 2, pp. 282–287, 1987, doi:  
1408 10.1093/ije/16.2.282.
- 1409 [180] V. H. Hackert *et al.*, "Q Fever: Single-Point Source Outbreak With High Attack Rates and  
1410 Massive Numbers of Undetected Infections Across an Entire Region," *Clin. Infect. Dis.*, vol.  
1411 55, no. 12, pp. 1591–1599, Dec. 2012, doi: 10.1093/cid/cis734.
- 1412 [181] P. M. Schneeberger, C. Wintenberger, W. van der Hoek, and J. P. Stahl, "Q fever in the  
1413 Netherlands – 2007–2010: What we learned from the largest outbreak ever," *Médecine  
1414 Mal. Infect.*, vol. 44, no. 8, pp. 339–353, Aug. 2014, doi: 10.1016/j.medmal.2014.02.006.
- 1415 [182] W. van der Hoek *et al.*, "Q fever in the Netherlands: an update on the epidemiology and  
1416 control measures," *Euro Surveill. Bull. Eur. Sur Mal. Transm. Eur. Commun. Dis. Bull.*, vol.  
1417 15, no. 12, Mar. 2010.
- 1418 [183] A. Parr, E. A. Whitney, and R. L. Berkelman, "Legionellosis on the Rise: A Review of  
1419 Guidelines for Prevention in the United States," *J. Public Health Manag. Pract.*, vol. 21, no.  
1420 5, pp. E17–E26, 2015, doi: 10.1097/PHH.000000000000123.
- 1421 [184] P. Ulleryd *et al.*, "Legionnaires' disease from a cooling tower in a community outbreak in  
1422 Lidköping, Sweden- epidemiological, environmental and microbiological investigation  
1423 supported by meteorological modelling," *BMC Infect. Dis.*, vol. 12, no. 1, p. 313, 2012, doi:  
1424 10.1186/1471-2334-12-313.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

- 1425 [185] E. Wedege *et al.*, "Seroepidemiological Study after a Long-Distance Industrial Outbreak  
1426 of Legionnaires' Disease," *Clin. Vaccine Immunol.*, vol. 16, no. 4, pp. 528–534, Apr. 2009,  
1427 doi: 10.1128/CVI.00458-08.
- 1428 [186] C. Nguyen *et al.*, "Recent Advances in Our Understanding of the Environmental,  
1429 Epidemiological, Immunological, and Clinical Dimensions of Coccidioidomycosis," *Clin.*  
1430 *Microbiol. Rev.*, vol. 26, no. 3, pp. 505–525, Jul. 2013, doi: 10.1128/CMR.00005-13.
- 1431 [187] D. J. D'Alessio, R. H. Heeren, S. L. Hendricks, P. Ogilvie, and M. L. Furcolow, "A starling  
1432 roost as the source of urban epidemic histoplasmosis in an area of low incidence," *Am.*  
1433 *Rev. Respir. Dis.*, vol. 92, no. 5, pp. 725–731, Nov. 1965, doi: 10.1164/arrd.1965.92.5.725.
- 1434 [188] F. E. Tosh, I. L. Doto, D. J. D'Alessio, A. A. Medeiros, S. L. Hendricks, and T. D. Chin, "The  
1435 second of two epidemics of histoplasmosis resulting from work on the same starling  
1436 roost," *Am. Rev. Respir. Dis.*, vol. 94, no. 3, pp. 406–413, Sep. 1966, doi:  
1437 10.1164/arrd.1966.94.3.406.
- 1438 [189] T. F. Sellers, "An Epidemic of Erythema Multiforme and Erythema Nodosum Caused by  
1439 Histoplasmosis," *Ann. Intern. Med.*, vol. 62, no. 6, pp. 1244–1262, Jun. 1965, doi:  
1440 10.7326/0003-4819-62-6-1244.
- 1441 [190] W. F. Schlech *et al.*, "Recurrent urban histoplasmosis, Indianapolis, Indiana, 1980-1981,"  
1442 *Am. J. Epidemiol.*, vol. 118, no. 3, pp. 301–312, Sep. 1983.
- 1443 [191] D. J. Drutz, "Urban Coccidioidomycosis and Histoplasmosis: Sacramento and  
1444 Indianapolis," *N. Engl. J. Med.*, vol. 301, no. 7, pp. 381–382, Aug. 1979, doi:  
1445 10.1056/NEJM197908163010711.
- 1446 [192] L. J. Wheat, "A Large Urban Outbreak of Histoplasmosis: Clinical Features," *Ann. Intern.*  
1447 *Med.*, vol. 94, no. 3, pp. 331–337, Mar. 1981, doi: 10.7326/0003-4819-94-3-331.
- 1448 [193] A. Lauer *et al.*, "Combining Forces - The Use of Landsat TM Satellite Imagery, Soil  
1449 Parameter Information, and Multiplex PCR to Detect *Coccidioides immitis* Growth Sites in  
1450 Kern County, California," *PLoS ONE*, vol. 9, no. 11, p. e111921, Nov. 2014, doi:  
1451 10.1371/journal.pone.0111921.
- 1452 [194] W. J. Harris and P. D. Roffers, "Assessing Erosion Potential and *Coccidioides immitis*  
1453 Probability Using Existing Geologic and Soils Data," in *Digital Mapping Techniques '10—*  
1454 *Workshop Proceedings" U.S. Geological Survey Open-File Report 2012–1171*, Sacramento,  
1455 CA, 2010, [Online]. Available: <http://pubs.usgs.gov/of/2012/1171/>.
- 1456 [195] G. Thompson, J. Brown, K. Benedict, and B. Park, "Coccidioidomycosis: epidemiology,"  
1457 *Clin. Epidemiol.*, p. 185, Jun. 2013, doi: 10.2147/CLEP.S34434.
- 1458 [196] G. Sondermeyer, L. Lee, D. Gilliss, F. Tabnak, and D. Vugia, "Coccidioidomycosis-  
1459 associated Hospitalizations, California, USA, 2000–2011," *Emerg. Infect. Dis.*, vol. 19, no.  
1460 10, Oct. 2013, doi: 10.3201/eid1910.130427.



M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

- 1461 [197] D. Q. Tong, J. X. L. Wang, T. E. Gill, H. Lei, and B. Wang, "Intensified dust storm activity  
1462 and Valley fever infection in the southwestern United States: Dust and Valley Fever  
1463 Intensification," *Geophys. Res. Lett.*, vol. 44, no. 9, pp. 4304–4312, May 2017, doi:  
1464 10.1002/2017GL073524.
- 1465 [198] K. Benedict and B. J. Park, "Invasive Fungal Infections after Natural Disasters," *Emerg.*  
1466 *Infect. Dis.*, vol. 20, no. 3, pp. 349–355, Mar. 2014, doi: 10.3201/eid2003.131230.
- 1467 [199] R. W. Jibson, E. L. Harp, E. Schneider, R. A. Hajjeh, and R. A. Spiegel, "An outbreak of  
1468 coccidioidomycosis (valley fever) caused by landslides triggered by the 1994 Northridge,  
1469 California, earthquake," *Geol. Soc. Rev. Eng. Geol.*, vol. 12, pp. 53–61, 1998.
- 1470 [200] S. E. Thompson and G. G. Katul, "Implications of nonrandom seed abscission and global  
1471 stilling for migration of wind-dispersed plant species," *Glob. Change Biol.*, vol. 19, no. 6,  
1472 pp. 1720–1735, Jun. 2013, doi: 10.1111/gcb.12173.
- 1473 [201] Y. Mazar, E. Cytryn, Y. Erel, and Y. Rudich, "Effect of Dust Storms on the Atmospheric  
1474 Microbiome in the Eastern Mediterranean," *Environ. Sci. Technol.*, vol. 50, no. 8, pp. 4194–  
1475 4202, Apr. 2016, doi: 10.1021/acs.est.5b06348.
- 1476 [202] H. Behzad, K. Mineta, and T. Gojobori, "Global Ramifications of Dust and Sandstorm  
1477 Microbiota," *Genome Biol. Evol.*, vol. 10, no. 8, pp. 1970–1987, Aug. 2018, doi:  
1478 10.1093/gbe/evy134.
- 1479 [203] T. Weil *et al.*, "Legal immigrants: invasion of alien microbial communities during winter  
1480 occurring desert dust storms," *Microbiome*, vol. 5, no. 1, p. 32, Dec. 2017, doi:  
1481 10.1186/s40168-017-0249-7.
- 1482 [204] H. Peter, P. Hörtnagl, I. Reche, and R. Sommaruga, "Bacterial diversity and composition  
1483 during rain events with and without Saharan dust influence reaching a high mountain lake  
1484 in the Alps," *Environ. Microbiol. Rep.*, vol. 6, no. 6, pp. 618–624, Dec. 2014, doi:  
1485 10.1111/1758-2229.12175.
- 1486 [205] C. A. Kellogg *et al.*, "Characterization of Aerosolized Bacteria and Fungi From Desert  
1487 Dust Events in Mali, West Africa," *Aerobiologia*, vol. 20, no. 2, pp. 99–110, Jun. 2004, doi:  
1488 10.1023/B:AERO.0000032947.88335.bb.
- 1489 [206] D. W. Griffin, "Atmospheric Movement of Microorganisms in Clouds of Desert Dust and  
1490 Implications for Human Health," *Clin. Microbiol. Rev.*, vol. 20, no. 3, pp. 459–477, Jul. 2007,  
1491 doi: 10.1128/CMR.00039-06.
- 1492 [207] P. N. Polymenakou, "Atmosphere: A Source of Pathogenic or Beneficial Microbes?,"  
1493 *Atmosphere*, vol. 3, no. 4, pp. 87–102, Jan. 2012, doi: 10.3390/atmos3010087.
- 1494 [208] D. Pappagianis and H. Einstein, "Tempest from Tehachapi takes toll or Coccidioides  
1495 conveyed aloft and afar," *West. J. Med.*, vol. 129, no. 6, pp. 527–530, Dec. 1978.
- 1496 [209] J. E. Hermansen, U. Torp, and L. P. Prahm, "Studies of Transport of Live Spores of Cereal  
1497 Mildew and Rust Fungi across the North Sea," *Grana*, vol. 17, no. 1, pp. 41–46, Apr. 1978,  
1498 doi: 10.1080/00173137809428851.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

- 1499 [210] C. C. Mundt, L. D. Wallace, T. W. Allen, C. A. Hollier, R. C. Kemerait, and E. J. Sikora,  
1500 "Initial epidemic area is strongly associated with the yearly extent of soybean rust spread  
1501 in North America," *Biol. Invasions*, vol. 15, no. 7, pp. 1431–1438, Jul. 2013, doi:  
1502 10.1007/s10530-012-0381-z.
- 1503 [211] N. M. Flynn *et al.*, "An Unusual Outbreak of Windborne Coccidioidomycosis," *N. Engl. J.*  
1504 *Med.*, vol. 301, no. 7, pp. 358–361, Aug. 1979, doi: 10.1056/NEJM197908163010705.
- 1505 [212] "desertdust.jpeg (JPEG Image, 890 × 690 pixels)."  
1506 <https://geochange.er.usgs.gov/sw/impacts/geology/dust/desertdust.jpeg> (accessed Jan.  
1507 27, 2020).
- 1508 [213] P. L. Williams, D. L. Sable, P. Mendez, and L. T. Smyth, "Symptomatic Coccidioidomycosis  
1509 following a Severe Natural Dust Storm," *Chest*, vol. 76, no. 5, pp. 566–570, Nov. 1979, doi:  
1510 10.1378/chest.76.5.566.
- 1511 [214] W. A. Sprigg *et al.*, "Regional dust storm modeling for health services: The case of valley  
1512 fever," *Aeolian Res.*, vol. 14, pp. 53–73, Sep. 2014, doi: 10.1016/j.aeolia.2014.03.001.
- 1513 [215] A. De Visscher, *Air dispersion modeling: foundations and applications*. Hoboken, New  
1514 Jersey: John Wiley & Sons, Inc, 2014.
- 1515 [216] S. R. Hanna, G. A. Briggs, and R. P. Hosker, "Handbook of Atmospheric Diffusion," US  
1516 Department of Energy, Springfield, VA, DOE/TIC-11223, 1982.
- 1517 [217] *Tracking and Predicting the Atmospheric Dispersion of Hazardous Material Releases:*  
1518 *Implications for Homeland Security*. Washington, D.C.: National Academies Press, 2003.
- 1519 [218] D. Randerson, "Atmospheric science and power production," DOE/TIC-27601, 6503687,  
1520 Jul. 1984. doi: 10.2172/6503687.
- 1521 [219] S. P. Arya, *Air pollution meteorology and dispersion*. New York: Oxford University Press,  
1522 1999.
- 1523 [220] D. B. Turner, "Workbook of Atmospheric Dispersion Estimates," US Environmental  
1524 Protection Agency, Office of Air Programs, Research Triangle Park, NC, AP-26, 1970.
- 1525 [221] M. Z. Jacobson, *Fundamentals of atmospheric modeling*, 2nd ed. Cambridge, UK ; New  
1526 York: Cambridge University Press, 2005.
- 1527 [222] R. B. Stull, *An Introduction to Boundary Layer Meteorology*. Dordrecht: Springer  
1528 Netherlands, 1988.
- 1529 [223] D. H. Slade (Ed.), "Meteorology and Atomic Energy," Air Resources Laboratories for the  
1530 US Atomic Energy Commission, Jul. 1968.
- 1531 [224] S. K. Shah and E. Bou-Zeid, "Direct numerical simulations of turbulent Ekman layers with  
1532 increasing static stability: modifications to the bulk structure and second-order statistics,"  
1533 *J. Fluid Mech.*, vol. 760, pp. 494–539, Dec. 2014, doi: 10.1017/jfm.2014.597.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

- 1534 [225] S. M. I. Gohari and S. Sarkar, "Stratified Ekman layers evolving under a finite-time  
1535 stabilizing buoyancy flux," *J. Fluid Mech.*, vol. 840, pp. 266–290, Apr. 2018, doi:  
1536 10.1017/jfm.2018.58.
- 1537 [226] J. C. Chang and S. R. Hanna, "Air quality model performance evaluation," *Meteorol.*  
1538 *Atmospheric Phys.*, vol. 87, no. 1–3, Sep. 2004, doi: 10.1007/s00703-003-0070-7.
- 1539 [227] P. Zannetti, Ed., *Air quality modeling: theories, methodologies, computational*  
1540 *techniques, and available databases and software*, vol. IV-Advances and Updates. United  
1541 States of America: EnviroComp ; Air & Waste Management Association, 2010.
- 1542 [228] G. Sugiyama *et al.*, "Atmospheric Dispersion Modeling: Challenges of the Fukushima  
1543 Daiichi Response," *Health Phys.*, vol. 102, no. 5, pp. 493–508, May 2012, doi:  
1544 10.1097/HP.0b013e31824c7bc9.
- 1545 [229] J. S. Nasstrom, G. Sugiyama, R. L. Baskett, S. C. Larsen, and M. M. Bradley, "The National  
1546 Atmospheric Release Advisory Center modelling and decision-support system for  
1547 radiological and nuclear emergency preparedness and response," *Int. J. Emerg. Manag.*,  
1548 vol. 4, no. 3, p. 524, 2007, doi: 10.1504/IJEM.2007.014301.
- 1549 [230] J. C. Weil, "Evaluation of the NARAC Modeling System Final Report to the Lawrence  
1550 Livermore National Laboratory," Lawrence Livermore National Laboratory, Livermore, CA,  
1551 UCRL-AR-217329, Nov. 2005.
- 1552 [231] K. T. Foster, G. Sugiyama, J. S. Nasstrom, J. M. L. Jr., S. T. Chan, and B. M. Bowen, "The  
1553 use of an operational model evaluation system for model intercomparison," *Int. J. Environ.*  
1554 *Pollut.*, vol. 14, no. 1/2/3/4/5/6, p. 77, 2000, doi: 10.1504/IJEP.2000.000528.
- 1555 [232] S. Warner, J. F. Heagy, N. Platt, and M. B. Dillon, "Transport and Dispersion Model  
1556 Predictions of Elevated Source Tracer Experiments in the Copenhagen Area: Comparisons  
1557 of Hazard Prediction and Assessment Capability (HPAC) and National Atmospheric Release  
1558 Advisory Center (NARAC) Emergency Response Model Predictions," Institute of Defense  
1559 Analysis, Alexandria, VA, Technical Report D-3276, Jul. 2006.
- 1560 [233] J. S. Nasstrom and J. C. Pace, "Evaluation of the effect of meteorological data resolution  
1561 on Lagrangian particle dispersion simulations using the ETEX experiment," *Atmos.*  
1562 *Environ.*, vol. 32, no. 24, pp. 4187–4194, Dec. 1998, doi: 10.1016/S1352-2310(98)00180-0.
- 1563 [234] S. G. Perry *et al.*, "AERMOD: A Dispersion Model for Industrial Source Applications. Part  
1564 II: Model Performance against 17 Field Study Databases," *J. Appl. Meteorol.*, vol. 44, no. 5,  
1565 pp. 694–708, May 2005, doi: 10.1175/JAM2228.1.
- 1566 [235] US Environmental Protection Agency, "Exposure Factors Handbook 2011 Edition (Final),"  
1567 US Environmental Protection Agency, Washington DC, EPA/600/R-09/052F.
- 1568 [236] E. C. Riley, G. Murphy, and R. L. Riley, "Airborne spread of measles in a suburban  
1569 elementary school," *Am. J. Epidemiol.*, vol. 107, no. 5, pp. 421–432, May 1978, doi:  
1570 10.1093/oxfordjournals.aje.a112560.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

- 1571 [237] G. N. Sze To and C. Y. H. Chao, "Review and comparison between the Wells–Riley and  
1572 dose-response approaches to risk assessment of infectious respiratory diseases," *Indoor*  
1573 *Air*, vol. 20, no. 1, pp. 2–16, Feb. 2010, doi: 10.1111/j.1600-0668.2009.00621.x.
- 1574 [238] C. B. Keil, "A Tiered Approach to Deterministic Models for Indoor Air Exposures," *Appl.*  
1575 *Occup. Environ. Hyg.*, vol. 15, no. 1, pp. 145–151, Jan. 2000, doi:  
1576 10.1080/104732200301962.
- 1577 [239] T. L. Thatcher, M. M. Lunden, K. L. Revzan, R. G. Sextro, and N. J. Brown, "A  
1578 Concentration Rebound Method for Measuring Particle Penetration and Deposition in the  
1579 Indoor Environment," *Aerosol Sci. Technol.*, vol. 37, no. 11, pp. 847–864, Nov. 2003, doi:  
1580 10.1080/02786820300940.
- 1581 [240] F. H. Shair and K. L. Heitner, "Theoretical model for relating indoor pollutant  
1582 concentrations to those outside," *Environ. Sci. Technol.*, vol. 8, no. 5, pp. 444–451, May  
1583 1974, doi: 10.1021/es60090a006.
- 1584 [241] S. R. Hayes, "Use of an Indoor Air Quality Model (IAQM) to Estimate Indoor Ozone  
1585 Levels," *J. Air Waste Manag. Assoc.*, vol. 41, no. 2, pp. 161–170, Feb. 1991, doi:  
1586 10.1080/10473289.1991.10466833.
- 1587 [242] J. M. Leone, J. S. Nasstrom, D. M. Maddix, D. J. Larson, G. Sugiyama, and D. L. Ermak,  
1588 "Lagrangian Operational Dispersion Integrator (LODI) User's Guide v1.0," Lawrence  
1589 Livermore National Laboratory, Livermore, CA, UCRL-AM-212798, 2001.
- 1590 [243] G. Sugiyama and S. T. Chan, "A new meteorological data assimilation model for real-  
1591 time emergency response," presented at the Tenth Joint Conference on the Applications  
1592 of Air Pollution Meteorology, Phoenix, AZ, Jan. 1998, pp. 285–289.
- 1593 [244] "Residential Energy Consumption Survey (RECS) - Data - U.S. Energy Information  
1594 Administration (EIA)." <https://www.eia.gov/consumption/residential/data/2015/>  
1595 (accessed Jan. 19, 2020).
- 1596 [245] M. Georgiev *et al.*, "Q fever in humans and farm animals in four European countries,  
1597 1982 to 2010," *Euro Surveill. Bull. Eur. Sur Mal. Transm. Eur. Commun. Dis. Bull.*, vol. 18,  
1598 no. 8, Feb. 2013.
- 1599 [246] National Association of State Public Health Veterinarians and National Assembly of State  
1600 Animal Health Officials, "Prevention and Control of *Coxiella burnetii* Infection among  
1601 Humans and Animals: Guidance for a Coordinated Public Health and Animal Health  
1602 Response," 2013. Accessed: Mar. 01, 2020. [Online]. Available:  
1603 [http://nasphv.org/Documents/Q\\_Fever\\_2013.pdf](http://nasphv.org/Documents/Q_Fever_2013.pdf).
- 1604 [247] T. J. O'Neill, J. M. Sargeant, and Z. Poljak, "The Effectiveness of *Coxiella burnetii* Vaccines  
1605 in Occupationally Exposed Populations: A Systematic Review and Meta-Analysis,"  
1606 *Zoonoses Public Health*, vol. 61, no. 2, pp. 81–96, Mar. 2014, doi: 10.1111/zph.12054.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

- 1607 [248] P. M. Reeves, S. R. Paul, A. E. Sluder, T. A. Brauns, and M. C. Poznansky, "Q-vaxcelerate:  
1608 A distributed development approach for a new *Coxiella burnetii* vaccine," *Hum. Vaccines*  
1609 *Immunother.*, vol. 13, no. 12, pp. 2977–2981, Dec. 2017, doi:  
1610 10.1080/21645515.2017.1371377.
- 1611 [249] C. Eldin *et al.*, "From Q Fever to *Coxiella burnetii* Infection: a Paradigm Change," *Clin.*  
1612 *Microbiol. Rev.*, vol. 30, no. 1, pp. 115–190, Jan. 2017, doi: 10.1128/CMR.00045-16.
- 1613 [250] J. H. McQuiston and J. E. Childs, "Q fever in humans and animals in the United States,"  
1614 *Vector Borne Zoonotic Dis. Larchmt. N*, vol. 2, no. 3, pp. 179–191, 2002, doi:  
1615 10.1089/15303660260613747.
- 1616 [251] G. J. Kersh *et al.*, "Presence of *Coxiella burnetii* DNA in the Environment of the United  
1617 States, 2006 to 2008," *Appl. Environ. Microbiol.*, vol. 76, no. 13, pp. 4469–4475, Jul. 2010,  
1618 doi: 10.1128/AEM.00042-10.
- 1619 [252] S. R. Porter, G. Czaplicki, J. Mainil, R. Guattéo, and C. Saegerman, "Q Fever: Current  
1620 State of Knowledge and Perspectives of Research of a Neglected Zoonosis," *Int. J.*  
1621 *Microbiol.*, vol. 2011, pp. 1–22, 2011, doi: 10.1155/2011/248418.
- 1622 [253] N. R. Parker, J. H. Barralet, and A. M. Bell, "Q fever," *The Lancet*, vol. 367, no. 9511, pp.  
1623 679–688, Feb. 2006, doi: 10.1016/S0140-6736(06)68266-4.
- 1624 [254] S. Bacci, S. Villumsen, P. Valentiner-Branth, B. Smith, K. A. Kroghfelt, and K. Mølbak,  
1625 "Epidemiology and clinical features of human infection with *Coxiella burnetii* in Denmark  
1626 during 2006-07," *Zoonoses Public Health*, vol. 59, no. 1, pp. 61–68, Feb. 2012, doi:  
1627 10.1111/j.1863-2378.2011.01419.x.
- 1628 [255] H. K. Miller *et al.*, "Trends in Q fever serologic testing by immunofluorescence from four  
1629 large reference laboratories in the United States, 2012–2016," *Sci. Rep.*, vol. 8, no. 1, p.  
1630 16670, Dec. 2018, doi: 10.1038/s41598-018-34702-2.
- 1631 [256] H. W. Kaufman, Z. Chen, J. Radcliff, H. J. Batterman, and J. Leake, "Q fever: an under-  
1632 reported reportable communicable disease," *Epidemiol. Infect.*, vol. 146, no. 10, pp. 1240–  
1633 1244, Jul. 2018, doi: 10.1017/S0950268818001395.
- 1634 [257] "NHANES 2003-2004: *Coxiella Burnetii* (Q Fever) Antibodies - Serum (Surplus) Data  
1635 Documentation, Codebook, and Frequencies." [https://wwwn.cdc.gov/Nchs/Nhanes/2003-  
1636 2004/SSQFEV\\_C.htm](https://wwwn.cdc.gov/Nchs/Nhanes/2003-2004/SSQFEV_C.htm) (accessed Feb. 06, 2020).
- 1637 [258] M. G. Walsh, "Assessing Q fever in a representative sample from the United States  
1638 population: identification of a potential occupational hazard," *Epidemiol. Infect.*, vol. 140,  
1639 no. 1, pp. 42–46, Jan. 2012, doi: 10.1017/S0950268811000227.
- 1640 [259] F. S. Dahlgren, D. L. Haberling, and J. H. McQuiston, "Q Fever is Underestimated in the  
1641 United States: A Comparison of Fatal Q Fever Cases from Two National Reporting  
1642 Systems," *Am. J. Trop. Med. Hyg.*, vol. 92, no. 2, pp. 244–246, Feb. 2015, doi:  
1643 10.4269/ajtmh.14-0502.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

- 1644 [260] B. Schimmer *et al.*, “Low seroprevalence of Q fever in The Netherlands prior to a series  
1645 of large outbreaks,” *Epidemiol. Infect.*, vol. 140, no. 1, pp. 27–35, Jan. 2012, doi:  
1646 10.1017/S0950268811000136.
- 1647 [261] H. F. Gidding *et al.*, “Q fever seroprevalence in Australia suggests one in twenty people  
1648 have been exposed,” *Epidemiol. Infect.*, vol. 148, p. e18, 2020, doi:  
1649 10.1017/S0950268820000084.  
1650



## 1651 **Supplemental Material A: Airborne Disease Transmission Literature** 1652 **Review**

1653 Air is not a sterile medium, as initially demonstrated in the early 19<sup>th</sup> century experiments of  
1654 Louis Pasteur. Bacteria and fungi are ubiquitous in the atmosphere and reach concentrations of  
1655 about  $10^4$  and  $10^3$  cells  $m^{-3}$  in air, respectively [104]–[107]. These facts are well understood and  
1656 elucidated in the field of Aerobiology which has documented the life cycles, including transport  
1657 and dispersion, of naturally occurring airborne viruses, microorganisms, and bioaerosols [108]–  
1658 [111]. However, there appears to be much confusion on the potential for airborne disease  
1659 transmission, particularly at longer spatial scales due likely in part to the dispersed nature of  
1660 this literature.

1661 To provide the reader context for the main manuscript, this section briefly presents a set of  
1662 well-documented airborne disease transmission examples on spatial scales ranging from a  
1663 meter to thousands of kilometers. The specific cases discussed here are from the human  
1664 disease as well as veterinary and agricultural biosafety<sup>30</sup> literatures and have multiple studies  
1665 showing airborne disease transmission. This synopsis is not intended to be comprehensive and  
1666 we do not cite all relevant literature. We note that [8] is a useful literature review of  
1667 atmospheric dispersion modeling for infectious diseases, with a focus on human and veterinary  
1668 studies.

1669

### 1670 **Near Range (< 5 m)**

1671 Near distance airborne disease spread ( $\leq 5$  m) is common and occurs when infected individuals  
1672 generate large quantities of infectious droplet (and droplet nuclei) particles when coughing or  
1673 sneezing [33], [112]. Tuberculosis and the Measles virus (Rubeola) have long been known to  
1674 transmit over this distance [1], [2]. Bordatella pertussis (Whooping Cough), Varicella Zoster  
1675 virus (Chickenpox), Mumps virus, Rubella virus (German Measles) and Neisseria meningitides  
1676 (bacterial meningitis) are additional examples [113], [114]. This near range airborne disease  
1677 spread is known to contribute to the overall disease burden as lower respiratory infections and  
1678 Tuberculosis are the 4<sup>th</sup> and 10<sup>th</sup> leading causes of death world-wide [5]. Finally, two percent of  
1679 US adults (6.5 million) are hospitalized each year for treatment of community acquired  
1680 pneumonias caused in part by the near-range airborne transmission of common bacteria and  
1681 viruses including Influenza [115].<sup>31</sup>

---

<sup>30</sup> airborne microbial threats to animal livestock or resulting from agricultural activities

<sup>31</sup> The airborne disease transmission pathway can contribute to overall disease transmission, even when other – droplet ( $> 5 \mu m$  AD particles) and contact – pathways are important, e.g., [6], [7].



## 1682 **Short Range (5 m to 50 m)**

1683 Airborne disease spread is also known to occur over short distances (5 m to 50 m) [34]. The  
1684 spread of human pathogens within buildings has been particularly well documented in hospital  
1685 environments [97], [116]–[118]. Furthermore, outdoor airborne particles are known to infiltrate  
1686 indoors and cause disease in building occupants.<sup>32</sup> Building air filtration systems and other  
1687 measures are in active use to reduce the incidence of airborne animal diseases, e.g., Newcastle  
1688 Disease virus, and porcine reproductive and respiratory syndrome (PRRS virus) [120]–[123].  
1689 Research also indicates that air filtration is beneficial to control MRSA in veterinary settings  
1690 [124]. Furthermore, high-risk patient areas in hospitals are designed with physical and  
1691 ventilation barriers to minimize infections in immune compromised patients. Hospital design  
1692 features include, but are not limited to, permanently sealed hospital room windows and HEPA  
1693 air filtration [116], [125], [126]. Ultraviolet germicidal irradiation is also routinely used to  
1694 reduce airborne disease risk in hospital and other facilities, especially for Tuberculosis control  
1695 [127].

1696 The Newcastle Disease (ND) virus, an avian paramyxovirus, is one well-known example of an  
1697 airborne disease that can transmit over short distances. ND virus is a commercially important  
1698 pathogen in poultry production and virulent strains can be devastating, with flock mortality  
1699 approaching 100% [128], [129]. ND virus has multiple routes of transmission, including  
1700 airborne. ND vaccines have been a mainstay of ND control, but a number of pandemics have  
1701 occurred and the disease remains endemic in many countries [129]. With regards to the  
1702 plausibility of airborne transmission, we note some ND live virus vaccines are delivered via fine  
1703 aerosolized powders [130]. Furthermore, experimental field studies have documented short-  
1704 range (60 m) airborne dispersion based on positive viral cultures of air samples [131], [132].  
1705 Recent experimental work has reconfirmed an airborne transmission route for ND virus [129].  
1706 Furthermore, outfitting buildings with negative air ionization and dilute viricidal chlorine  
1707 aerosols may be useful in attenuating airborne disease transmission [121], [122].

1708 In plant biology and biosafety studies, short-range (<50 m) airborne particle and pathogen  
1709 transmissions are thought to be the most frequent scenarios. For example, initial median  
1710 windborne (anemochorous) plant seed dispersals are typically short (<10 m) but the 95%th  
1711 percentile for airborne seed dispersion occurs over longer distances and varies significantly by  
1712 species [133]–[135]. In plant pathology studies of Wheat Stripe Rust (*Puccinia striiformis* f. sp.  
1713 *Tritici*) and the wind-dispersed banana plant fungus *Mycosphaerella fijiensis*) [91], [136], single-

---

<sup>32</sup> The physics of outdoor-origin particles penetrating buildings and exposing indoor individuals has been studied, e.g., [30] and is demonstrated by (a) indoor measurements of outdoor-origin PM<sub>2.5</sub> particles [34], [119] and (b) airborne *Bacillus thuringiensis* bacteria infiltration into buildings [23].

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

1714 field experimental studies are used to model initial local plot/field-level airborne pathogen  
1715 dispersal and clearly demonstrate short-range airborne infection transmissions. These studies  
1716 have been also used to develop source (emission) estimates for larger scale long-distance  
1717 disease spread and propagated epidemics.

1718

### 1719 **Medium Range (50 m to 500 m)**

1720 Medium range airborne dispersions of infectious pathogens are well-documented in the plant  
1721 biosafety, veterinary and human disease Epidemiology literature. These papers include both  
1722 observational and experimental field studies coupled with physics-based airborne transport and  
1723 dispersion modeling. Human data for downwind infections are primarily from epidemiology  
1724 studies of unexpected disease outbreaks, supported by toxicology, clinical studies and  
1725 environmental studies using background disease rate data.

1726 Epidemiologic disease outbreak studies provide human data for medium range ( $\leq 500$  m)  
1727 airborne transmission of disease. Well-documented examples include ongoing community-level  
1728 outbreaks of Legionnaire's Disease (*Legionella pneumophila*) from building cooling towers  
1729 [137]–[145]; Q Fever (*Coxiella burnetii*) transmission from livestock farms to their surrounding  
1730 communities [37]; as well as Histoplasmosis (*Histoplasma capsulatum*) and Aspergillosis  
1731 *fumigatus* and *flavus* dispersions from construction work or sites where contaminated soil is  
1732 disturbed [25]–[29], [146].

1733 On this spatial scale, best-practices and regulatory standards aim to reduce the risk of airborne  
1734 transport of infectious particles. Guidelines exist to control occupational and environmental  
1735 construction-associated dust during building renovations. In endemic regions these guidelines  
1736 are codified into law to reduce infections [147], [148]. Furthermore, there is a long standing, yet  
1737 still evolving, literature that supports existing regulatory standards aimed at protecting workers  
1738 and nearby communities from airborne pathogen dispersal from environmental sites such as  
1739 composting facilities, sewage processing and waste-water aerosols, agricultural gray water  
1740 aerosols, livestock feed yards and land applications of manure [17], [149]–[155]. As one  
1741 example, a protective ring of up to 250 m is commonly specified under the assumption that  
1742 existing air monitors detect little to no airborne material beyond that point [152], [153].

1743

1744

## 1745 **Long Range (500 m to 500 km)**

1746 Long range airborne infectious pathogen transmission is also well-documented in plant biology,  
1747 the plant and veterinary biosafety literature, as well as in human disease outbreak  
1748 epidemiology studies. Long-distance atmospheric transmission mechanisms, termed LDD in this  
1749 literature, have been shown to play a crucial ecological role in plant species invasion, migration  
1750 and survival as well as plant pathogen dispersal [54], [57], [156]–[159]. This field is well  
1751 advanced in its understanding of the connection between airborne pathogen transport and  
1752 dispersion and disease epidemics [58], [160]–[163].

1753 Biosafety experimental field studies also clearly demonstrate kilometer-range dispersion of  
1754 plant pathogens. For example, fungal plant pathogens are currently an increasing threat to  
1755 world food security [164]. A wind-dispersed banana plant fungus (*Mycosphaerella fijiensis*) field  
1756 experiment documented 1 km airborne dispersal in one generation [91]. Studies such as these  
1757 and others, e.g., [90], together with the above cited plant biology and biosafety literature,  
1758 demonstrate that the infection probability first decreases quickly with distance which is  
1759 followed by regimen of kilometer-range LDD events (termed a long “dispersion tail”).

1760 In the United States, long-distance airborne spread of economically significant plant disease  
1761 across the landscape is an ongoing concern. Predictable seasonal airborne pathogen incursion  
1762 pathways across the continent are well-identified and routinely monitored to protect crop  
1763 yields. These continental-scale incursions typically proceed in a stepwise series of shorter (long-  
1764 distance) airborne dispersals. Chief examples are the seasonal airborne south to north US  
1765 dispersion incursion pathways across the Midwest Great Plains for wheat stem rust (*Puccinia*  
1766 *graminis* f. sp. *tritici*); the pandemic spread of tobacco blue mold spores (*Peronospora tabacina*)  
1767 across the Eastern US; and the seasonal US airborne invasion of soybean rust (*Phakopsora*  
1768 *pachyrhizi* Sydow) [89], [93], [159], [165], [166].

1769 In the Veterinary literature there are many examples of probable kilometer-range airborne  
1770 infection transmission. For example, Newcastle Disease virus, Equine Influenza (A/H3N8), Highly  
1771 Pathogenic Avian Influenza A(H7N7) are important ongoing diseases and each has evidence for  
1772 long-range airborne virus transmission [132], [167]–[170]. The best described long distance  
1773 airborne transmitted disease in animals is Foot and Mouth Disease virus, an economically  
1774 significant disease of veterinary livestock. Long-distance FMDV aerosols are suspected to have  
1775 contributed to a number of costly, regional-scale disease outbreaks in Europe, including  
1776 airborne transmission from continental Europe to the United Kingdom [171], [172]. This disease  
1777 has motivated the significant development and testing of scientific models for long distance  
1778 infectious aerosol dispersals with the aim of limiting epidemic spread [58], [160]–[162], [173]–  
1779 [176].

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

1780 In the human epidemiology literature, many well documented examples exist for airborne  
1781 disease transmissions over distances greater than 1 kilometer downwind. *Coxiella burnetii*, an  
1782 endemic disease of ruminants and livestock, is also the cause of Q Fever in humans [59]. Long-  
1783 distance airborne transmission disease outbreaks from animal farms to human populations  
1784 have occurred in many European countries [42], [83], [177]–[179]. Notably the recent regional-  
1785 scale Q Fever epidemic in 2007-2010 in the Netherlands was caused by infectious aerosols  
1786 emitted from small animal farms [40], [41], [180]–[182]. The epidemic resulted in 4,000 clinical  
1787 cases and 2,700 hospitalizations [180]. A more recent 2018 follow up of this outbreak showed  
1788 that among the 519 chronic Q Fever cases identified, 86 patients had died [69]. *Legionella*  
1789 *pneumophila* dispersions from building cooling towers are also an ongoing source of kilometer-  
1790 range community Legionnaire’s Disease outbreaks despite the introduction of preventive legal  
1791 regulations for cooling equipment maintenance [142], [183]. Significant airborne Legionnaire’s  
1792 disease outbreaks have been reported in many countries including the US, France, Norway,  
1793 Sweden, and Spain [43], [44], [137]–[141], [143]–[145], [184], [185].

1794 The fungal pathogens *Histoplasma capsulatum* and *Coccidioides immitis* and *posadasii* cause  
1795 significant human disease due to inhalation (Histoplasmosis and Coccidioidomycosis [or Valley  
1796 Fever], respectively). Both are endemic in the US: Histoplasmosis in the Eastern and  
1797 Midwestern states, Coccidioidomycosis in the American West and Southwest [29], [186]. Based  
1798 on observational epidemiologic studies, three city-wide airborne outbreaks of Histoplasmosis  
1799 have occurred, two at a community level [187]–[189] and the third being a series of 3 large  
1800 outbreaks that occurred in urban Indianapolis, IN [190]–[192].

1801 Coccidioidomycosis occurs after inhalation of fungal spores which are widely distributed in  
1802 southwestern US soils [193], [194]. Forty percent of exposed persons will have clinical  
1803 symptoms, ranging from an influenza-like illness to disseminated disease and chronic  
1804 meningitis. Symptomatic disseminated disease requires aggressive treatment and has increased  
1805 rates of hospitalization and mortality [195], [196]. Desert dust cloud dispersions containing  
1806 *Coccidioides* spores are an important ongoing cause of disease in endemic areas [197]. In  
1807 addition long-distance airborne dust cloud *Coccidioides* dispersal events triggered by natural  
1808 disasters have caused significant regional Coccidioidomycosis outbreaks in the US state of  
1809 California [198]. Kilometer-scale airborne transmission occurred in the Los Angeles area  
1810 following the 1994 Northridge earthquake, where strong aftershocks generated landslides on  
1811 the slopes of the Santa Susana Mountains creating large, contaminated dust clouds [45], [46],  
1812 [199]. These clouds were blown by ambient winds into the urban Simi Valley and Ventura  
1813 County areas – causing a Coccidioidomycosis outbreak (203 total cases; 55 hospitalizations; 3  
1814 fatalities).

1815

## 1816 **Continental and Global Range (> 500 km)**

1817 Continental-scale airborne dispersion events, especially plant seed dispersions, have been well  
1818 studied and influence the spread of invasive species, metapopulation dynamics, and plant  
1819 diversity [134], [156], [157], [200]. Continental-scale transport of common environmental  
1820 bacteria species, either on normal atmospheric air currents or in association with dust cloud  
1821 dispersions, has also been well-demonstrated [55], [105], [201], [202]. As one example,  
1822 bacterial communities from the Saharan desert are known to travel airborne to high European  
1823 Alpine lakes [203], [204]. Pathogenic bacteria have also been observed in the ambient  
1824 atmosphere, including plant, animal, and human pathogens [205]–[207]. Furthermore, airborne  
1825 transmission of *Neisseria meningitidis*, a major cause of Meningitis world-wide, is currently  
1826 under investigation in the endemic Sahel region of North Africa as outbreaks occur most often  
1827 in dry months with frequent dust storms [202], [206].

1828 Airborne continental-scale disease spread often proceeds as a series of sequential long range  
1829 airborne transmission events over the landscape (saltatory transmission). However, individual  
1830 continental-scale airborne disease transmission events, i.e., a single airborne plume  
1831 transporting pathogens more than 500 km, are also documented in the literature [54], [89],  
1832 [208], [209]. Most but not all of the existing examples are from agricultural biosafety studies  
1833 where these events are termed “single-step” LDD pathogen invasions [54]. These types of  
1834 events are thought to be rare and often associated with extreme weather events or natural  
1835 disasters [89], [198]. However, routinely occurring, “single-step” LDD events could be more  
1836 frequent, although the possibility has not been systematically investigated. For example, a  
1837 sentinel study LDD of airborne pathogenic plant fungi (*Erysiplic graminis*, f.sp. *hordei* [barley  
1838 mildew] and *Erysiplic graminis*, f.sp. *tritici* [wheat mildew]) demonstrated transmission over a  
1839 distance of 650 km across the North Sea from Great Britain to Scandinavia [209]. Samples were  
1840 obtained using disease-free receptor plant populations compared to unexposed control plants  
1841 and a multi-year series of samples were obtained in the highest expected transmission regions.

1842 A major weather-related “single-step” LDD event was the 2,000 km airborne dispersion of Asian  
1843 soybean rust (*Phakopsora pachyrhizi*) across the Caribbean from northwestern South America  
1844 to the US during Hurricane Ivan [89]. This 2004 event marked the invasion of Asian soybean rust  
1845 into the North American continent. The event was anticipated as the spread of Asian soybean  
1846 rust from Brazil northward in South America was being monitored and Brazil had lost a  
1847 significant fraction of its soybean production to this pathogen. Among other measures (and  
1848 prior to the event itself), predictive atmospheric dispersion modeling for potential transport to  
1849 the US during tropical cyclone seasons were conducted and the US Department of Agriculture  
1850 deployed disease forecasting systems and field-tested a detailed response plan for use in the  
1851 event the soybean rust was identified [89]. Soybean rust was detected infesting soybean fields

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

1852 in Louisiana (as predicted) within two weeks after Hurricane Ivan had passed. Subsequently  
1853 Asian soybean rust has remained endemic in many southern states, especially in the initial  
1854 epidemic outbreak area [210].

1855  
1856 A clear human-disease example of single-plume continental-scale airborne disease transmission  
1857 is the 600 km dispersion of *Coccidioides immitis* spores in California which resulted in  
1858 widespread Coccidioidomycosis outbreaks [211]. In this 1977 event, a 160 km h<sup>-1</sup> windstorm  
1859 scoured 15 cm of *Coccidioides immitis* contaminated topsoil from Kern County, located in the  
1860 southernmost basin of California's great central San Joaquin Valley, carrying a resulting dust  
1861 cloud to an altitude of 1,500 meters (Image, reference [212]). The dust was transported  
1862 northward and dispersed over a 87,000 km<sup>2</sup> area [191], [208], [211], [213] - burying freeways  
1863 and shutting down interstate transportation. There were 3 immediate storm-related fatalities  
1864 and 3 firefighters died in a forest fire spread by the strong winds. Sacramento, a low endemicity  
1865 area 500 km to the north, experienced a large Coccidioidomycosis outbreak (115 cases and 6  
1866 fatalities reported vs. a background incidence of 0 to 6 cases per year). Overall fifteen California  
1867 counties northward in the dust cloud dispersion area reported a ten-fold increase in  
1868 Coccidioidomycosis cases and 9 counties reported lesser increases [211]. This 1977 *Coccidioides*  
1869 *intimus* dispersion, with a total of more than 379 new cases, serves as a historical benchmark  
1870 for the potential magnitude of Coccidioidomycosis cases from a significant dust storm [208].  
1871 Integrated Coccidioidomycosis case surveillance and dust storm forecasting are currently  
1872 standard in US endemic areas [214].

1873



1874 **Supplemental Material B: Key Atmospheric Transport and Dispersion**  
1875 **Modeling Concepts**

1876 Atmospheric physics, as well as atmospheric transport and dispersion models of airborne  
1877 hazards, are well-established and extensive fields. This supplemental material aims to briefly  
1878 introduce the reader to key concepts needed for this report. We note that while the theory  
1879 developed in this study is applicable at a wide range of spatial and temporal scales, the  
1880 epidemiological datasets that are compared to theoretical predictions relate to exposures that  
1881 occur near the earth's surface (in the atmospheric boundary layer), from 0.05 km to a few tens  
1882 of km downwind of an airborne release, and less than a few hours from the time of initial  
1883 release. The interested reader is referred to [215]–[222] for further details of atmospheric air  
1884 flow physics, dispersion, and modeling including those present at other spatial and temporal  
1885 scales.

1886  
1887 **Mean Air Flow in the Atmosphere**

1888 The mean (time-averaged) air flows are driven by a spatial gradient in atmospheric pressure.  
1889 When the horizontal surface pressure gradient between two locations is a few millibar over a  
1890 hundred kilometers (tenths of  $\text{mb km}^{-1}$ ), as occurs near the center of a high-pressure weather  
1891 system; the atmosphere is relatively calm and horizontal surface mean wind speeds are light,  
1892 typically less than  $2 \text{ m s}^{-1}$ . Larger surface pressure gradients, several to tens of  $\text{mb km}^{-1}$ , result in  
1893 moderate surface winds ( $3$  to  $7 \text{ m s}^{-1}$ ) which are sufficient to stir leaves and twigs. Finally, larger  
1894 pressure gradients, which can occur during storms, produce strong winds ( $> 8 \text{ m s}^{-1}$ ). The spatial  
1895 and temporal distribution of wind, i.e., the “wind field,” may be quite complex as local  
1896 topography can steer the direction of local winds. For example, winds can be channeled along  
1897 river and mountain valleys and within urban streets or be blocked by hills or mountains.

1898  
1899



## 1900 **Atmospheric Turbulence**

1901 In addition to the regional (mean) air flow described in the previous paragraph, smaller scale  
1902 motions (turbulent eddies) are typically present in the atmosphere. These turbulent motions  
1903 are due to two major causes. *Mechanically generated* turbulent motions are generated by drag  
1904 resulting from the wind moving over and around physical objects on the earth's surface. The  
1905 largest mechanically generated eddy size is proportional to the height above ground and  
1906 obstacle size. *Buoyancy generated* turbulent motions are generated, for example, when the  
1907 solar heating of the earth's surface causes warmer (buoyant) air to rise and be replaced by  
1908 colder air. Buoyancy forces can also decrease turbulent motions, for example, when the surface  
1909 is cooler than the air. The size of the largest buoyancy generated eddies depends on the  
1910 atmospheric conditions and can be up to approximately 4,000 m.

1911 Once generated, atmospheric eddies interact with each other and the earth's surface. These  
1912 interactions result in the original eddies breaking into smaller eddies. The original eddy's  
1913 (turbulent kinetic) energy is transferred to the smaller eddies. This process continues,  
1914 generating successively smaller eddies until the millimeter size eddies dissipate into heat. This  
1915 breakdown process results in a well-characterized spectrum of eddy sizes for a given set of  
1916 atmospheric and surface conditions. One important consequence is that turbulent motions in  
1917 the atmosphere are correlated over shorter distances (and times) and become uncorrelated at  
1918 larger distances (and times). Commonly, turbulent motions are correlated on a few minutes  
1919 timescale.

1920 For many common atmospheric conditions, atmospheric eddies are at least an order of  
1921 magnitude smaller (spatially and temporally) than the scales of motion present in the regional  
1922 (mean) air flow. This separation provides a natural division of air motions that transport (mean  
1923 winds) and dilute (turbulent eddies) contaminated air [222]. This separation results in a gap in  
1924 the atmospheric energy spectra associated with timescales on the order of an hour.

1925

## 1926 **Atmospheric Dispersion Physics**

1927 If a small amount of airborne material is added to a mass of air (called an air parcel), its  
1928 presence will not significantly affect the regional wind, eddies, or other atmospheric  
1929 properties.<sup>33</sup> Thus the *transport and dilution of these contaminated air parcels can be*  
1930 *determined from atmospheric (meteorological) and surface considerations alone and does not*  
1931 *depend on properties of the contaminant.* Furthermore, the *airborne exposure to such dilute*  
1932 *materials can be mathematically represented as the sum of the exposure to many simpler*  
1933 *releases* at specific locations and short time periods (superposition principle). Consequently,  
1934 insights (and model results) derived for the transport and dilution of single particles released  
1935 from a single location and time directly contribute to the characterization of more complex  
1936 cases.

1937 During transport by ambient winds, dispersion occurs when the turbulent eddies, described in  
1938 the prior subsection, mix surrounding air with the contaminated air parcel which reduces the  
1939 contamination concentration in the original air parcel and increases the contamination in  
1940 neighboring air parcels. **Figure B1** shows photographs of this process using point-source smoke  
1941 aerosol released at a constant rate into a constant airflow. The upper two panels are  
1942 instantaneous snapshots which clearly demonstrate high moment-to-moment (stochastic)  
1943 variations in plume concentrations that result from the effect of turbulent eddies. The bottom  
1944 panel shows a time-lapse photograph of a smoke plume taken over several minutes. This panel  
1945 shows two important turbulent dispersion regimes: First, near the release, the time-average  
1946 plume crosswind spread (“width”) depends linearly on distance (and time) from the release  
1947 because the turbulent motions dispersing the plume are correlated with each other. Second,  
1948 and farther downwind, the plume spread becomes proportional to the square root of distance  
1949 (time) from the release because the turbulent motions that disperse the contamination are no  
1950 longer correlated with the motions present at the time of pollutant release to the atmosphere.

1951 The plume crosswind spread increases with increasing averaging time since larger turbulent  
1952 motions affect the plume spread at larger averaging times, see **Figure B2**. In some cases, the  
1953 growth rate of the plume width can dramatically slow after the plume outgrows the size of  
1954 typical mechanically or buoyancy generated eddies. However, other processes can result in the  
1955 plume width continuing to grow, for example, due to differential advection – where different  
1956 parts of the plume are blown in different directions and at different speeds by variations in the

---


<sup>33</sup> The number of particles required to change the behavior of the atmospheric depends on the (a) atmospheric volume of interest, (b) particle size and density, (c) release duration, and (d) ambient wind speed [9]. For context, assuming a light wind ( $1 \text{ m s}^{-1}$ ) and monodisperse particles as dense as water ( $1000 \text{ kg m}^{-3}$ ); a  $1 \text{ m}^3$  release volume can contain at least  $10^{16}$   $0.1 \text{ }\mu\text{m}$  diameter particles,  $10^{13}$   $1 \text{ }\mu\text{m}$  diameter particles, or  $10^{10}$   $10 \text{ }\mu\text{m}$  diameter particles without violating this assumption.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

1957 mean wind. Differential advection can occur under several conditions including, but not limited  
1958 to, (a) variation of the mean wind with height, (b) regional scale, horizontal, mean wind  
1959 variability, and (b) variation of the mean wind with time, e.g., diurnal wind cycles. Differential  
1960 advection effects are not shown in **Figures B1** and **B2**. *We note that in the absence of additional*  
1961 *loss mechanisms (such as radioactive decay or deposition to the earth's surface), an airborne*  
1962 *plume will continue to transport (and dilute) far downwind – indeed plumes of airborne material*  
1963 *have been observed on global scales.*


1964  
1965 **Figure B1. Laboratory photographs of plume dispersion (air flows from left to right). The top**  
1966 **two frames** show a snapshot of an individual plume at two different times which highlight  
1967 **the effects of the individual eddies**. The bottom frame shows a time averaged concentration  
1968 **over several minutes** and more clearly highlight the changes in the growth rate of the plume  
1969 **width with time and downwind distance**. (Adapted from image provided by Snyder, EPA)  
1970



1971

1972 **Figure B2. Illustration of the increase in plume width with averaging time taken from Slade**  
1973 **[223]. The left panel shows the nominal plume outline for one of three exemplar averaging**  
1974 **time (wind blows along the x-axis). The right panel shows the crosswind (y axis) relative**  
1975 **plume concentration at a single, nominal downwind point for the three averaging times**  
1976 **considered.**

1977



1978

1979

## 1980 Atmospheric Dispersion Models

1981 Atmospheric transport and dispersion models simulate the previously discussed physical  
1982 processes of mean wind transport and turbulent diffusion. Direct Numerical Simulation  
1983 modeling, which explicitly considers all physical processes, can simulate all relevant air motions  
1984 and contaminant concentrations, e.g., [224], [225]. However, due to their high computational  
1985 burden and extensive, and often unavailable, input data requirements, these models are not  
1986 practical outside a research environment. As such, *all practical dispersion models resolve only a*  
1987 *portion of the atmospheric motions and physical processes while the effects of the unresolved*  
1988 *processes are parameterized, often using statistical descriptions of turbulent motions and fits to*  
1989 *empirical data.* As a consequence, these model results are inherently statistical in nature and,  
1990 depending on the model type, predict (a) the ensemble-average (expected value) result (vast  
1991 majority of models), (b) the distribution of results (concentration fluctuation models), or (c) a  
1992 single realization from a distribution of possible flows (Computational Fluid Dynamics models  
1993 using Large Eddy Simulation). Due to their ubiquity and relevance to the theory developed in  
1994 this paper, we focus here on the ensemble average models. By analogy, the actual plume at any  
1995 given time is one of the top two panels in **Figure B1** while the ensemble average dispersion  
1996 model is predicting the time-averaged bottom panel (in steady state conditions).

1997

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

1998 There are several common types of ensemble average models, including the classic Gaussian  
1999 plume model, in which downwind concentrations are calculated analytically; Gaussian puff  
2000 models, in which one or more expanding “puffs” of contaminant are transported downwind;  
2001 and Lagrangian particle models, in which downwind concentrations are inferred from the  
2002 Monte Carlo simulations of the trajectories of computational marker particles.<sup>34</sup> These model  
2003 types differ in their ability to resolve key spatial and temporal features as well as to describe  
2004 complex scenarios. The more detailed model types typically have enhanced computational and  
2005 input data requirements relative to the simpler models. All of these models will produce nearly  
2006 identical results for basic scenarios and simpler flows (e.g., constant wind speed and direction)  
2007 in which in the simpler models are valid (and have been validated against experimental data).  
2008 Gaussian plume models are analytic solutions to transport and diffusion equations for simple  
2009 conditions are often used as part of the verification process for the more complex numerical  
2010 models. *We note that the scenarios used in this study are closely related to a set of classic,*  
2011 *straightforward scenarios and so the modeling results presented in this report are expected to*  
2012 *be very similar to those that would be produced by different models.*

2013 Atmospheric transport and dispersion models are generally considered to be accurate when  
2014 they can reproduce individual measurements paired in time and space to within a factor of ten  
2015 (or better) for a variety of different terrains, downwind distances, and environmental  
2016 conditions [226], [227]. For example, one modeling system (which is used in this study) is the  
2017 LLNL ADAPT/LODI diagnostic wind field and Lagrangian particle models [228], [229]. The LLNL  
2018 ADAPT/LODI models have been validated against a wide range of source terms, environmental  
2019 conditions, and downwind distances (0.05 to 1,500 km) [230]–[233]. About 50% of the model-  
2020 measurement comparisons are (a) within a factor of 2 to 5 for simpler releases (source terms)  
2021 and environmental conditions and (b) within a factor of 10 for more complex conditions. Most  
2022 of these validation studies use gas tracers; however one experiment used particulate matter.

2023 *When model and measurement data are compared in a way that reduces the importance of*  
2024 *stochastic variability, model accuracy can markedly improve.* One case is the Quartile-Quartile  
2025 (Q-Q) plot which is used, in part, to validate operational transport and dispersion models, e.g.,  
2026 [230], [234]. This plot compares *distributions* of measured and modeled concentration data and  
2027 does not have the requirement that the model/measurement data is paired in time or space. As  
2028 one example, when comparing model predictions and measurements from a single tracer study  
2029 that took place in Copenhagen, 38% of the point to point comparisons are within a factor of 2  
2030 but the Q-Q plot demonstrates much better agreement, see **Figure B3** [230]. Another useful

---


<sup>34</sup> These computational marker particles are a large sample from the possible particles emitted and are used in estimating downwind concentrations along the prescribed contaminant emission amount. These particles do NOT directly represent individual physical aerosols.

M Dillon and  
C Dillon


Particle Model for  
Airborne Disease Transmission

2031 metric is integration within respect to time and/or space. For the Copenhagen study, all the  
2032 model predictions agreed within a factor of 2 of the observed concentrations when integrated  
2033 along arcs equidistant from the release site (crosswind integrated air concentrations), see  
2034 **Figure B4**.  
2035

2036 **Figure B3. Observed versus predicted ground-level concentrations in the Copenhagen**  
2037 **experiment: a) point-by-point comparison, and b) quantile-quantile comparison; only**  
2038 **nonzero concentrations included. Dashed line corresponds to geometric mean (0.78) of LODI**  
2039 **predicted concentration ( $C_{LODI}$ ) to Observed Concentrations ( $C_{obs}$ ). Image adapted from [230].**



2040 **Figure B4. Comparison between observed ( $C^y_{obs}$ ) and predicted ( $C^y_{LODI}$ ) crosswind-integrated**  
2041 **concentration at the surface for all Copenhagen experiments except day 7; dotted lines**  
2042 **correspond to factor of 2 over- and under- prediction. Image adapted from [230].**  
2043



2044



M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

## 2045 **Supplemental Material C: General Theory**

2046 In this supplemental material, we derive key theoretical concepts that are implemented in the  
2047 main paper. Theoretically, the total number of infections can be calculated by individually  
2048 considering every exposed person. However, this approach can be challenging to implement  
2049 due to computational considerations, including the need to acquire high resolution input data,  
2050 and such approaches potentially obscure useful interpretations. Therefore to facilitate the use  
2051 of **Equations 1, 2, and 3** presented in the main paper, we derive here a series of self-consistent  
2052 equations for exposure and infection probability applicable to individuals (indicated by the  
2053 index  $p$ ), (sub)groups of individuals with the same exposure but varying response to exposure  
2054 (index  $s$ ), groups of individuals with varying exposures and response to a given exposure (index  
2055  $g$ ), and geographic regions containing a group of people (index  $r$ ).  
2056



M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2057 **Section Variables Definitions**

2058

2059  $r$  = a specific geographic region

2060  $r_{ref}$  = a geographic region used as a reference in a relative incidence analysis

2061  $r_{source}$  = geographic region where infectious airborne particles are emitted

2062

2063  $p$  = an individual person that could be infected (i.e., a susceptible individual)

2064  $TP$  = total number of exposed, susceptible individuals (people)

2065  $s$  = a specific (sub)group of individuals with the same exposure but varying response to that  
2066 exposure

2067  $TS$  = total number individuals in (sub)group  $s$

2068  $g$  = a specific group of individuals with varying exposures and responses to a given exposure

2069  $TSG$  = total number of subgroups in group  $g$

2070

2071 particle type = specifies particle size and infectivity as a function of time and environmental  
2072 properties

2073  $b$  = a specific particle type

2074  $TB$  = total number of particle types

2075

2076 [*Adjustment Factor*]( $g, b$ ) = scaling factor for group  $g$  that accounts for the deviation of  $b$ -  
2077 type particle exposure and response from that of the reference exposure and response (no  
2078 units)

2079 [*Adjustment Factor*]( $r, b$ ) = scaling factor for region  $r$  that accounts for the deviation of  $b$ -  
2080 type particle exposure and response from that of the reference exposure and response (no  
2081 units)

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2082

2083  $[Area](r)$  = area of region  $r$  ( $m^2$ )

2084

2085  $[Effective\ Source\ Term](r, r_{source}, b)$  = mathematical construct used to scale infection  
2086 probability from one region to another for  $b$ -type particles. ( $m^3\ s^{-1}\ people^{-1}$ )

2087

2088  $[Exposure](p)$  = number and type of infectious airborne particles in the breathing volume  
2089 (respiratory second volume)<sup>35</sup> of individual  $p$  (particles  $s\ m^{-3}$ )

2090  $[Exposure](p, b)$  = the number of  $b$ -type infectious airborne particles in the breathing  
2091 volume (respiratory second volume) of individual  $p$  (particles  $s\ m^{-3}$ )

2092  $[Exposure](s, b)$  = number of  $b$ -type infectious airborne particles in each individual's  
2093 breathing volume (respiratory second volume) for individuals in (sub)group  $s$  (particles  $s$   
2094  $m^{-3}$ )

2095  $[Exposure]_{ref}(g, b)$  = reference number of  $b$ -type airborne particles in the breathing volume  
2096 (respiratory second volume) of an individual in group  $g$  (particles  $s\ m^{-3}$ )

2097  $[Exposure]_{ref}(r, b)$  = reference number of  $b$ -type airborne particles in the breathing volume  
2098 (respiratory second volume) of an individual in region  $r$  (particles  $s\ m^{-3}$ )

2099

2100  $[Exposure\ Adjustment\ Factor](g, s, b)$  = scaling factor that for group  $g$ , subgroup  $s$  accounts  
2101 for the deviation  $b$ -type particle exposure from the reference exposure (no units)

2102  $[Exposure\ Adjustment\ Factor](r, s, b)$  = scaling factor that for region  $r$ , subgroup  $s$  accounts  
2103 for the deviation  $b$ -type particle exposure from the reference exposure (no units)

2104

2105  $Health\ Effect\ Model(p, [Exposure](p))$  = mathematical model describing the probability  
2106 that an individual  $p$  will be infected given the individual's specific exposure (no units)

---

<sup>35</sup> Respiratory minute volume is a traditional unit in pulmonary medicine – this study uses respiratory second volume.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2107

2108  $[Infection\ Probability](p)$  = probability that an individual  $p$  becomes infected (no units)

2109  $[Infection\ Probability](s)$  = mean probability that a random individual in (sub)group  $s$   
2110 becomes infected. All individuals in (sub)group  $s$  have the same exposure. (no units)

2111  $[Infection\ Probability](g)$  = mean probability that a random individual in group  $g$  becomes  
2112 infected (no units)

2113  $[Infection\ Probability](r)$  = mean probability that a random individual in region  $r$  becomes  
2114 infected (no units)

2115  $[Infection\ Probability](r, b)$  = mean probability that a random individual in region  $r$   
2116 becomes infected by a  $b$ -type particle (no units)

2117

2118  $[Infections]$  = total number of people infected (people)

2119  $[Infections](r, b)$  = total number of people infected by  $b$ -type particles in region  $r$  (people)

2120

2121  $[Infectious\ People](r_{source})$  = total number of people capable of emitting infectious particles  
2122 in source region  $r_{source}$  (people)

2123

2124  $[Metric\ of\ Interest\ Probability](p)$  = probability that an individual  $p$  exhibits the metric of  
2125 interest (no units)

2126

2127  $[Normalized\ TSIAC](r, b)$  =  $b$ -type particle air concentration integrated over region  $r$  and the  
2128 passage of the airborne infectious plume assuming a single particle was released at the  
2129 source ( $s\ m^{-1}$ )

2130  $[Normalized\ TSIAC](r, r_{source}, b)$  =  $b$ -type particle air concentration integrated over region  $r$   
2131 and the passage of the airborne infectious plume assuming a single particle was released  
2132 from source region  $r_{source}$  ( $s\ m^{-1}$ )

2133

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2134 [*Population Density*]( $r$ ) = population density in region  $r$  (people  $m^{-2}$ )

2135

2136 [*Population Probability*]( $g, s$ ) = probability that an individual in group  $g$  is in subgroup  $s$  (no  
2137 units)

2138

2139 [*Relative Infection Probability*]( $r, b$ ) = ratio of the region  $r$  infection probability to  
2140 reference region infection probability due to exposure to  $b$ -type particles (no units)

2141

2142 [*Release Probability*]( $b$ ) = probability that a particle released into the environment is a  $b$ -  
2143 type particle (dimensionless)

2144

2145 [*Response Adjustment Factor*]( $g, s, b$ ) = scaling factor that for group  $g$ , subgroup  $s$  accounts  
2146 for the deviation of  $b$ -type particle response from the reference response (no units)

2147

2148 [*Single Particle Infection Probability*]( $p, b$ ) = the probability that individual  $p$  will become  
2149 infected after being exposed to a single  $b$ -type particle. This term includes the probability  
2150 that particle(s) will be inhaled and deposit in the respiratory system. ( $m^3 s^{-1} \text{ particle}^{-1}$ )

2151 [*Single Particle Infection Probability*]( $s, b$ ) = the mean probability that a random  
2152 individual in (sub)group  $s$  will become infected after being exposed to a single  $b$ -type  
2153 particle. This term includes the probability that particle(s) will be inhaled and deposit in the  
2154 respiratory system. ( $m^3 s^{-1} \text{ particle}^{-1}$ )

2155 [*Single Particle Infection Probability*]<sub>ref</sub>( $g, b$ ) = reference probability that an individual in  
2156 group  $g$  will become infected after being exposed to a single  $b$ -type particle. This term  
2157 includes the probability that particle(s) will be inhaled and deposit in the respiratory  
2158 system. ( $m^3 s^{-1} \text{ particle}^{-1}$ )

2159 [*Single Particle Infection Probability*]<sub>ref</sub>( $r, b$ ) = reference probability that an individual in  
2160 region  $r$  will become infected after being exposed to a single  $b$ -type particle. This term  
2161 includes the probability that particle(s) will be inhaled and deposit in the respiratory  
2162 system. ( $m^3 s^{-1} \text{ particle}^{-1}$ )

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2163 [*Single Particle Metric of Interest Probability*]( $p, b$ ) = the probability that individual  $p$   
2164 will exhibit the metric of interest after being exposed to a single  $b$ -type particle. This term  
2165 includes the probability that particle(s) will be inhaled and deposit in the respiratory  
2166 system. ( $\text{m}^3 \text{s}^{-1} \text{particle}^{-1}$ )

2167

2168 [*Source Adjustment Factor*]( $r_{source}, b$ ) = scaling factor that accounts for the deviation of  $b$ -  
2169 type particles emitted from the  $r_{source}$  region from that of a reference source region (no  
2170 units)

2171

2172 [*Subgroup Adjustment Factor*]( $g, s, b$ ) = scaling factor that accounts for the deviation of  
2173 group  $g$ , subgroup  $s$ ,  $b$ -type particle exposure and response from that of the reference  
2174 exposure and response (no units)

2175

2176 [*Total Particles Released*] = total number of particles released into the atmosphere  
2177 (particles)

2178

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

## 2179 **Conceptual Model**

2180 The general environmentally-mediated infection process can be mathematically represented by  
2181 **Equations C1 and C2.**

2182 **(Equation C1)**

$$2183 \quad [Infections] = \sum_{p=1}^{TP} [Infection Probability](p)$$

2184 **(Equation C2)**

$$2185 \quad [Infection Probability](p) = Health\ Effect\ Model(p, [Exposure](p))$$

2186

2187

## 2188 **Rare Exposures**

2189 If there are  $TB$  different types of particles AND any individual inhales either one or no particles,  
2190 then the probability of an individual  $p$  becoming infected is shown in **Equation C3**.<sup>36</sup>

2191 **(Equation C3)**

$$2192 \quad [Infection Probability](p) \\ 2193 \quad \approx \sum_{b=1}^{TB} ([Exposure](p, b) \cdot [Single\ Particle\ Infection\ Probability](p, b))$$

2194

2195

---

<sup>36</sup> For context, an airborne exposure of  $10^4$  particles  $s\ m^{-3}$  would result in a typical individual inhaling a single particle (assuming a breathing rate of  $10^{-4}\ m^3\ s^{-1}$  [235]).

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2196 **Subgroups**

2197 Consider a (sub)group  $s$  comprised of  $TS$  individuals with same exposure, but varying response  
2198 to that exposure,<sup>37</sup> then **Equations C4** and **C5** provides the mean infection probability for  
2199 (sub)group  $s$ .

2200 **(Equation C4)**

2201  $[Infection\ Probability](s)$

$$\begin{aligned}
 2202 \quad &\equiv \frac{\sum_{p=1}^{TS} [Infection\ Probability](p)}{TS} \\
 2203 \quad &\approx \frac{\sum_{p=1}^{TS} \sum_{b=1}^{TB} ([Exposure](p, b) \cdot [Single\ Particle\ Infection\ Probability](p, b))}{TS} \\
 2204 \quad &= \sum_{b=1}^{TB} \left( [Exposure](s, b) \cdot \frac{\sum_{p=1}^{TS} [Single\ Particle\ Infection\ Probability](p, b)}{TS} \right) \\
 2205 \quad &= \sum_{b=1}^{TB} ([Exposure](s, b) \cdot [Single\ Particle\ Infection\ Probability](s, b))
 \end{aligned}$$

2206 **(Equation C5)**

$$\begin{aligned}
 2207 \quad &[Single\ Particle\ Infection\ Probability](s, b) \\
 2208 \quad &\equiv \frac{\sum_{p=1}^{TS} [Single\ Particle\ Infection\ Probability](p, b)}{TS} \\
 2209 \quad &
 \end{aligned}$$

---

<sup>37</sup> One example is a group of people in a room where the air is well mixed.



M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

## 2210 **Groups**

2211 When exposures within a group of people are not constant,<sup>38</sup> each subgroup can be considered  
2212 a separate, constant exposure group and the overall group's (mean) infection probability is  
2213 equal to the population weighted average of the individual subgroup infection probabilities, see  
2214 **Equation C6.**

2215 **(Equation C6)**

2216 
$$[\textit{Infection Probability}](g) = \sum_{s=1}^{TSG} \left( [\textit{Population Probability}](g, s) \cdot [\textit{Infection Probability}](s) \right)$$

2217 
$$\approx \sum_{b=1}^{TB} \sum_{s=1}^{TSG} \left( \frac{[\textit{Population Probability}](g, s)}{[\textit{Single Particle Infection Probability}](s, b)} \cdot [\textit{Exposure}](s, b) \right)$$

2218  
2219

---

<sup>38</sup> One example is a neighborhood where people are in different buildings that provide varying degrees of protection from an outdoor plume of airborne, infectious particles.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2220 We assume that the individual exposures and health effects can be defined as a ratio to a  
2221 reference exposure and response, respectively. While these ratios can take any value and vary  
2222 by individual, the individual-specific value cannot change. With these assumptions, **Equation C6**  
2223 can be re-written as **Equation C7 to C11**.

2224 **(Equation C7)**

$$2225 \quad [Infection\ Probability](g) = \sum_{b=1}^{TB} \left( \begin{array}{l} [Single\ Particle\ Infection\ Probability]_{ref}(g, b) \\ \cdot [Exposure]_{ref}(g, b) \\ \cdot [Adjustment\ Factor](g, b) \end{array} \right)$$

2226 **(Equation C8)**

$$2227 \quad [Adjustment\ Factor](g, b) = \sum_{s=1}^{TSG} \left( \begin{array}{l} [Population\ Probability](g, s) \\ \cdot [Subgroup\ Adjustment\ Factor](g, s, b) \end{array} \right)$$

2228 **(Equation C9)**

$$2229 \quad [Subgroup\ Adjustment\ Factor](g, s, b) \\ 2230 \quad = [Exposure\ Adjustment\ Factor](g, s, b) \\ 2231 \quad \cdot [Response\ Adjustment\ Factor](g, s, b)$$

2232 **(Equation C10)**

$$2233 \quad [Exposure\ Adjustment\ Factor](g, s, b) = \frac{[Exposure](s, b)}{[Exposure]_{ref}(g, b)}$$

2234 **(Equation C11)**

$$2235 \quad [Response\ Adjustment\ Factor](g, s, b) \\ 2236 \quad = \frac{[Single\ Particle\ Infection\ Probability](s, b)}{[Single\ Particle\ Infection\ Probability]_{ref}(g, b)}$$

2237

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2238 **Absolute Infection Probability for Geographic Regions**

2239 Geographic regions, e.g., zip codes and census tracts, are often used when reporting  
2240 epidemiological data and defining outbreak response zones, e.g., quarantine and/or  
2241 vaccination. For this case, we define region  $r$  as a type of group and **Equation C7** can be  
2242 rewritten as **Equation C12** where the reference exposure is defined by **Equation C13**.

2243 **(Equation C12)**

$$\begin{aligned}
 & \text{2244} \quad [Infection\ Probability](r) \\
 & \text{2245} \quad \approx [Total\ Particles\ Released] \\
 & \quad \quad \quad \sum_{b=1}^{TB} \left( \begin{array}{l} [Release\ Probability](b) \\ \cdot [Single\ Particle\ Infection\ Probability]_{ref}(r, b) \\ \cdot [Adjustment\ Factor](r, b) \\ \cdot [Normalized\ TSIAC](r, b) \end{array} \right) \\
 & \text{2246} \quad \times \frac{\quad}{[Area](r)}
 \end{aligned}$$

2247 **(Equation C13)**

$$\begin{aligned}
 & \text{2248} \quad [Exposure]_{ref}(r, b) \\
 & \text{2249} \quad = \frac{[Total\ Particles\ Released] \cdot [Release\ Probability](b) \cdot [Normalized\ TSIAC](r, b)}{[Area](r)}
 \end{aligned}$$

2250

2251 When considering outdoor plumes of infectious particles, we adapt the Regional Shelter  
2252 Analysis (RSA) methodology to assign each location (subgroup  $s$ ) a “protection factor” which is  
2253 defined as the ratio of the outdoor to indoor exposures. As shown in [30], [31]; building  
2254 protection factors depend only on the building operating conditions, environmental  
2255 parameters, and the particle type. Thus, for a given particle type, the assigned protection  
2256 factors are identical to the inverse of the  $[Exposure\ Adjustment\ Factor](r, s, b)$  where  
2257  $[Exposure]_{ref}(r, b)$  is the outdoor time-integrated air concentration of  $b$ -type particles during  
2258 the passage of the airborne infectious plume over region  $r$ .

2259

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

## 2260 Relative Infection Probability for Geographic Regions

2261 Given a plume of airborne infectious particles from a single source, then **Equation C12** implies  
2262 **Equation C14** when a single particle type dominates the exposures. **Equation C14** does not  
2263 depend on the release or the infectivity of individual particles. When the two regions are similar  
2264 (e.g., both  $r$  and  $r_{ref}$  are residential areas with similar demographics) the adjustment factor ratio  
2265 is unity. We demonstrate the utility of **Equation C14** in the 4. *Results* and 5. *Discussion* sections.

2266 **(Equation C14)**

$$\begin{aligned}
 2267 \quad [Relative\ Infection\ Probability](r, b) &= \frac{[Infection\ Probability](r, b)}{[Infection\ Probability](r_{ref}, b)} \\
 2268 \quad &= \left( \frac{[Normalized\ TSIAC](r, b)}{[Normalized\ TSIAC](r_{ref}, b)} \right) \cdot \left( \frac{[Area](r_{ref})}{[Area](r)} \right) \\
 2269 \quad &\cdot \left( \frac{[Adjustment\ Factor](r, b)}{[Adjustment\ Factor](r_{ref}, b)} \right)
 \end{aligned}$$

2270

2271

## 2272 Extrapolating Regional Infection Probabilities

2273 When a clear case of region-to-region airborne disease transmission has been identified and a  
2274 single particle type dominates the exposures, **Equation C16**, derived from **Equations C15(a-b)**,  
2275 estimates an effective source term for each infectious person in the source region.

2276 **(Equation C15a)**

$$\begin{aligned}
 2277 \quad [Infections](r_{ref}, b) & \\
 2278 \quad &\approx [Total\ Particles\ Released] \cdot [Release\ Probability](b) \\
 2279 \quad &\cdot [Normalized\ TSIAC](r_{ref}, r_{source\ 1}, b) \\
 2280 \quad &\cdot [Single\ Particle\ Infection\ Probability]_{ref}(r_{ref}, b) \\
 2281 \quad &\cdot [Adjustment\ Factor](r_{ref}, b) \cdot [Population\ Density](r_{ref})
 \end{aligned}$$

2282

2283

2284

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2285 (Equation C15b)

$$\begin{aligned}
 & \left( \begin{aligned} & [Total\ Particles\ Released] \cdot [Release\ Probability](b) \\ & \cdot [Single\ Particle\ Infection\ Probability]_{ref}(r_{ref}, b) \\ & \cdot [Adjustment\ Factor](r_{ref}, b) \end{aligned} \right) \\
 & \approx \frac{[Infections](r_{ref}, b)}{[Normalized\ TSIAC](r_{ref}, r_{source\ 1}, b) \cdot [Population\ Density](r_{ref})}
 \end{aligned}$$

2288 (Equation C16)

$$\begin{aligned}
 & [Effective\ Source\ Term](r_{ref}, r_{source\ 1}, b) \\
 & \equiv \frac{\left( \begin{aligned} & [Total\ Particles\ Released] \cdot [Release\ Probability](b) \\ & \cdot [Single\ Particle\ Infection\ Probability]_{ref}(r_{ref}, b) \\ & \cdot [Adjustment\ Factor](r_{ref}, b) \end{aligned} \right)}{[Infectious\ People](r_{source\ 1})} \\
 & = \frac{[Infection\ Probability](r_{ref}) \cdot [Area](r_{ref})}{[Normalized\ TSIAC](r_{ref}, r_{source\ 1}, b) \cdot [Infectious\ People](r_{source\ 1})}
 \end{aligned}$$

2292

2293 Given the effective source term (**Equation C16**), the infection rates in other regions and times

2294 can then be estimated with **Equation C17a**. Alternately, **Equation C17b** can be used without the

2295 need to calculate the intermediate “effective source” quantity. The new term, the source

2296 adjustment factor, is introduced which adjusts for the number of airborne infectious particles

2297 emitted, e.g., a reduction in cough-emitted infectious particles due to use of respiratory masks.

2298 As with **Equation C14**, the reference and source regions disease adjustment factor may also be

2299 similar, i.e., their ratio may be unity, if buildings and demographics are similar in both source

2300 and target regions.

2301

2302

2303

2304

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2305 **(Equation C17a)**

2306  $[Infection\ Probability](r)$

2307 
$$= \frac{\left( \begin{array}{l} [Effective\ Source\ Term](r_{ref}, r_{source\ 1}, b) \\ \cdot [Normalized\ TSIAC](r, r_{source\ 2}, b) \\ \cdot [Infectious\ People](r_{source\ 2}) \end{array} \right)}{[Area](r)}$$

2308 
$$\cdot \left( \frac{[Adjustment\ Factor](r, b)}{[Adjustment\ Factor](r_{ref}, b)} \right)$$

2309 
$$\cdot \left( \frac{[Source\ Adjustment\ Factor](r_{source\ 2}, b)}{[Source\ Adjustment\ Factor](r_{source\ 1}, b)} \right)$$

2310 **(Equation C17b)**

2311  $[Infection\ Probability](r)$

2312 
$$= [Infection\ Probability](r_{ref}) \cdot \left( \frac{[Normalized\ TSIAC](r, r_{source\ 2}, b)}{[Normalized\ TSIAC](r_{ref}, r_{source\ 1}, b)} \right)$$

2313 
$$\cdot \left( \frac{[Infectious\ People](r_{source\ 2})}{[Infectious\ People](r_{source\ 1})} \right) \cdot \left( \frac{[Adjustment\ Factor](r, b)}{[Adjustment\ Factor](r_{ref}, b)} \right)$$

2314 
$$\cdot \left( \frac{[Source\ Adjustment\ Factor](r_{source\ 2}, b)}{[Source\ Adjustment\ Factor](r_{source\ 1}, b)} \right) \cdot \left( \frac{[Area](r_{ref})}{[Area](r)} \right)$$

2315

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

## 2316 Relationship to Disease and Other Metrics

2317 The Supplemental Material equations presented up to this point focus on infection probability.  
2318 However, not all infections result in disease. In addition, other metrics, such as probability of  
2319 needing medical resources, may also be of interest. When the probability of the metric of  
2320 interest, e.g., disease, can be linearly related to exposure, see **Equation C18**, then it is  
2321 straightforward to adapt the prior equations for the metric of interest by replacing  
2322  $[Infection\ Probability](p)$  with  $[Metric\ of\ Interest\ Probability](p)$ . We note that while  
2323  $[Single\ Particle\ Metric\ of\ Interest\ Probability](p, b)$  can take any value and vary by  
2324 individual and/or particle type, the value for a specific individual and particle type cannot  
2325 change. We note that the adjustment factors can vary by metric.

2326 *The relative incidence of multiple metrics of interest, such as infection and disease are the same,*  
2327 *since **Equation C14** is unchanged by this substitution.*

2328 **(Equation C18)**

$$\begin{aligned} 2329 \quad & [Metric\ of\ Interest\ Probability](p) \\ 2330 \quad & = \sum_{b=1}^{TB} \left( \frac{[Exposure](p, b)}{[Single\ Particle\ Probability\ for\ Metric\ of\ Interest](p, b)} \right) \end{aligned}$$

2331



M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

## 2332 **Supplemental Material D: Indoor Particle Dynamics**

2333 This supplemental material derives equations to estimate three related, but distinct building  
2334 properties: (1) the degree to which indoor individuals are exposed to outdoor-origin airborne  
2335 particulates, (2) the degree to which indoor individuals are exposed to indoor-origin airborne  
2336 particulates, and (3) the fraction of indoor-origin particulates that exit the building and enter the  
2337 outdoor atmosphere. The first section, building protection, is adapted (with minor edits) from a  
2338 prior publication [30] which also provides detailed discussion on the relevant indoor particle  
2339 dynamics and representative estimates for both (a) parameter values (which are also used in  
2340 the other sections) and (b) protection estimates for US buildings and Census Tracts. The other  
2341 two subsections, which extend the building protection material, are new.

2342 While we do not discuss prior approaches in detail in this report, we note the Wells-Riley model  
2343 which estimated the indoor infection risk to susceptible populations who share the same  
2344 building as potentially infectious individuals. The Wells-Riley model also provided quantitative  
2345 guidance on the indoor loss rates and ventilation rates required to reduce disease spread [3],  
2346 [236]. Later extensions of this model have addressed many of its original limitations. However,  
2347 all versions retain the concept of a “quantum of infection” whose definition combines many key  
2348 physical properties, including the probability of infection when there is exposure to infectious  
2349 particles [237].

2350

2351 **Section Variables Definitions**

2352

2353  $\lambda_{dep}$  (*particle size*) = the particle size dependent indoor deposition loss rate ( $\text{h}^{-1}$ )

2354  $\lambda_{decay}$  = the “generic” first-order airborne decay (loss) rate ( $\text{h}^{-1}$ )

2355  $\lambda_{in}$  = the rate at which outdoor airborne particles enters the building – typically via infiltration  
2356 or ventilation. Includes losses that occur during transport from outdoor to indoor ( $\text{h}^{-1}$ )

2357  $\lambda_{inf}$  = the air infiltration rate at which air enters a building, i.e., the air change rate ( $\text{h}^{-1}$ )

2358  $\lambda_{internal}$  = the rate at which indoor airborne particles are lost within the building – typically by  
2359 deposition to surfaces or by filtration ( $\text{h}^{-1}$ )

2360  $\lambda_{out}$  = the rate at which indoor airborne particles exit the building – typically via exfiltration or  
2361 ventilation ( $\text{h}^{-1}$ )

2362  $\lambda_T$  = the total building ventilation rate = sum of the infiltration and mechanical ventilation rates  
2363 ( $\text{h}^{-1}$ )

2364

2365 [*Building Exit Fraction*] = fraction of indoor airborne material that exits the building and  
2366 enters the outdoor atmosphere. (no units)

2367 [*Building Floor Area*] = floor area of the building ( $\text{m}^2$ )

2368 [*Building Protection Factor*] = ratio of the outdoor to indoor exposure. Similar to sunscreen  
2369 and personal protective respirator rating systems, higher protection factor values indicate  
2370 lower exposures and thus increased protection. (protection factor)

2371 [*Building Volume*] = volume of the building ( $\text{m}^3$ )

2372 [*Normalized TSIAC*]<sub>indoor</sub> = indoor time and space integrated air concentration assuming a  
2373 unit amount of material is released ( $\text{s m}^{-1}$ )

2374 [*Room Height*] = height of building occupied space (m)

2375 [*Total Particles Released*] = total number of particles released into the indoor air (particles)

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2376

2377  $C_{Indoor}(t)$  = the indoor particle air concentration at time  $t$  ( $\text{g m}^{-3}$ )

2378  $C_{Outdoor}(t)$  = the outdoor particle air concentration at time  $t$  ( $\text{g m}^{-3}$ )

2379  $L_{inf}(\textit{particle size})$  = the particle size dependent efficiency by which particles can penetrate  
2380 the building shell (dimensionless)

2381  $L_{out}(\textit{particle size})$  = the particle size dependent efficiency by which particles in indoor air exit  
2382 the building through cracks and other penetrations in the building shell (dimensionless)

2383  $F_{filter}(\textit{particle size})$  = the particle size dependent filtration efficiency (dimensionless)

2384  $F_{oa}$  = the fraction of outdoor air passing through the HVAC supply fan (dimensionless)

2385  $F_{r,fan}$  = the fraction of time the forced air furnace recirculation fan is on, i.e., the fan's duty  
2386 cycle (dimensionless)

2387  $r_{fan}$  = the rate at which a building volume of air recirculates through the furnace systems when  
2388 the fan is on ( $\text{h}^{-1}$ )

2389  $v_{fan}$  = the rate at which a ventilation or HVAC supply fan delivers air to the building when the  
2390 fan is on and combines the outside and recirculation air rates (building volume  $\text{h}^{-1}$ )

2391  $t$  = time (h)

2392  $\tau$  = an integration variable (h)

2393

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

## 2394 **Building Protection Against Outdoor-Origin Particles**


2395 Indoor individuals can be exposed to particles of outdoor origin when these contaminants enter  
2396 buildings through mechanical ventilation, e.g., heating, ventilation and air conditioning (HVAC)  
2397 systems, natural ventilation (e.g., open windows), and/or infiltration (e.g., exterior wall cracks).  
2398 Particles may also be transported into buildings via deposition on outdoor surfaces or fomites  
2399 that are subsequently tracked indoors by individuals, or otherwise transported, into the  
2400 building and then resuspended into the indoor air. These transport pathways are illustrated in  
2401 the top panel of **Figure D1**. Once indoors, airborne particles can be removed from the indoor air  
2402 through (a) air leaving the building through mechanical or natural ventilation and exfiltration;  
2403 (b) active filtration within ventilation systems (if present); (c) deposition on indoor surfaces  
2404 (some particles may resuspend); and (d) other processes, including radioactive decay, chemical  
2405 reactions, stand-alone indoor air filtration systems, and the loss of infectivity of airborne  
2406 infectious agents, among others. The latter three loss terms are illustrated in the bottom panel  
2407 of **Figure D1**.

2408 Modeling indoor contaminant concentrations requires choosing among a variety of models with  
2409 increasing complexity, ranging from simple single-compartment models to multizone models to  
2410 highly detailed computational fluid dynamics models. While increasingly detailed and complex  
2411 models may reduce modeling conservatism and uncertainty, the number and fidelity of the  
2412 input parameters also increases (see [238] for a general discussion). Detailed parameters are  
2413 not generally available for many buildings of interest therefore we make two key modeling  
2414 assumptions: (a) that indoor volumes can be represented as a single compartment, which can  
2415 be used to describe the time evolution of indoor contaminant concentrations, and (b) that  
2416 concentrations within that single compartment are spatially uniform [36], [119], [239], [240].<sup>39</sup>

2417

---

<sup>39</sup> We note that the contaminants of concern here are from the outdoors which, due to the air change mechanisms, can result in a relatively uniform indoor spatial contaminant distribution. For example in modeling indoor concentrations of outdoor ozone, *Hayes* [241] demonstrated that the indoor/outdoor ozone concentration ratio was insensitive to the degree of indoor mixing in both single- and multicompartments models for residences and office buildings. For context, the mixing time constants for both buoyant and mechanical flow conditions in laboratory studies of room mixing are short, 10 min to < 1 h, compared to the exposure times of interest [35], [36].



2418

2419

2420 **Figure D1. Illustrations of (top) mechanisms by which airborne material and fomites can**  
2421 **travel between the outdoor and indoor environments and (bottom) indoor loss mechanisms.**

2422

2423 These assumptions are codified in the single box model (**Equation D1a**) which can be used to  
2424 describe the time evolution of indoor air concentrations after outdoor contaminants have  
2425 entered a given building. This study includes the additional, commonly used assumption that  
2426 the transport and loss terms, i.e., the  $\lambda$  parameters, are independent of both time and air  
2427 concentration on the timescales of interest. **Equation D1a** thus reduces to **Equation D1b**.  
2428 Derivations provided in the methodology report [31] demonstrate that **Equation D2** provides  
2429 the building protection factor (the ratio of outdoor to indoor exposure).<sup>40</sup>  
2430

<sup>40</sup> These equations assume that (a) initial ( $t = 0$ ) indoor air concentrations are zero and (b) material removed from the indoor air is not reintroduced at a later time (e.g., resuspension of deposited particles).

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2431 (Equation D1a)

$$2432 \quad \frac{dC_{Indoor}}{dt} = \lambda_{in} \cdot C_{Outdoor}(t) - (\lambda_{out} + \lambda_{internal}) \cdot C_{Indoor}(t)$$

2433 (Equation D1b)

$$2434 \quad C_{Indoor}(t) = \lambda_{in} \cdot \int_0^t C_{Outdoor}(\tau) \cdot e^{-(\lambda_{out} + \lambda_{internal})(t-\tau)} d\tau$$

2435 (Equation D2)

$$2436 \quad [Building Protection Factor] = \frac{\int C_{Outdoor}(t)dt}{\int C_{Indoor}(t)dt} = \frac{(\lambda_{out} + \lambda_{internal})}{\lambda_{in}}$$

2437

2438 We adapt **Equation D2** to develop two generalized building PF equations to cover the range of  
2439 building types typically found in the US. The equation terms are grouped to correspond to the  
2440  $\lambda_{in}$ ,  $\lambda_{out}$ , and  $\lambda_{internal}$  terms in **Equation D2**. Each PF equation is based on one of two common  
2441 combinations of (a) the three airflow mechanisms described above and (b) the relevant indoor  
2442 loss mechanisms. In addition to any filtration that might be present, and already incorporated  
2443 into the airflow terms, we consider two additional indoor loss mechanisms: (1) deposition of  
2444 airborne particles to indoor surfaces,  $\lambda_{dep}$ , and (2) a generic first-order airborne loss  
2445 mechanism,  $\lambda_{decay}$ , which can be used to represent radioactive decay (radiological hazards) or  
2446 airborne loss of infectivity (biological hazards). Several parameters are particle size dependent.  
2447 For readability, these dependencies are not shown in the equations themselves, but are noted  
2448 in the variable list definitions above. See [30] for a detailed discussion of parameters and their  
2449 common values.

2450

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2451 **Equation D3** specifies the protection factor for buildings with filtered recirculation. In the US,  
2452 these are typically residences. Outdoor airborne material enters the building only through the  
2453 infiltration pathway. The forced air furnace recirculation air filter, if present, removes indoor  
2454 airborne particles.

2455 **(Equation D3)**

$$2456 \quad [Building Protection Factor] = \frac{\lambda_{inf} + (F_{filter} \cdot F_{r,fan} \cdot r_{fan} + \lambda_{dep} + \lambda_{decay})}{(\lambda_{inf} \cdot L_{inf})}$$

2457

2458 **Equation D4** specifies the protection factor for buildings with an active HVAC system. In the US,  
2459 these are typically commercial buildings. Outdoor airborne material enters the building through  
2460 either infiltration or the HVAC system outdoor air intake. The HVAC system air filter removes  
2461 airborne particles from both the entering and recirculating air. This equation implicitly assumes  
2462 that the HVAC system is always moving building air although not necessarily heating or cooling  
2463 it, i.e., the fan duty cycle is 100%.

2464 **(Equation D4)**

$$2465 \quad [Building Protection Factor] = \frac{\lambda_T + (F_{filter} \cdot v_{fan} \cdot (1 - F_{oa}) + \lambda_{dep} + \lambda_{decay})}{(\lambda_{inf} \cdot L_{inf} + v_{fan} \cdot F_{oa} \cdot (1 - F_{filter}))}$$

2466

2467



M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

## 2468 **Normalized Indoor Exposures**

2469 With the additional assumptions that outdoor concentrations are zero and all indoor emissions  
2470 occur at a single time ( $t = 0$ ), **Equation D1a** simplifies to **Equations D5(a-b)**. When a unit  
2471 amount of material is released at  $t = 0$ , **Equation D5** reduces to **Equation D6**.

2472 **(Equation D5a)**

$$2473 \quad \frac{dC_{Indoor}(t)}{dt} = -(\lambda_{out} + \lambda_{internal}) \cdot C_{Indoor}(t)$$

2474 **(Equation D5b)**

$$2475 \quad C_{Indoor}(t) = C_{Indoor}(t = 0) \cdot e^{-(\lambda_{out} + \lambda_{internal})t}$$

2476 **(Equation D6)**

$$2477 \quad [Normalized\ TSIAC]_{indoor} = [Building\ Floor\ Area] \cdot \int_0^{\infty} C_{Indoor}(t) dt$$

$$2478 \quad = [Building\ Floor\ Area] \times \left( \frac{1}{[Building\ Volume]} \right) \times (\lambda_{out} + \lambda_{internal})^{-1}$$

$$2479 \quad = \frac{1}{[Room\ Height] \cdot (\lambda_{out} + \lambda_{internal})}$$

2480

2481

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2482 We now adapt the general building protection equations to estimate the  
2483  $[Normalized\ TSIAC]_{indoor}$ . The equation terms are grouped to correspond to the  $\lambda_{out}$  and  
2484  $\lambda_{internal}$  terms in **Equation D6**.

2485

2486 **Equation D7** specifies  $[Normalized\ TSIAC]_{indoor}$  for buildings with filtered recirculation (US  
2487 residences).

2488 **(Equation D7)**

2489  $[Normalized\ TSIAC]_{indoor}$   
2490 
$$= \frac{1}{[Room\ Height] \cdot (\lambda_{inf} + (F_{filter} \cdot F_{r, fan} \cdot r_{fan} + \lambda_{dep} + \lambda_{decay}))}$$

2491

2492

2493 **Equation D8** specifies  $[Normalized\ TSIAC]_{indoor}$  for buildings with an active HVAC system (US  
2494 commercial buildings).

2495 **(Equation D8)**

2496  $[Normalized\ TSIAC]_{indoor}$   
2497 
$$= \frac{1}{[Room\ Height] \cdot (\lambda_T + (F_{filter} \cdot v_{fan} \cdot (1 - F_{oa}) + \lambda_{dep} + \lambda_{decay}))}$$

2498

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

## 2499 Fraction of Indoor Airborne Particles Released to the Outdoors

2500 **Equation D9** shows the fraction of indoor airborne material that exits the building and enters  
2501 the outdoor atmosphere. This equation is based on (a) the (normalized) indoor concentration,  
2502 (b) the rate at which indoor air (and airborne material) leaves the building, and (c) particulate  
2503 losses that occur while airborne particles are suspended in indoor air exiting the building.

2504 **(Equation D9)**

$$\begin{aligned}
 2505 \quad [Building\ Exit\ Fraction] &= \frac{\int_0^{\infty} (C_{Indoor}(t) \cdot [Building\ Volume]) \cdot (\lambda_{out} \cdot L_{out}) dt}{[Total\ Particles\ Released]} \\
 2506 \quad &= [Normalized\ TSIAC]_{indoor} \cdot [Room\ Height] \cdot \lambda_{out} \cdot L_{out} \\
 2507 \quad &= \frac{\lambda_{out} \cdot L_{out}}{(\lambda_{out} + \lambda_{internal})}
 \end{aligned}$$

2508 For buildings with filtered recirculation (US residences), outdoor air enters the building only  
2509 through the infiltration pathway and so  $\lambda_{out} = \lambda_{inf}$  and **Equation D10** shows the fraction of  
2510 material released indoors that exits the building. The entrance and exit airflow paths may differ.  
2511 For examples, outdoor air could enter the building through wall cracks while some of the indoor  
2512 air could exit the building through exhaust fans. Thus, entrance and exit loss fractions,  $L_{in}$  and  
2513  $L_{out}$ , respectively, can in theory differ. However at a practical level, there is little data on which  
2514 to estimate the  $L_{out}$  term. In addition, small, e.g., 1  $\mu\text{m}$  aerodynamic diameter, particle losses  
2515 are minimal. Therefore we assume  $L_{out} = L_{inf}$  and the *[Exit Fraction] is equal to the inverse*  
2516 *of the building protection factor as derived in [30]*. For context, 35%, on average, of the  
2517 airborne, 1  $\mu\text{m}$  aerodynamic diameter, stable (do not lose infectivity in the air) particles  
2518 released in US single family homes are expected to exit the building (and be released to the  
2519 outdoor atmosphere) [30].

2520 **(Equation D10)**

$$\begin{aligned}
 2521 \quad [Building\ Exit\ Fraction] &= \frac{\lambda_{inf} \cdot L_{inf}}{\lambda_{inf} + (F_{filter} \cdot F_{r, fan} \cdot r_{fan} + \lambda_{dep} + \lambda_{decay})} \\
 2522 \quad &= \frac{1}{[Building\ Protection\ Factor]} \cdot \left( \frac{L_{out}}{L_{inf}} \right)
 \end{aligned}$$

2523

2524

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2525 For buildings with an active HVAC system (US commercial buildings), indoor airborne material  
2526 exits the building through either infiltration or through mechanical means, e.g., the HVAC  
2527 system exhaust. Again we note that the entrance and exit airflow paths may differ, but as a  
2528 practical matter assume (a) that they are the same ( $\lambda_{out} = \lambda_{inf}$ ;  $L_{out} = L_{inf}$ ) and (b) no  
2529 particles are lost while the indoor air is exiting through the exhaust system. **Equation D11**,  
2530 *which shows the fraction of material released indoors that exits the building, is not the same as*  
2531 *the building protection factor derived in [30].*

2532 **(Equation D11)**

2533 
$$[\textit{Building Exit Fraction}] = \frac{(\lambda_{inf} \cdot L_{inf} + v_{fan} \cdot F_{oa})}{\lambda_T + (F_{filter} \cdot v_{fan} \cdot (1 - F_{oa}) + \lambda_{dep} + \lambda_{decay})}$$

2534  
2535

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

## 2536 **Supplemental Material E: Outdoor Normalized Time and Space** 2537 **Integrated Air Concentrations**

2538 Outdoor normalized time and space integrated air concentration (Normalized TSIAC) values are  
2539 a key component in our estimation of the single particle atmospheric transmission rates  
2540 discussed in the main text. In this Supplemental Material, we describe how these values were  
2541 calculated. For context, we also provide absolute and relative infection probabilities for a wider  
2542 range of input parameter values than discussed in the main text.

2543 We use the Lawrence Livermore National Laboratory Atmospheric Data Assimilation and  
2544 Parameterization Techniques (ADAPT) and Lagrangian Operational Dispersion Integrator (LODI)  
2545 meteorological and atmospheric dispersion models to calculate outdoor normalized time and  
2546 space integrated air concentrations [242], [243]. The LODI/ADAPT model accuracy and  
2547 validation are discussed in **Supplemental Material B: Key Atmospheric Transport and**  
2548 **Dispersion Modeling Concepts**, *Atmospheric Dispersion Models* section.

2549 We consider a suite of atmospheric conditions, **Table E1**, which were chosen to span a  
2550 reasonably wide, but not comprehensive, range of common atmospheric conditions. The  
2551 atmospheric conditions were held constant during the plume passage. Following this table, we  
2552 provide the methodology and specific modeling assumptions used.

2553 **Tables E2(a-b) to E5(a-b)** provide the predicted outdoor Normalized TSIAC as a function of  
2554 distance from an emission source, atmospheric conditions, and airborne loss rate. The  
2555 Normalized TSIAC values are specified for both discs and circle arcs at distances ranging from 50  
2556 m to 20 km. Each table corresponds to one airborne (infectivity) loss rate (0, 0.1, 1, or 10 h<sup>-1</sup>  
2557 loss rates were modeled). Each table column corresponds to 1 of 7 commonly encountered  
2558 wind speeds and atmospheric stabilities as specified in **Table E1**.

2559 For context, **Figures E1 to E4** provide downwind, upper bound estimates for two cases: (a) the  
2560 average per-person, single particle, absolute infection probability and (b) the corresponding  
2561 urban area infections. **Figures E5 to E8** provide relative infection probabilities relative to 1 km  
2562 disc or arc values. Each figure corresponds to a single airborne (infectivity) loss rate.

2563

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2564 **Table E1. Summary of modeled atmospheric conditions**

<b>Qualitative Description</b>	<b>Stability Class (MO Length in m)</b>	<b>Wind Speed at 10 m above ground level in m s<sup>-1</sup></b>	<b>Boundary Layer Height in m</b>
Clear, cold night with light winds	F (25)	1.0	300
Clear night with gentle breeze	E (50)	4.5	500
Overcast with light winds	C (-50)	1.0	1,000
Overcast with gentle breeze	D (∞)	4.5	800
Overcast with strong breeze	D (∞)	10	800
Clear day with gentle breeze	B (-25)	4.5	1,200
Clear, hot day with light winds	A (-10)	1.0	1,500

2565

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2566 We modeled the downwind impacts assuming:

- 2567 • The release quantity is one (effective) particle.
- 2568 • All particles have 1  $\mu\text{m}$  aerodynamic diameter.
- 2569 • The released particle has a constant probability of being emitted from a point within  
2570 a 1 hr period.
- 2571 • Gravitational settling is the only deposition mechanism considered. The inclusion of  
2572 other deposition mechanisms including (but not limited to) Brownian diffusion,  
2573 rainout, impaction, and interception would all serve to reduce the modeled air  
2574 concentrations and so our neglect of these mechanisms is consistent with the intent  
2575 of providing an upper bound on the number of downwind infections.
- 2576 • 4 different 1<sup>st</sup> order airborne loss rates (in addition to gravitational settling) are  
2577 considered: 0, 0.1, 1, and 10  $\text{h}^{-1}$ . These airborne loss rates are used to characterize  
2578 the effects of airborne loss of particle infectivity.
- 2579 • Resuspension (the re-emission of deposited material back into the atmosphere) is  
2580 neglected.
- 2581 • Flat terrain with a surface roughness of 0.1 m corresponding to a suburban setting.  
2582 In forested and downtown regions, the earth's surface is typically rougher –  
2583 resulting in lower surface air concentrations during stable and neutral atmospheric  
2584 conditions.
- 2585 • The modeled wind blew from the west ( $270^\circ$ ) to the east with no vertical or  
2586 horizontal variation in wind direction (modeled wind speeds increase with height  
2587 above ground).

2588

2589



M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2590 Downwind concentrations were predicted using 2 modeling grids. The first had a 30 km  
2591 horizontal extent and 100 m horizontal resolution grid cells. The second had a 1.5 km horizontal  
2592 extent and 6 m horizontal resolution grid cells

2593 For each case, LODI was run with 1,000,000 marker particles<sup>41</sup> to calculate the (ensemble)  
2594 average surface (lowest 20 m) normalized air concentrations integrated over the entire plume  
2595 passage (i.e., until no marker particles remain in the modeling domain) for each model grid cell.  
2596 For each atmospheric condition, the following procedure was used to calculate the normalized  
2597 space and time integrated air concentration provided in **Tables E2(a-b) to E5(a-b)**.

2598 First, we developed an interpolation function for each modeling grid using the MATLAB  
2599 *griddedInterpolant* function configured to return either the value at the nearest sample  
2600 grid point to the requested location (if the requested location is within the sample grid)  
2601 or zero (if the requested location is outside the sample grid).

2602 Second, we calculated the normalized time integrated air concentrations for a fixed set  
2603 of radial distances by numerically integrating previously developed interpolation  
2604 functions (using the MATLAB *integral* and *integral2* functions, as appropriate) for (a) a  
2605 disk and (b) circle arc, both centered on the release. For the 1.5 km extent grid, the  
2606 distances considered were 50 m to 1,100 m at 50 m increments. For the 30 km extent  
2607 grid, the distances considered were 2,000 m to 20,000 m at 1,000 m increments.

2608 Third, we developed a second, linear interpolation function using the *griddedInterpolant*  
2609 function from the distances considered and the normalized time integrated air  
2610 concentrations calculated in step 2. This function was used for remainder of the  
2611 analysis.

2612

---

<sup>41</sup> These computational marker particles are a large sample from the possible particles emitted and are used in estimating downwind concentrations along the prescribed contaminant emission amount. These particles do NOT directly represent individual physical aerosols.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2613 **Table E2a. Normalized Time and Space Integrated Particle Air Concentration for a Disc with**  
2614 **the specified distance from the release assuming no airborne loss rate ( $\lambda_{decay} = 0 \text{ h}^{-1}$ ).**

Distance Downwind (m)	Clear, cold night with light winds (s m <sup>-1</sup> )	Clear night with gentle breeze (s m <sup>-1</sup> )	Overcast with light winds (s m <sup>-1</sup> )	Overcast with gentle winds (s m <sup>-1</sup> )	Overcast with strong winds (s m <sup>-1</sup> )	Clear day with gentle winds (s m <sup>-1</sup> )	Clear, hot day with light winds (s m <sup>-1</sup> )
50	2.2E+01	4.4E+00	1.1E+01	3.4E+00	1.5E+00	2.1E+00	7.1E+00
100	4.0E+01	8.0E+00	1.6E+01	5.6E+00	2.5E+00	3.0E+00	9.5E+00
150	5.6E+01	1.1E+01	1.9E+01	7.2E+00	3.3E+00	3.6E+00	1.1E+01
200	7.0E+01	1.3E+01	2.2E+01	8.4E+00	3.8E+00	3.9E+00	1.2E+01
250	8.3E+01	1.5E+01	2.4E+01	9.4E+00	4.3E+00	4.2E+00	1.3E+01
300	9.4E+01	1.7E+01	2.5E+01	1.0E+01	4.6E+00	4.5E+00	1.3E+01
350	1.0E+02	1.9E+01	2.6E+01	1.1E+01	5.0E+00	4.6E+00	1.4E+01
400	1.1E+02	2.0E+01	2.8E+01	1.2E+01	5.3E+00	4.8E+00	1.4E+01
450	1.2E+02	2.2E+01	2.9E+01	1.2E+01	5.5E+00	5.0E+00	1.4E+01
500	1.3E+02	2.3E+01	2.9E+01	1.3E+01	5.8E+00	5.1E+00	1.5E+01
550	1.4E+02	2.4E+01	3.0E+01	1.3E+01	6.0E+00	5.2E+00	1.5E+01
600	1.4E+02	2.5E+01	3.1E+01	1.4E+01	6.2E+00	5.3E+00	1.5E+01
650	1.5E+02	2.6E+01	3.1E+01	1.4E+01	6.4E+00	5.4E+00	1.5E+01
700	1.5E+02	2.7E+01	3.2E+01	1.4E+01	6.5E+00	5.5E+00	1.6E+01
750	1.6E+02	2.8E+01	3.2E+01	1.5E+01	6.7E+00	5.5E+00	1.6E+01
800	1.6E+02	2.9E+01	3.3E+01	1.5E+01	6.8E+00	5.6E+00	1.6E+01
850	1.7E+02	2.9E+01	3.3E+01	1.5E+01	7.0E+00	5.7E+00	1.6E+01
900	1.7E+02	3.0E+01	3.4E+01	1.6E+01	7.1E+00	5.7E+00	1.6E+01
950	1.8E+02	3.1E+01	3.4E+01	1.6E+01	7.2E+00	5.8E+00	1.6E+01
1,000	1.8E+02	3.1E+01	3.4E+01	1.6E+01	7.4E+00	5.8E+00	1.6E+01
1,050	1.8E+02	3.2E+01	3.5E+01	1.6E+01	7.5E+00	5.9E+00	1.7E+01
1,100	1.9E+02	3.3E+01	3.5E+01	1.7E+01	7.6E+00	5.9E+00	1.7E+01
2,000	2.3E+02	3.8E+01	3.6E+01	1.8E+01	8.1E+00	6.7E+00	1.9E+01
3,000	2.6E+02	4.2E+01	3.8E+01	1.9E+01	8.7E+00	7.1E+00	1.9E+01
4,000	2.8E+02	4.6E+01	4.0E+01	2.0E+01	9.2E+00	7.3E+00	2.0E+01
5,000	3.0E+02	4.8E+01	4.1E+01	2.1E+01	9.6E+00	7.5E+00	2.1E+01
6,000	3.1E+02	5.1E+01	4.2E+01	2.2E+01	9.9E+00	7.7E+00	2.1E+01
7,000	3.1E+02	5.3E+01	4.3E+01	2.2E+01	1.0E+01	7.9E+00	2.2E+01
8,000	3.2E+02	5.5E+01	4.4E+01	2.3E+01	1.0E+01	8.0E+00	2.2E+01
9,000	3.3E+02	5.7E+01	4.5E+01	2.3E+01	1.1E+01	8.2E+00	2.2E+01
10,000	3.3E+02	5.8E+01	4.5E+01	2.4E+01	1.1E+01	8.3E+00	2.3E+01
11,000	3.4E+02	6.0E+01	4.6E+01	2.4E+01	1.1E+01	8.4E+00	2.3E+01
12,000	3.4E+02	6.1E+01	4.7E+01	2.4E+01	1.1E+01	8.5E+00	2.4E+01
13,000	3.5E+02	6.2E+01	4.7E+01	2.5E+01	1.2E+01	8.7E+00	2.4E+01
14,000	3.5E+02	6.4E+01	4.8E+01	2.5E+01	1.2E+01	8.8E+00	2.4E+01
15,000	3.5E+02	6.5E+01	4.9E+01	2.6E+01	1.2E+01	8.9E+00	2.5E+01
16,000	3.5E+02	6.6E+01	4.9E+01	2.6E+01	1.2E+01	9.0E+00	2.5E+01
17,000	3.6E+02	6.7E+01	5.0E+01	2.6E+01	1.2E+01	9.1E+00	2.5E+01
18,000	3.6E+02	6.8E+01	5.0E+01	2.6E+01	1.2E+01	9.2E+00	2.6E+01
19,000	3.6E+02	6.9E+01	5.1E+01	2.7E+01	1.3E+01	9.3E+00	2.6E+01
20,000	3.6E+02	7.0E+01	5.1E+01	2.7E+01	1.3E+01	9.4E+00	2.7E+01

2615

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2616 **Table E2b. Normalized Time and Space Integrated Particle Air Concentration for a Circle Arc at**  
2617 **the specified distance from the release assuming no airborne loss rate ( $\lambda_{decay} = 0 \text{ h}^{-1}$ ).**

Distance Downwind (m)	Clear, cold night with light winds (s m <sup>-2</sup> )	Clear night with gentle breeze (s m <sup>-2</sup> )	Overcast with light winds (s m <sup>-2</sup> )	Overcast with gentle winds (s m <sup>-2</sup> )	Overcast with strong winds (s m <sup>-2</sup> )	Clear day with gentle winds (s m <sup>-2</sup> )	Clear, hot day with light winds (s m <sup>-2</sup> )
50	4.0E-01	8.0E-02	1.4E-01	5.4E-02	2.4E-02	2.4E-02	6.9E-02
100	3.4E-01	6.4E-02	8.1E-02	3.6E-02	1.6E-02	1.3E-02	3.5E-02
150	3.0E-01	5.3E-02	5.6E-02	2.8E-02	1.2E-02	8.9E-03	2.3E-02
200	2.6E-01	4.5E-02	4.2E-02	2.2E-02	9.9E-03	6.5E-03	1.6E-02
250	2.3E-01	3.9E-02	3.4E-02	1.8E-02	8.3E-03	5.1E-03	1.3E-02
300	2.1E-01	3.4E-02	2.8E-02	1.6E-02	7.1E-03	4.2E-03	1.0E-02
350	1.9E-01	3.1E-02	2.3E-02	1.4E-02	6.2E-03	3.5E-03	8.5E-03
400	1.7E-01	2.8E-02	2.0E-02	1.2E-02	5.5E-03	3.1E-03	7.2E-03
450	1.6E-01	2.5E-02	1.8E-02	1.1E-02	5.0E-03	2.7E-03	6.2E-03
500	1.5E-01	2.3E-02	1.6E-02	9.8E-03	4.5E-03	2.3E-03	5.5E-03
550	1.4E-01	2.2E-02	1.4E-02	9.0E-03	4.1E-03	2.1E-03	4.9E-03
600	1.3E-01	2.0E-02	1.3E-02	8.3E-03	3.8E-03	1.9E-03	4.4E-03
650	1.2E-01	1.9E-02	1.2E-02	7.7E-03	3.5E-03	1.7E-03	3.9E-03
700	1.1E-01	1.8E-02	1.1E-02	7.3E-03	3.3E-03	1.6E-03	3.6E-03
750	1.0E-01	1.7E-02	9.8E-03	6.8E-03	3.1E-03	1.4E-03	3.3E-03
800	9.6E-02	1.6E-02	9.0E-03	6.4E-03	2.9E-03	1.3E-03	3.1E-03
850	9.0E-02	1.5E-02	8.3E-03	6.0E-03	2.8E-03	1.3E-03	2.9E-03
900	8.4E-02	1.4E-02	7.7E-03	5.8E-03	2.6E-03	1.2E-03	2.7E-03
950	7.8E-02	1.4E-02	7.2E-03	5.5E-03	2.5E-03	1.1E-03	2.5E-03
1,000	7.2E-02	1.3E-02	6.7E-03	5.2E-03	2.4E-03	1.0E-03	2.3E-03
1,050	6.7E-02	1.2E-02	6.1E-03	4.9E-03	2.3E-03	9.7E-04	2.2E-03
1,100	5.9E-02	1.2E-02	5.5E-03	4.7E-03	2.2E-03	9.0E-04	2.0E-03
2,000	3.8E-02	5.5E-03	2.6E-03	1.7E-03	7.7E-04	4.5E-04	1.1E-03
3,000	2.3E-02	4.0E-03	1.7E-03	1.2E-03	5.3E-04	2.9E-04	7.3E-04
4,000	1.6E-02	3.1E-03	1.3E-03	8.9E-04	4.2E-04	2.3E-04	5.9E-04
5,000	1.2E-02	2.6E-03	1.1E-03	7.4E-04	3.6E-04	1.9E-04	5.2E-04
6,000	9.5E-03	2.3E-03	9.6E-04	6.4E-04	3.2E-04	1.7E-04	4.6E-04
7,000	7.8E-03	2.0E-03	8.6E-04	5.6E-04	2.8E-04	1.5E-04	4.4E-04
8,000	6.6E-03	1.8E-03	8.1E-04	5.1E-04	2.6E-04	1.4E-04	4.3E-04
9,000	5.7E-03	1.7E-03	7.6E-04	4.7E-04	2.4E-04	1.3E-04	4.0E-04
10,000	4.9E-03	1.5E-03	7.0E-04	4.3E-04	2.3E-04	1.3E-04	3.8E-04
11,000	4.4E-03	1.4E-03	6.9E-04	4.1E-04	2.2E-04	1.3E-04	3.7E-04
12,000	3.9E-03	1.4E-03	6.7E-04	3.9E-04	2.1E-04	1.2E-04	3.7E-04
13,000	3.6E-03	1.3E-03	6.3E-04	3.7E-04	2.0E-04	1.2E-04	3.7E-04
14,000	3.2E-03	1.2E-03	6.1E-04	3.5E-04	1.9E-04	1.1E-04	3.6E-04
15,000	3.0E-03	1.2E-03	5.9E-04	3.3E-04	1.8E-04	1.1E-04	3.6E-04
16,000	2.7E-03	1.1E-03	5.7E-04	3.2E-04	1.7E-04	1.1E-04	3.6E-04
17,000	2.5E-03	1.1E-03	5.9E-04	3.1E-04	1.7E-04	1.1E-04	3.6E-04
18,000	2.4E-03	1.1E-03	5.7E-04	2.9E-04	1.7E-04	1.0E-04	3.5E-04
19,000	2.2E-03	1.0E-03	5.4E-04	2.8E-04	1.6E-04	1.1E-04	3.5E-04
20,000	2.1E-03	9.9E-04	5.2E-04	2.8E-04	1.6E-04	1.0E-04	3.6E-04

2618

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2619 **Table E3a. Normalized Time and Space Integrated Particle Air Concentration for a Disc with**  
2620 **the specified distance from the release assuming airborne loss rate ( $\lambda_{decay} = 0.1 \text{ h}^{-1}$ ).**

Distance Downwind (m)	Clear, cold night with light winds (s m <sup>-1</sup> )	Clear night with gentle breeze (s m <sup>-1</sup> )	Overcast with light winds (s m <sup>-1</sup> )	Overcast with gentle winds (s m <sup>-1</sup> )	Overcast with strong winds (s m <sup>-1</sup> )	Clear day with gentle winds (s m <sup>-1</sup> )	Clear, hot day with light winds (s m <sup>-1</sup> )
50	2.2E+01	4.4E+00	1.1E+01	3.4E+00	1.5E+00	2.1E+00	7.1E+00
100	4.0E+01	8.0E+00	1.6E+01	5.6E+00	2.5E+00	3.0E+00	9.5E+00
150	5.6E+01	1.1E+01	1.9E+01	7.2E+00	3.3E+00	3.6E+00	1.1E+01
200	7.0E+01	1.3E+01	2.2E+01	8.4E+00	3.8E+00	3.9E+00	1.2E+01
250	8.2E+01	1.5E+01	2.4E+01	9.4E+00	4.3E+00	4.2E+00	1.3E+01
300	9.3E+01	1.7E+01	2.5E+01	1.0E+01	4.6E+00	4.5E+00	1.3E+01
350	1.0E+02	1.9E+01	2.6E+01	1.1E+01	5.0E+00	4.6E+00	1.4E+01
400	1.1E+02	2.0E+01	2.7E+01	1.2E+01	5.3E+00	4.8E+00	1.4E+01
450	1.2E+02	2.2E+01	2.8E+01	1.2E+01	5.5E+00	5.0E+00	1.4E+01
500	1.3E+02	2.3E+01	2.9E+01	1.3E+01	5.8E+00	5.1E+00	1.5E+01
550	1.3E+02	2.4E+01	3.0E+01	1.3E+01	6.0E+00	5.2E+00	1.5E+01
600	1.4E+02	2.5E+01	3.1E+01	1.4E+01	6.2E+00	5.3E+00	1.5E+01
650	1.5E+02	2.6E+01	3.1E+01	1.4E+01	6.3E+00	5.4E+00	1.5E+01
700	1.5E+02	2.7E+01	3.2E+01	1.4E+01	6.5E+00	5.5E+00	1.5E+01
750	1.6E+02	2.8E+01	3.2E+01	1.5E+01	6.7E+00	5.5E+00	1.6E+01
800	1.6E+02	2.8E+01	3.3E+01	1.5E+01	6.8E+00	5.6E+00	1.6E+01
850	1.7E+02	2.9E+01	3.3E+01	1.5E+01	7.0E+00	5.7E+00	1.6E+01
900	1.7E+02	3.0E+01	3.3E+01	1.6E+01	7.1E+00	5.7E+00	1.6E+01
950	1.7E+02	3.1E+01	3.4E+01	1.6E+01	7.2E+00	5.8E+00	1.6E+01
1,000	1.8E+02	3.1E+01	3.4E+01	1.6E+01	7.4E+00	5.8E+00	1.6E+01
1,050	1.8E+02	3.2E+01	3.5E+01	1.6E+01	7.5E+00	5.9E+00	1.6E+01
1,100	1.8E+02	3.2E+01	3.5E+01	1.7E+01	7.6E+00	5.9E+00	1.7E+01
2,000	2.3E+02	3.7E+01	3.6E+01	1.8E+01	8.1E+00	6.7E+00	1.8E+01
3,000	2.5E+02	4.2E+01	3.8E+01	1.9E+01	8.7E+00	7.1E+00	1.9E+01
4,000	2.7E+02	4.5E+01	3.9E+01	2.0E+01	9.1E+00	7.3E+00	2.0E+01
5,000	2.8E+02	4.8E+01	4.0E+01	2.1E+01	9.5E+00	7.5E+00	2.0E+01
6,000	2.9E+02	5.0E+01	4.1E+01	2.1E+01	9.9E+00	7.7E+00	2.1E+01
7,000	3.0E+02	5.2E+01	4.2E+01	2.2E+01	1.0E+01	7.8E+00	2.1E+01
8,000	3.0E+02	5.4E+01	4.3E+01	2.2E+01	1.0E+01	8.0E+00	2.2E+01
9,000	3.1E+02	5.6E+01	4.3E+01	2.3E+01	1.1E+01	8.1E+00	2.2E+01
10,000	3.1E+02	5.7E+01	4.4E+01	2.3E+01	1.1E+01	8.2E+00	2.2E+01
11,000	3.1E+02	5.9E+01	4.4E+01	2.4E+01	1.1E+01	8.4E+00	2.3E+01
12,000	3.2E+02	6.0E+01	4.5E+01	2.4E+01	1.1E+01	8.5E+00	2.3E+01
13,000	3.2E+02	6.1E+01	4.5E+01	2.4E+01	1.1E+01	8.6E+00	2.3E+01
14,000	3.2E+02	6.2E+01	4.6E+01	2.5E+01	1.2E+01	8.7E+00	2.3E+01
15,000	3.2E+02	6.4E+01	4.6E+01	2.5E+01	1.2E+01	8.8E+00	2.4E+01
16,000	3.3E+02	6.5E+01	4.7E+01	2.5E+01	1.2E+01	8.9E+00	2.4E+01
17,000	3.3E+02	6.6E+01	4.7E+01	2.6E+01	1.2E+01	9.0E+00	2.4E+01
18,000	3.3E+02	6.7E+01	4.8E+01	2.6E+01	1.2E+01	9.1E+00	2.4E+01
19,000	3.3E+02	6.8E+01	4.8E+01	2.6E+01	1.3E+01	9.2E+00	2.5E+01
20,000	3.3E+02	6.8E+01	4.8E+01	2.7E+01	1.3E+01	9.3E+00	2.5E+01

2621

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2622 **Table E3b. Normalized Time and Space Integrated Particle Air Concentration for a Circle Arc at**  
2623 **the specified distance from the release assuming airborne loss rate ( $\lambda_{decay} = 0.1 \text{ h}^{-1}$ ).**

Distance Downwind (m)	Clear, cold night with light winds (s m <sup>-2</sup> )	Clear night with gentle breeze (s m <sup>-2</sup> )	Overcast with light winds (s m <sup>-2</sup> )	Overcast with gentle winds (s m <sup>-2</sup> )	Overcast with strong winds (s m <sup>-2</sup> )	Clear day with gentle winds (s m <sup>-2</sup> )	Clear, hot day with light winds (s m <sup>-2</sup> )
50	4.0E-01	8.0E-02	1.3E-01	5.4E-02	2.4E-02	2.4E-02	6.9E-02
100	3.4E-01	6.4E-02	8.0E-02	3.6E-02	1.6E-02	1.3E-02	3.5E-02
150	3.0E-01	5.3E-02	5.6E-02	2.8E-02	1.2E-02	8.9E-03	2.3E-02
200	2.6E-01	4.4E-02	4.2E-02	2.2E-02	9.9E-03	6.5E-03	1.6E-02
250	2.3E-01	3.9E-02	3.3E-02	1.8E-02	8.2E-03	5.1E-03	1.3E-02
300	2.1E-01	3.4E-02	2.8E-02	1.6E-02	7.1E-03	4.2E-03	1.0E-02
350	1.9E-01	3.1E-02	2.3E-02	1.4E-02	6.2E-03	3.5E-03	8.4E-03
400	1.7E-01	2.8E-02	2.0E-02	1.2E-02	5.5E-03	3.1E-03	7.1E-03
450	1.5E-01	2.5E-02	1.7E-02	1.1E-02	4.9E-03	2.7E-03	6.1E-03
500	1.4E-01	2.3E-02	1.5E-02	9.8E-03	4.5E-03	2.3E-03	5.4E-03
550	1.3E-01	2.1E-02	1.4E-02	9.0E-03	4.1E-03	2.1E-03	4.8E-03
600	1.2E-01	2.0E-02	1.3E-02	8.3E-03	3.8E-03	1.9E-03	4.3E-03
650	1.1E-01	1.9E-02	1.1E-02	7.7E-03	3.5E-03	1.7E-03	3.8E-03
700	1.1E-01	1.7E-02	1.0E-02	7.2E-03	3.3E-03	1.6E-03	3.5E-03
750	1.0E-01	1.7E-02	9.6E-03	6.7E-03	3.1E-03	1.4E-03	3.3E-03
800	9.3E-02	1.6E-02	8.8E-03	6.3E-03	2.9E-03	1.3E-03	3.0E-03
850	8.6E-02	1.5E-02	8.1E-03	6.0E-03	2.8E-03	1.2E-03	2.8E-03
900	8.0E-02	1.4E-02	7.5E-03	5.7E-03	2.6E-03	1.2E-03	2.6E-03
950	7.5E-02	1.3E-02	7.0E-03	5.4E-03	2.5E-03	1.1E-03	2.4E-03
1,000	6.9E-02	1.3E-02	6.5E-03	5.1E-03	2.4E-03	1.0E-03	2.3E-03
1,050	6.3E-02	1.2E-02	6.0E-03	4.9E-03	2.3E-03	9.7E-04	2.1E-03
1,100	5.6E-02	1.2E-02	5.3E-03	4.6E-03	2.1E-03	8.9E-04	1.9E-03
2,000	3.5E-02	5.4E-03	2.4E-03	1.6E-03	7.6E-04	4.4E-04	1.0E-03
3,000	2.1E-02	3.9E-03	1.6E-03	1.1E-03	5.3E-04	2.9E-04	6.8E-04
4,000	1.4E-02	3.1E-03	1.2E-03	8.7E-04	4.2E-04	2.2E-04	5.3E-04
5,000	1.0E-02	2.5E-03	9.6E-04	7.2E-04	3.5E-04	1.9E-04	4.6E-04
6,000	7.8E-03	2.2E-03	8.3E-04	6.2E-04	3.1E-04	1.6E-04	4.0E-04
7,000	6.2E-03	1.9E-03	7.3E-04	5.4E-04	2.8E-04	1.5E-04	3.7E-04
8,000	5.2E-03	1.7E-03	6.7E-04	4.8E-04	2.6E-04	1.3E-04	3.6E-04
9,000	4.3E-03	1.6E-03	6.2E-04	4.5E-04	2.4E-04	1.3E-04	3.3E-04
10,000	3.7E-03	1.5E-03	5.6E-04	4.1E-04	2.2E-04	1.2E-04	3.0E-04
11,000	3.2E-03	1.4E-03	5.4E-04	3.8E-04	2.1E-04	1.2E-04	2.9E-04
12,000	2.8E-03	1.3E-03	5.1E-04	3.7E-04	2.0E-04	1.1E-04	2.8E-04
13,000	2.5E-03	1.2E-03	4.7E-04	3.5E-04	1.9E-04	1.1E-04	2.8E-04
14,000	2.2E-03	1.1E-03	4.4E-04	3.3E-04	1.9E-04	1.1E-04	2.6E-04
15,000	2.0E-03	1.1E-03	4.2E-04	3.1E-04	1.8E-04	1.0E-04	2.5E-04
16,000	1.8E-03	1.0E-03	4.0E-04	2.9E-04	1.7E-04	9.9E-05	2.5E-04
17,000	1.7E-03	1.0E-03	4.0E-04	2.8E-04	1.7E-04	1.0E-04	2.4E-04
18,000	1.5E-03	9.6E-04	3.8E-04	2.7E-04	1.6E-04	9.4E-05	2.3E-04
19,000	1.4E-03	9.2E-04	3.5E-04	2.5E-04	1.6E-04	9.9E-05	2.3E-04
20,000	1.3E-03	8.9E-04	3.3E-04	2.5E-04	1.5E-04	9.4E-05	2.3E-04

2624

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2625 **Table E4a. Normalized Time and Space Integrated Particle Air Concentration for a Disc with**  
2626 **the specified distance from the release assuming airborne loss rate ( $\lambda_{decay} = 1 \text{ h}^{-1}$ ).**

Distance Downwind (m)	Clear, cold night with light winds (s m <sup>-1</sup> )	Clear night with gentle breeze (s m <sup>-1</sup> )	Overcast with light winds (s m <sup>-1</sup> )	Overcast with gentle winds (s m <sup>-1</sup> )	Overcast with strong winds (s m <sup>-1</sup> )	Clear day with gentle winds (s m <sup>-1</sup> )	Clear, hot day with light winds (s m <sup>-1</sup> )
50	2.1E+01	4.4E+00	1.1E+01	3.4E+00	1.5E+00	2.1E+00	7.0E+00
100	3.9E+01	7.9E+00	1.6E+01	5.6E+00	2.5E+00	3.0E+00	9.4E+00
150	5.3E+01	1.1E+01	1.9E+01	7.2E+00	3.2E+00	3.5E+00	1.1E+01
200	6.6E+01	1.3E+01	2.1E+01	8.4E+00	3.8E+00	3.9E+00	1.2E+01
250	7.6E+01	1.5E+01	2.3E+01	9.3E+00	4.2E+00	4.2E+00	1.2E+01
300	8.6E+01	1.7E+01	2.4E+01	1.0E+01	4.6E+00	4.4E+00	1.3E+01
350	9.4E+01	1.9E+01	2.5E+01	1.1E+01	4.9E+00	4.6E+00	1.3E+01
400	1.0E+02	2.0E+01	2.6E+01	1.1E+01	5.2E+00	4.8E+00	1.4E+01
450	1.1E+02	2.1E+01	2.7E+01	1.2E+01	5.5E+00	4.9E+00	1.4E+01
500	1.1E+02	2.2E+01	2.8E+01	1.3E+01	5.7E+00	5.0E+00	1.4E+01
550	1.2E+02	2.3E+01	2.9E+01	1.3E+01	5.9E+00	5.1E+00	1.4E+01
600	1.2E+02	2.4E+01	2.9E+01	1.3E+01	6.1E+00	5.2E+00	1.5E+01
650	1.3E+02	2.5E+01	3.0E+01	1.4E+01	6.3E+00	5.3E+00	1.5E+01
700	1.3E+02	2.6E+01	3.0E+01	1.4E+01	6.5E+00	5.4E+00	1.5E+01
750	1.4E+02	2.7E+01	3.1E+01	1.4E+01	6.6E+00	5.5E+00	1.5E+01
800	1.4E+02	2.8E+01	3.1E+01	1.5E+01	6.8E+00	5.5E+00	1.5E+01
850	1.4E+02	2.8E+01	3.1E+01	1.5E+01	6.9E+00	5.6E+00	1.5E+01
900	1.5E+02	2.9E+01	3.2E+01	1.5E+01	7.0E+00	5.7E+00	1.5E+01
950	1.5E+02	3.0E+01	3.2E+01	1.6E+01	7.2E+00	5.7E+00	1.6E+01
1,000	1.5E+02	3.0E+01	3.2E+01	1.6E+01	7.3E+00	5.8E+00	1.6E+01
1,050	1.5E+02	3.1E+01	3.2E+01	1.6E+01	7.4E+00	5.8E+00	1.6E+01
1,100	1.5E+02	3.1E+01	3.3E+01	1.6E+01	7.5E+00	5.9E+00	1.6E+01
2,000	1.8E+02	3.6E+01	3.3E+01	1.7E+01	7.9E+00	6.6E+00	1.7E+01
3,000	1.9E+02	3.9E+01	3.4E+01	1.8E+01	8.5E+00	6.9E+00	1.8E+01
4,000	1.9E+02	4.2E+01	3.5E+01	1.9E+01	8.9E+00	7.1E+00	1.8E+01
5,000	2.0E+02	4.4E+01	3.5E+01	2.0E+01	9.3E+00	7.3E+00	1.8E+01
6,000	2.0E+02	4.6E+01	3.5E+01	2.0E+01	9.6E+00	7.4E+00	1.8E+01
7,000	2.0E+02	4.7E+01	3.6E+01	2.1E+01	9.8E+00	7.5E+00	1.8E+01
8,000	2.0E+02	4.8E+01	3.6E+01	2.1E+01	1.0E+01	7.6E+00	1.9E+01
9,000	2.0E+02	4.9E+01	3.6E+01	2.1E+01	1.0E+01	7.7E+00	1.9E+01
10,000	2.0E+02	5.0E+01	3.6E+01	2.1E+01	1.0E+01	7.8E+00	1.9E+01
11,000	2.0E+02	5.1E+01	3.6E+01	2.2E+01	1.1E+01	7.8E+00	1.9E+01
12,000	2.0E+02	5.2E+01	3.6E+01	2.2E+01	1.1E+01	7.9E+00	1.9E+01
13,000	2.0E+02	5.2E+01	3.6E+01	2.2E+01	1.1E+01	8.0E+00	1.9E+01
14,000	2.0E+02	5.3E+01	3.6E+01	2.2E+01	1.1E+01	8.0E+00	1.9E+01
15,000	2.0E+02	5.4E+01	3.6E+01	2.2E+01	1.1E+01	8.1E+00	1.9E+01
16,000	2.0E+02	5.4E+01	3.6E+01	2.3E+01	1.1E+01	8.1E+00	1.9E+01
17,000	2.0E+02	5.5E+01	3.6E+01	2.3E+01	1.1E+01	8.2E+00	1.9E+01
18,000	2.0E+02	5.5E+01	3.6E+01	2.3E+01	1.2E+01	8.2E+00	1.9E+01
19,000	2.0E+02	5.5E+01	3.6E+01	2.3E+01	1.2E+01	8.3E+00	1.9E+01
20,000	2.0E+02	5.6E+01	3.6E+01	2.3E+01	1.2E+01	8.3E+00	1.9E+01

2627

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2628 **Table E4b. Normalized Time and Space Integrated Particle Air Concentration for a Circle Arc at**  
2629 **the specified distance from the release assuming airborne loss rate ( $\lambda_{decay} = 1 \text{ h}^{-1}$ ).**

Distance Downwind (m)	Clear, cold night with light winds (s m <sup>-2</sup> )	Clear night with gentle breeze (s m <sup>-2</sup> )	Overcast with light winds (s m <sup>-2</sup> )	Overcast with gentle winds (s m <sup>-2</sup> )	Overcast with strong winds (s m <sup>-2</sup> )	Clear day with gentle winds (s m <sup>-2</sup> )	Clear, hot day with light winds (s m <sup>-2</sup> )
50	3.8E-01	8.0E-02	1.3E-01	5.4E-02	2.4E-02	2.4E-02	6.8E-02
100	3.2E-01	6.3E-02	7.8E-02	3.6E-02	1.6E-02	1.3E-02	3.4E-02
150	2.7E-01	5.2E-02	5.3E-02	2.7E-02	1.2E-02	8.8E-03	2.2E-02
200	2.3E-01	4.3E-02	3.9E-02	2.1E-02	9.8E-03	6.4E-03	1.5E-02
250	2.0E-01	3.8E-02	3.1E-02	1.8E-02	8.2E-03	5.0E-03	1.2E-02
300	1.8E-01	3.3E-02	2.5E-02	1.5E-02	7.0E-03	4.1E-03	9.4E-03
350	1.6E-01	2.9E-02	2.1E-02	1.3E-02	6.1E-03	3.4E-03	7.6E-03
400	1.4E-01	2.7E-02	1.8E-02	1.2E-02	5.4E-03	3.0E-03	6.4E-03
450	1.2E-01	2.4E-02	1.5E-02	1.0E-02	4.9E-03	2.6E-03	5.5E-03
500	1.1E-01	2.2E-02	1.3E-02	9.4E-03	4.4E-03	2.3E-03	4.8E-03
550	1.0E-01	2.0E-02	1.2E-02	8.6E-03	4.0E-03	2.0E-03	4.2E-03
600	9.3E-02	1.9E-02	1.1E-02	7.9E-03	3.7E-03	1.8E-03	3.7E-03
650	8.5E-02	1.8E-02	9.5E-03	7.3E-03	3.5E-03	1.7E-03	3.3E-03
700	7.8E-02	1.6E-02	8.6E-03	6.9E-03	3.2E-03	1.5E-03	3.0E-03
750	7.2E-02	1.5E-02	7.8E-03	6.4E-03	3.0E-03	1.4E-03	2.7E-03
800	6.5E-02	1.4E-02	7.1E-03	6.0E-03	2.9E-03	1.3E-03	2.5E-03
850	6.0E-02	1.4E-02	6.5E-03	5.6E-03	2.7E-03	1.2E-03	2.3E-03
900	5.5E-02	1.3E-02	6.0E-03	5.4E-03	2.6E-03	1.1E-03	2.1E-03
950	5.0E-02	1.2E-02	5.5E-03	5.1E-03	2.4E-03	1.0E-03	2.0E-03
1,000	4.6E-02	1.2E-02	5.0E-03	4.8E-03	2.3E-03	9.7E-04	1.8E-03
1,050	4.1E-02	1.1E-02	4.6E-03	4.6E-03	2.2E-03	9.1E-04	1.7E-03
1,100	3.6E-02	1.1E-02	4.1E-03	4.3E-03	2.1E-03	8.4E-04	1.5E-03
2,000	1.7E-02	4.7E-03	1.5E-03	1.4E-03	7.2E-04	4.0E-04	6.4E-04
3,000	7.5E-03	3.1E-03	8.0E-04	9.5E-04	4.9E-04	2.5E-04	3.5E-04
4,000	3.9E-03	2.3E-03	4.9E-04	6.9E-04	3.8E-04	1.8E-04	2.2E-04
5,000	2.3E-03	1.9E-03	3.3E-04	5.5E-04	3.1E-04	1.5E-04	1.6E-04
6,000	1.4E-03	1.5E-03	2.3E-04	4.5E-04	2.7E-04	1.2E-04	1.1E-04
7,000	9.3E-04	1.3E-03	1.7E-04	3.8E-04	2.3E-04	1.1E-04	8.4E-05
8,000	6.4E-04	1.1E-03	1.3E-04	3.2E-04	2.1E-04	9.1E-05	6.6E-05
9,000	4.5E-04	9.7E-04	1.0E-04	2.9E-04	1.9E-04	8.4E-05	5.0E-05
10,000	3.2E-04	8.6E-04	7.4E-05	2.5E-04	1.8E-04	7.7E-05	3.8E-05
11,000	2.3E-04	7.7E-04	5.9E-05	2.3E-04	1.7E-04	7.2E-05	2.9E-05
12,000	1.7E-04	6.9E-04	4.7E-05	2.1E-04	1.6E-04	6.5E-05	2.3E-05
13,000	1.3E-04	6.3E-04	3.6E-05	1.9E-04	1.5E-04	6.0E-05	1.9E-05
14,000	9.7E-05	5.8E-04	2.8E-05	1.7E-04	1.4E-04	5.6E-05	1.4E-05
15,000	7.4E-05	5.3E-04	2.2E-05	1.5E-04	1.3E-04	5.1E-05	1.1E-05
16,000	5.7E-05	4.8E-04	1.7E-05	1.4E-04	1.2E-04	4.8E-05	9.2E-06
17,000	4.4E-05	4.5E-04	1.4E-05	1.3E-04	1.2E-04	4.7E-05	7.3E-06
18,000	3.4E-05	4.2E-04	1.1E-05	1.2E-04	1.1E-04	4.2E-05	5.8E-06
19,000	2.7E-05	3.8E-04	8.7E-06	1.1E-04	1.1E-04	4.2E-05	4.6E-06
20,000	2.1E-05	3.6E-04	6.9E-06	1.0E-04	1.0E-04	3.8E-05	3.8E-06

2630



M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2631 **Table E5a. Normalized Time and Space Integrated Particle Air Concentration for a Disc with**  
2632 **the specified distance from the release assuming airborne loss rate ( $\lambda_{decay} = 10 \text{ h}^{-1}$ ).**

Distance Downwind (m)	Clear, cold night with light winds (s m <sup>-1</sup> )	Clear night with gentle breeze (s m <sup>-1</sup> )	Overcast with light winds (s m <sup>-1</sup> )	Overcast with gentle winds (s m <sup>-1</sup> )	Overcast with strong winds (s m <sup>-1</sup> )	Clear day with gentle winds (s m <sup>-1</sup> )	Clear, hot day with light winds (s m <sup>-1</sup> )
50	1.7E+01	4.3E+00	9.7E+00	3.3E+00	1.5E+00	2.1E+00	6.5E+00
100	2.8E+01	7.5E+00	1.4E+01	5.4E+00	2.5E+00	2.9E+00	8.5E+00
150	3.6E+01	1.0E+01	1.6E+01	6.8E+00	3.2E+00	3.4E+00	9.4E+00
200	4.1E+01	1.2E+01	1.7E+01	7.8E+00	3.7E+00	3.7E+00	1.0E+01
250	4.4E+01	1.4E+01	1.8E+01	8.6E+00	4.1E+00	4.0E+00	1.0E+01
300	4.7E+01	1.5E+01	1.8E+01	9.2E+00	4.4E+00	4.2E+00	1.1E+01
350	4.9E+01	1.6E+01	1.9E+01	9.8E+00	4.7E+00	4.3E+00	1.1E+01
400	5.1E+01	1.7E+01	1.9E+01	1.0E+01	5.0E+00	4.4E+00	1.1E+01
450	5.2E+01	1.8E+01	2.0E+01	1.1E+01	5.2E+00	4.6E+00	1.1E+01
500	5.3E+01	1.8E+01	2.0E+01	1.1E+01	5.4E+00	4.6E+00	1.1E+01
550	5.3E+01	1.9E+01	2.0E+01	1.1E+01	5.5E+00	4.7E+00	1.1E+01
600	5.4E+01	2.0E+01	2.0E+01	1.2E+01	5.7E+00	4.8E+00	1.1E+01
650	5.4E+01	2.0E+01	2.0E+01	1.2E+01	5.8E+00	4.8E+00	1.1E+01
700	5.5E+01	2.1E+01	2.0E+01	1.2E+01	6.0E+00	4.9E+00	1.1E+01
750	5.5E+01	2.1E+01	2.0E+01	1.2E+01	6.1E+00	4.9E+00	1.1E+01
800	5.5E+01	2.1E+01	2.0E+01	1.2E+01	6.2E+00	5.0E+00	1.1E+01
850	5.5E+01	2.2E+01	2.0E+01	1.3E+01	6.3E+00	5.0E+00	1.1E+01
900	5.5E+01	2.2E+01	2.0E+01	1.3E+01	6.4E+00	5.1E+00	1.1E+01
950	5.5E+01	2.2E+01	2.0E+01	1.3E+01	6.5E+00	5.1E+00	1.1E+01
1,000	5.5E+01	2.3E+01	2.0E+01	1.3E+01	6.6E+00	5.1E+00	1.1E+01
1,050	5.6E+01	2.3E+01	2.0E+01	1.3E+01	6.7E+00	5.2E+00	1.1E+01
1,100	5.6E+01	2.3E+01	2.1E+01	1.3E+01	6.8E+00	5.2E+00	1.1E+01
2,000	6.1E+01	2.5E+01	2.1E+01	1.3E+01	7.0E+00	5.6E+00	1.2E+01
3,000	6.1E+01	2.5E+01	2.1E+01	1.4E+01	7.3E+00	5.7E+00	1.2E+01
4,000	6.1E+01	2.6E+01	2.1E+01	1.4E+01	7.4E+00	5.7E+00	1.2E+01
5,000	6.1E+01	2.6E+01	2.1E+01	1.4E+01	7.6E+00	5.8E+00	1.2E+01
6,000	6.1E+01	2.6E+01	2.1E+01	1.4E+01	7.6E+00	5.8E+00	1.2E+01
7,000	6.1E+01	2.6E+01	2.1E+01	1.4E+01	7.7E+00	5.8E+00	1.2E+01
8,000	6.1E+01	2.6E+01	2.1E+01	1.4E+01	7.7E+00	5.8E+00	1.2E+01
9,000	6.1E+01	2.6E+01	2.1E+01	1.4E+01	7.8E+00	5.8E+00	1.2E+01
10,000	6.1E+01	2.6E+01	2.1E+01	1.4E+01	7.8E+00	5.8E+00	1.2E+01
11,000	6.1E+01	2.6E+01	2.1E+01	1.4E+01	7.8E+00	5.8E+00	1.2E+01
12,000	6.1E+01	2.6E+01	2.1E+01	1.4E+01	7.8E+00	5.8E+00	1.2E+01
13,000	6.1E+01	2.6E+01	2.1E+01	1.4E+01	7.8E+00	5.8E+00	1.2E+01
14,000	6.1E+01	2.6E+01	2.1E+01	1.4E+01	7.8E+00	5.8E+00	1.2E+01
15,000	6.1E+01	2.6E+01	2.1E+01	1.4E+01	7.8E+00	5.8E+00	1.2E+01
16,000	6.1E+01	2.6E+01	2.1E+01	1.4E+01	7.8E+00	5.8E+00	1.2E+01
17,000	6.1E+01	2.6E+01	2.1E+01	1.4E+01	7.9E+00	5.8E+00	1.2E+01
18,000	6.1E+01	2.6E+01	2.1E+01	1.4E+01	7.9E+00	5.8E+00	1.2E+01
19,000	6.1E+01	2.6E+01	2.1E+01	1.4E+01	7.9E+00	5.8E+00	1.2E+01
20,000	6.1E+01	2.6E+01	2.1E+01	1.4E+01	7.9E+00	5.8E+00	1.2E+01

2633

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2634 **Table E5b. Normalized Time and Space Integrated Particle Air Concentration for a Circle Arc at**  
2635 **the specified distance from the release assuming airborne loss rate ( $\lambda_{decay} = 10 \text{ h}^{-1}$ ).**

Distance Downwind (m)	Clear, cold night with light winds (s m <sup>-2</sup> )	Clear night with gentle breeze (s m <sup>-2</sup> )	Overcast with light winds (s m <sup>-2</sup> )	Overcast with gentle winds (s m <sup>-2</sup> )	Overcast with strong winds (s m <sup>-2</sup> )	Clear day with gentle winds (s m <sup>-2</sup> )	Clear, hot day with light winds (s m <sup>-2</sup> )
50	2.7E-01	7.5E-02	1.1E-01	5.1E-02	2.4E-02	2.3E-02	5.7E-02
100	1.8E-01	5.6E-02	5.5E-02	3.3E-02	1.6E-02	1.2E-02	2.5E-02
150	1.2E-01	4.4E-02	3.3E-02	2.4E-02	1.2E-02	7.9E-03	1.4E-02
200	8.6E-02	3.5E-02	2.1E-02	1.8E-02	9.0E-03	5.6E-03	9.0E-03
250	6.3E-02	2.9E-02	1.5E-02	1.4E-02	7.4E-03	4.2E-03	6.2E-03
300	4.6E-02	2.4E-02	1.1E-02	1.2E-02	6.2E-03	3.4E-03	4.4E-03
350	3.4E-02	2.1E-02	7.9E-03	9.8E-03	5.3E-03	2.8E-03	3.2E-03
400	2.6E-02	1.8E-02	6.0E-03	8.4E-03	4.7E-03	2.3E-03	2.4E-03
450	2.0E-02	1.6E-02	4.6E-03	7.3E-03	4.1E-03	2.0E-03	1.9E-03
500	1.5E-02	1.4E-02	3.6E-03	6.4E-03	3.7E-03	1.7E-03	1.5E-03
550	1.2E-02	1.2E-02	2.9E-03	5.6E-03	3.3E-03	1.5E-03	1.2E-03
600	9.3E-03	1.1E-02	2.3E-03	5.0E-03	3.0E-03	1.3E-03	9.4E-04
650	7.3E-03	9.6E-03	1.9E-03	4.5E-03	2.8E-03	1.1E-03	7.5E-04
700	5.7E-03	8.6E-03	1.5E-03	4.1E-03	2.5E-03	1.0E-03	6.1E-04
750	4.6E-03	7.8E-03	1.3E-03	3.7E-03	2.4E-03	9.0E-04	5.1E-04
800	3.6E-03	7.0E-03	1.0E-03	3.4E-03	2.2E-03	8.1E-04	4.3E-04
850	2.9E-03	6.5E-03	8.6E-04	3.1E-03	2.1E-03	7.4E-04	3.6E-04
900	2.3E-03	5.9E-03	7.2E-04	2.8E-03	1.9E-03	6.7E-04	3.0E-04
950	1.8E-03	5.4E-03	6.0E-04	2.6E-03	1.8E-03	6.0E-04	2.5E-04
1,000	1.5E-03	5.0E-03	5.0E-04	2.4E-03	1.7E-03	5.6E-04	2.1E-04
1,050	1.2E-03	4.6E-03	4.2E-04	2.2E-03	1.6E-03	5.2E-04	1.8E-04
1,100	9.2E-04	4.2E-03	3.4E-04	2.0E-03	1.5E-03	4.7E-04	1.5E-04
2,000	4.9E-05	1.1E-03	2.3E-05	4.1E-04	4.0E-04	1.4E-04	1.2E-05
3,000	2.6E-06	4.1E-04	2.1E-06	1.7E-04	2.2E-04	5.5E-05	1.0E-06
4,000	2.0E-07	1.9E-04	2.5E-07	7.6E-05	1.4E-04	2.6E-05	1.1E-07
5,000	2.1E-08	9.7E-05	3.3E-08	3.9E-05	9.3E-05	1.4E-05	1.4E-08
6,000	2.2E-09	5.2E-05	4.4E-09	2.1E-05	6.6E-05	7.4E-06	1.7E-09
7,000	2.2E-10	2.9E-05	6.0E-10	1.1E-05	4.7E-05	4.2E-06	1.9E-10
8,000	1.3E-11	1.7E-05	6.4E-11	6.5E-06	3.5E-05	2.4E-06	1.7E-11
9,000	3.7E-13	1.0E-05	3.2E-12	3.8E-06	2.7E-05	1.4E-06	5.5E-13
10,000	0.0E+00	6.3E-06	9.3E-14	2.2E-06	2.0E-05	8.5E-07	0.0E+00
11,000	0.0E+00	3.9E-06	0.0E+00	1.3E-06	1.6E-05	5.3E-07	0.0E+00
12,000	0.0E+00	2.5E-06	0.0E+00	8.1E-07	1.2E-05	3.1E-07	0.0E+00
13,000	0.0E+00	1.6E-06	0.0E+00	5.0E-07	9.6E-06	1.9E-07	0.0E+00
14,000	0.0E+00	1.0E-06	0.0E+00	3.0E-07	7.6E-06	1.1E-07	0.0E+00
15,000	0.0E+00	6.8E-07	0.0E+00	1.8E-07	5.8E-06	6.8E-08	0.0E+00
16,000	0.0E+00	4.4E-07	0.0E+00	1.1E-07	4.6E-06	4.3E-08	0.0E+00
17,000	0.0E+00	3.0E-07	0.0E+00	6.9E-08	3.7E-06	2.7E-08	0.0E+00
18,000	0.0E+00	1.9E-07	0.0E+00	4.2E-08	3.0E-06	1.6E-08	0.0E+00
19,000	0.0E+00	1.3E-07	0.0E+00	2.6E-08	2.3E-06	1.0E-08	0.0E+00
20,000	0.0E+00	8.7E-08	0.0E+00	1.7E-08	1.9E-06	6.2E-09	0.0E+00

2636


2637

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2638 **Figure E1. Predicted absolute infection probabilities and infections by distance, wind speed**  
2639 **and atmospheric stability for a single airborne particle with  $0 \text{ h}^{-1}$  airborne loss of infectivity.**  
2640 **Legend indicates Pasquill-Gifford-Turner atmospheric stability class (A to F) and the 10 m agl**  
2641 **wind speed. Individual person infection probability (top panels) is dimensionless. Urban area**  
2642 **infections (bottom panels) assumes a uniform population density of  $0.01 \text{ people m}^{-2}$  and has**  
2643 **dimensions of people (disc) or people  $\text{m}^{-1}$  (arc).**


**Figure E1a. Infection Probabilities and Urban Infections  
Within a Disc Centered on the Release**



2644

2645

Figure E1b. Infection Probabilities and Urban Infections  
Along an Arc Centered on the Release Source



2646


2647

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2648 **Figure E2. Predicted absolute infection probabilities and infections by distance, wind speed**  
2649 **and atmospheric stability for a single airborne particle with  $0.1 \text{ h}^{-1}$  airborne loss of infectivity.**  
2650 **Legend indicates Pasquill-Gifford-Turner atmospheric stability class (A to F) and the 10 m agl**  
2651 **wind speed. Individual person infection probability (top panels) is dimensionless. Urban area**  
2652 **infections (bottom panels) assumes a uniform population density of  $0.01 \text{ people m}^{-2}$  and has**  
2653 **dimensions of people (disc) or people  $\text{m}^{-1}$  (arc).**


**Figure E2a. Infection Probabilities and Urban Infections  
Within a Disc Centered on the Release**



2654

2655

Figure E2b. Infection Probabilities and Urban Infections  
Along an Arc Centered on the Release Source



2656


2657

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2658 **Figure E3. Predicted absolute infection probabilities and infections by distance, wind speed**  
2659 **and atmospheric stability for a single airborne particle with  $1 \text{ h}^{-1}$  airborne loss of infectivity.**  
2660 **Legend indicates Pasquill-Gifford-Turner atmospheric stability class (A to F) and the 10 m agl**  
2661 **wind speed. Individual person infection probability (top panels) is dimensionless. Urban area**  
2662 **infections (bottom panels) assumes a uniform population density of  $0.01 \text{ people m}^{-2}$  and has**  
2663 **dimensions of people (disc) or people  $\text{m}^{-1}$  (arc).**

**Figure E3a. Infection Probabilities and Urban Infections  
Within a Disc Centered on the Release**




2664

2665



Figure E3b. Infection Probabilities and Urban Infections  
Along an Arc Centered on the Release Source



2666


2667

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2668 **Figure E4. Predicted absolute infection probabilities and infections by distance, wind speed**  
2669 **and atmospheric stability for a single airborne particle with  $10 \text{ h}^{-1}$  airborne loss of infectivity.**  
2670 **Legend indicates Pasquill-Gifford-Turner atmospheric stability class (A to F) and the 10 m agl**  
2671 **wind speed. Individual person infection probability (top panels) is dimensionless. Urban area**  
2672 **infections (bottom panels) a uniform population density of  $0.01 \text{ people m}^{-2}$  and has**  
2673 **dimensions of people (disc) or people  $\text{m}^{-1}$  (arc).**

**Figure E4a. Infection Probabilities and Urban Infections  
Within a Disc Centered on the Release**




2674

2675

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

**Figure E4b. Infection Probabilities and Urban Infections  
Along an Arc Centered on the Release Source**




2676

2677

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2678 **Figure E5. Predicted relative infection probabilities by distance, wind speed and atmospheric**  
2679 **stability for a single airborne particle with  $0 \text{ h}^{-1}$  airborne loss of infectivity. Legend indicates**  
2680 **Pasquill-Gifford-Turner atmospheric stability class (A to F) and the 10 m agl wind speed.**  
2681 **Relative infection probability is dimensionless.**




2682

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2683 **Figure E6. Predicted relative infection probabilities by distance, wind speed and atmospheric**  
2684 **stability for a single airborne particle with  $0.1 \text{ h}^{-1}$  airborne loss of infectivity. Legend indicates**  
2685 **Pasquill-Gifford-Turner atmospheric stability class (A to F) and the 10 m agl wind speed.**  
2686 **Relative infection probability is dimensionless.**




2687

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2688 **Figure E7. Predicted relative infection probabilities by distance, wind speed and atmospheric**  
2689 **stability for a single airborne particle with  $1 \text{ h}^{-1}$  airborne loss of infectivity. Legend indicates**  
2690 **Pasquill-Gifford-Turner atmospheric stability class (A to F) and the 10 m agl wind speed.**  
2691 **Relative infection probability is dimensionless.**




2692

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2693 **Figure E8. Predicted relative infection probabilities by distance, wind speed and atmospheric**  
2694 **stability for a single airborne particle with  $10 \text{ h}^{-1}$  airborne loss of infectivity. Legend indicates**  
2695 **Pasquill-Gifford-Turner atmospheric stability class (A to F) and the 10 m agl wind speed.**  
2696 **Relative infection probability is dimensionless.**



2697



M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2698 **Supplemental Material F: Outbreak Model-Measurement Comparison**

2699

2700 see companion excel spreadsheet

2701

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

## 2702 **Supplemental Material G: Infection Estimates**

2703

### 2704 **Section Variables Definitions**

2705

2706 particle type = specifies particle size and infectivity as a function of time and environmental  
2707 properties

2708  $b$  = a specific particle type

2709  $r$  = a specific geographic region

2710

2711 [*Adjustment Factor*]( $r, b$ ) = scaling factor for region  $r$  that accounts for the deviation of  $b$ -  
2712 type particle exposure and response from that of the reference exposure and response (no  
2713 units)

2714 [*Expected Number of Infections in Region*]( $r, b$ ) = number of infections in region  $r$   
2715 resulting from exposure to  $b$ -type particles (people)

2716 [*Normalized TSIAC*]( $r, b$ ) =  $b$ -type particle air concentration integrated over region  $r$  and the  
2717 passage of the airborne infectious plume assuming a single particle was released at the  
2718 source ( $s\ m^{-1}$ )

2719 [*Population Density*]( $r$ ) = population density in region  $r$  (people  $m^{-2}$ )

2720 [*Release Probability*]( $b$ ) = probability that a particle released into the environment is a  $b$ -  
2721 type particle (dimensionless)

2722 [*Single Particle Infection Probability*]<sub>ref</sub>( $r, b$ ) = reference probability that an individual in  
2723 region  $r$  will become infected after being exposed to a single  $b$ -type particle. This term  
2724 includes the probability that particle(s) will be inhaled and deposit in the respiratory  
2725 system. ( $m^3\ s^{-1}\ particle^{-1}$ )

2726 [*Source Adjustment Factor*]( $r_{source}, b$ ) = scaling factor that accounts for the deviation of  $b$ -  
2727 type particles emitted from the  $r_{source}$  region from that of a reference source region (no  
2728 units)

2729 [*Total Particles Released*] = total number of infectious, airborne particles released into the  
2730 air (particles)

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2731 **Key Equation**

2732

2733 **Equation G1** is adapted from **Equations 1** and **2** in the main text.

2734

2735 **(Equation G1)**

2736 *[Expected Number of Infections in Region ](r, b)*

2737 
$$= \left( \begin{array}{l} [Total\ Particles\ Released] \\ \cdot [Release\ Probability](b) \\ \cdot [Source\ Adjustment\ Factor](r_{source}, b) \\ \cdot [Single\ Particle\ Infection\ Probability]_{ref}(r, b) \\ \cdot [Adjustment\ Factor](r, b) \\ \cdot [Normalized\ TSIAC](r, b) \\ \cdot [Population\ Density](r) \end{array} \right)$$

2738

2739

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2740 **Downwind Infections**

2741

2742 **(Equation G2)**

2743 *[Expected Number of Infections in Region](r, b)*

2744  $= 2 \times 10^{-6} \cdot [Total\ Particles\ Released] \cdot [Release\ Probability](b)$

2745

2746 *Assumptions*

2747 1) There is an approximately 20% chance of particles emitted indoors exiting the house  
2748 assuming the 1  $\mu\text{m}$  diameter particles lose infectivity at a rate of 1  $\text{hr}^{-1}$ :

2749  $[Source\ Adjustment\ Factor](r_{source}, b) = 0.19$  (no units)

2750 2) Each particle will cause infection if inhaled and each individual has a breathing rate of  
2751  $10^{-4} \text{ m}^3 \text{ s}^{-1}$ :

2752  $[Single\ Particle\ Infection\ Probability]_{ref}(r, b) = 10^{-4} \text{ m}^3 \text{ s}^{-1} \text{ particle}^{-1}$

2753 3) Downwind individuals are fully susceptible, but are physically protected to same degree  
2754 as typical US person is protected from an airborne, outdoor, 1  $\mu\text{m}$  diameter particle that  
2755 loses infectivity at a rate of 1  $\text{hr}^{-1}$ :

2756  $[Adjustment\ Factor](r, b) = 0.18$  (no units)

2757 4) Exposures occur in an urban area:

2758  $[Population\ Density](r) = 0.01 \text{ people m}^{-2}$

2759 5) Downwind individuals are located between 50 m and 20 km from the infected person,  
2760 the meteorology corresponds to clear night with a gentle breeze (stable atmospheric  
2761 conditions and a 10 m agl wind speed of 4.5  $\text{m s}^{-1}$ ), each particle has a 1  $\mu\text{m}$   
2762 aerodynamic diameter and the particle loses infectivity in the atmosphere at a rate of 1  
2763  $\text{hr}^{-1}$  (see **Table E4a**):

2764  $[Normalized\ TSIAC](r, b) = 56 \text{ s m}^{-1}$

2765

2766 **Within Building Assumptions**

2767

2768 (Equation G3)

2769 *[Expected Number of Infections in Region]*( $r, b$ )

2770  $= 4 \times 10^{-6} \cdot [Total\ Particles\ Released] \cdot [Release\ Probability](b)$

2771

2772

2773 *Assumptions*

2774 1) Airborne particles are released indoors:

2775  $[Source\ Adjustment\ Factor](r_{source}, b) = 1$

2776 2) Each particle will cause infection if inhaled and each individual has a breathing rate of  
2777  $10^{-4} m^3 s^{-1}$ :

2778 3)  $[Single\ Particle\ Infection\ Probability]_{ref}(r, b) = 10^{-4} m^3 s^{-1} particle^{-1}$

2779 4) Indoor individuals are fully susceptible and are not protected:

2780  $[Adjustment\ Factor](r, b) = 1$

2781 5) There is one susceptible individual in a typical US home. For context, a typical US single  
2782 family home has 200 m<sup>2</sup> of heated floor area and 2 total residents (Tables HC10.14 and  
2783 HC9.1, respectively, per [244]):

2784  $[Population\ Density](r) = 0.005\ people\ m^{-2}$

2785 6) Exposures are determined by **Equation D7** using typical US home values [30] and an  
2786 assumed room height of 3 m. Each particle has a 1 μm aerodynamic diameter and the  
2787 particle loses infectivity at a rate of 1 hr<sup>-1</sup>.

2788  $[Normalized\ TSIAC](r, b) = 8.4\ s\ m^{-1}$

2789

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

## 2790 **Supplemental Material H: U.S. Coxiella burnetti Infection and Disease** 2791 **Estimates**

2792 Q Fever is a veterinary disease of livestock that can be transmitted to humans by inhalation of  
2793 infectious aerosols [61] and has caused significant community and regional level disease  
2794 outbreaks, see **Supplemental Material A: Airborne Disease Transmission Literature Review**.  
2795 Control measures exist for animal and human Q Fever and vaccines are available in some  
2796 countries [245]–[248].

2797

### 2798 **Background**

2799 In the 1930's, it was first recognized that exposure to infected livestock could cause human  
2800 disease. During a 1935 disease outbreak, Q Fever was recognized in Australia. Initially the cause  
2801 was unknown and so investigators called it "Query" (of questionable cause) Fever. The  
2802 bacterium *Coxiella burnetti*, which causes Q Fever, was named after the two researchers who  
2803 first identified it (Herald Cox and McFarlane Burnet). Since this time, *Coxiella burnetti* infection  
2804 in animals has been shown to be common in almost all countries, including the United States  
2805 [249] and causes significant disease in commercial livestock including, but not limited to, cows,  
2806 sheep, and goats [250]. A recently summary indicates high US infection rates in goats (41.6%),  
2807 sheep (16.5%), and cattle (3.4%) [250].

2808 In the US soils, an environmental survey demonstrates widespread contamination, with 23.8%  
2809 of samples testing positive for *Coxiella* DNA [251]. US state-level positive sample rates range  
2810 from 6 to 44%. A subset of these samples was tested for viability and *Coxiella* was culturable in  
2811 the PCR positive specimens. As expected, the *Coxiella* DNA was detected in locations with  
2812 livestock; however, it was also often found in locations associated with human activity, such as  
2813 post offices, stores, and schools.

2814

2815

## 2816 **Human Infection and Disease Characteristics**

2817 Q Fever in humans is characteristically caused by inhalation of airborne bacteria, although  
2818 direct contact and ticks are also known infection pathways [61], [249]. The infectious aerosols  
2819 may be emitted directly from infected animals or the result of aerosolization of contaminated  
2820 particles or soil. Coxiella is highly infectious since exposure to only a few bacteria can cause  
2821 infection<sup>42</sup> and while there is some variation between research studies and also variation by  
2822 infectious dosage, in general it is thought that 40% to 50% of humans infected for the first time  
2823 become ill with Acute Q Fever. The proportion of infected persons who will develop Chronic Q  
2824 Fever is still uncertain as it can be much more difficult to diagnose [61], [249], [252]–[254].

2825 Acute Q Fever often exhibits as a short influenza-like illness, but the disease can be severe with  
2826 pneumonia, liver disease, or encephalitis requiring hospitalization. Acute Q Fever can lead to  
2827 fatalities, with a death rate of 1 to 2% [61]. Pregnant women are considered to face the same  
2828 risks as infected farm animals, namely increased risk abortion, stillbirth, and premature delivery  
2829 [249]. High titers of subtype Phase II Q Fever antibody (IgG IFA  $\geq 1:128$ ) are considered  
2830 supportive laboratory evidence for Acute Q Fever infection and are often used as a surrogate  
2831 surveillance measure for Q Fever in Public Health surveillance [61], [249], [255], [256]. In our  
2832 prevalence analysis presented in the next subsection, we use a more selective definition for  
2833 laboratory-supportive Acute Q Fever infection to increase the likelihood of identifying true  
2834 Acute Q Fever associated infections. Specifically, we define Acute Q Fever infection as a case  
2835 with (a) Phase II IgG IFA  $\geq 1:128$ , (b) Phase II antibodies  $\geq 4x$  Phase I antibodies, and (c) Phase I  
2836 IgG IFA  $< 1:800$ ).<sup>43</sup>

2837 Chronic Q Fever is challenging to diagnose and also to treat with existing antibiotics. It causes  
2838 significant heart disease and high mortality rates. Notably, Chronic Q Fever can develop in  
2839 infected individuals who have never had Acute Q Fever and so it may go unnoticed for years  
2840 after the initial infection. It is usually fatal if left untreated [69], [249]. For example a 2018  
2841 follow up of a recent 2008 to 2010 outbreak showed that among the 519 chronic Q Fever cases  
2842 identified, 86 patients had died [69]. A persistently high Phase I antibody level (IgG IFA  $\geq 1:800$ )  
2843 that persists after Acute Q Fever infection is a risk factor for Chronic Q Fever but is not  
2844 diagnostic [61].

---

<sup>42</sup> The dose required to infect 50% of the human subjects is 1.18 bacteria (95% CI: 0.76 to 40.2) [15], [83].

<sup>43</sup> Coxiella antibody “Phases” are a laboratory methods notation where Phase I antibodies occur first in embryonated egg cultures and Phase II antibodies later. In human Acute Q Fever, Phase II antibodies peak first at high levels ( $\geq 1:128$ ) 1 to 2 weeks after the start of symptoms when Phase I antibody levels are low. Phase I antibodies peak some weeks after. Our selective acute infection criteria was chosen to reflect these dynamics and relevant human levels [61], [249].



M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

## 2845 **Human Infection and Disease Prevalence**

2846 It is uncertain how many human Coxiella infections and cases of Q Fever there are as it is widely  
2847 acknowledged that many, if not most, cases of Q Fever are unrecognized and do not come to  
2848 medical attention [61], [249]. Existing Q Fever disease notification systems are “passive”  
2849 surveillance systems in which disease prevalence is determined by the number of cases  
2850 diagnosed and then reported by medical providers [252].<sup>44</sup> “Passive” surveillance systems,  
2851 while useful for trends analysis and disease outbreak identification, undercount the disease  
2852 prevalence as undiagnosed cases and persons without access to health care are not included. In  
2853 contrast, “active” surveillance provides less biased estimates. “Active” surveillance consists of  
2854 actively surveying the general population with a scientifically based sampling strategy and  
2855 collecting data and blood samples to determine each person’s infection or disease status.

2856 While no country has national estimates of Q Fever prevalence, we provide approximate  
2857 estimates for US prevalence here. The US National Health and Nutrition Examination Survey  
2858 (NHANES) used active surveillance to provide national representative Coxiella burnetti serum  
2859 antibody levels in the 2003 to 2004 survey [62], [257].<sup>45</sup> Q Fever seroprevalence was  
2860 determined by screening with an enzyme-linked immunosorbent assay and confirmed by using  
2861 standard immunofluorescent antibody (IFA) testing [61]. The overall US prevalence of any  
2862 positive antibody (any Phase I or Phase II IgG IFA  $\geq 1:16$ ) in US adults 20+ years of age was 3.1%  
2863 of the population (95%CI 2.1% to 4.3%) [62].<sup>46,47</sup> This suggests that 6.1 million persons (95% CI:  
2864 4.2 to 8.5 million) have some type of Q Fever infection, including acute infections, recovery  
2865 phase of acute or chronic infections. We note that while a recent analysis of the NHANES data  
2866 demonstrated a clear association with agricultural work, 80% of positive Coxiella NHANES test  
2867 results were in persons working in non-agricultural sectors [258]. Similarly, 60% of reported Q  
2868 Fever cases had no association with farming or animal processing based on a review of cases in

---

<sup>44</sup> In the US there is mandatory reporting of Q Fever to the US Centers for Disease Control and Prevention national disease reporting system, see <https://www.cdc.gov/qfever/info/index.html>.

<sup>45</sup> The NHANES survey provides nationally representative estimates using a demographically-based complex, multistage survey design to minimize bias [62], [257].

<sup>46</sup> Antibody prevalence in men and woman was 3.8% and 2.5%, respectively.

<sup>47</sup> NHANES 2003 to 2004 demographics and Coxiella serology data were downloaded from the NHANES website. Data assembly and analysis used SAS<sup>TM</sup> (Release 9.4, SAS Institute, Inc., Cary, NC). Survey design variables (strata and primary sampling units) and survey sample weights were used to account for differential probabilities of participant selection in the complex multistage survey design. Sample weights provide nationally representative estimates and adjust estimates for nonresponse and noncoverage. Statistical estimates are age-adjusted to the US population. Results with relative standard errors >30%, with <12 degrees of freedom, or low sample sizes are not presented.

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2869 the US Centers for Disease Control and Prevention's (CDC) National Notifiable Disease  
2870 Surveillance System (NNDSS) and state and local US Public Health Departments [259].

### 2871 **Acute Q Fever**

2872 We further analyzed the NHANES 2003 to 2004 Coxiella dataset to estimate the US  
2873 seroprevalence Acute Coxiella infection rates. Using the standard criterion (Phase II Q Fever  
2874 antibody IgG IFA  $\geq 1:128$ ) [255], [256], laboratory supportive evidence of Acute Q Fever  
2875 infection is 1.5% of the general US adult population (95% CI: 1.0% to 2.0%). This corresponds to  
2876 20% of all positive tested samples, an estimated 2.5 million persons. Using our stricter  
2877 definition, which has a higher likelihood of reflecting Acute Coxiella infection, the US population  
2878 prevalence was 0.9% of the general US adult population (95% CI: 0.4% to 1.4%), which  
2879 corresponds to 15% of all positive tested samples and an estimated 1.9 million persons, see  
2880 **Table H1**.

2881 Assuming 40% of persons acutely infected with Coxiella will develop Q Fever, the US incidence  
2882 of Acute Q Fever cases is estimated at 0.4% of the general US adult population (95% CI: 0.2% to  
2883 0.6%), which corresponds to 820,000 adults (95% CI: 410,000 to 1.2 million adults). Assuming a  
2884 1.5% fatality rate, this corresponds to 12,000 deaths (95% CI: 6,000 to 18,000).

2885 As previously mentioned, 70 Q Fever cases were reported (passive surveillance) nationally in  
2886 2003 and 2004 and 153 Acute Q Fever cases were reported in 2017 [64]–[66].

2887  
2888

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2889 **Table H1. NHANES 2003 to 2004 Coxiella burnetti IFA Serology Prevalence Analysis**

	N (people)	Cases (people)	Fraction US Adults (%)	95% CI (%)	CPS Total (million people)	CPS 95% CI (million people)
<i>General Serology Estimates</i>						
Any Positive QF Serology $\geq$ 1:16	4437	180	3.1	2.1 to 4.3	6.1	4.2 to 8.5
All QF Phase II Serologies $\geq$ 1:128	4437	91	1.5	1.0 to 2.0	3.1	2.1 to 4.1
<i>More Selective Serology Estimates</i>						
Acute Q Fever Supportive	4437	50	0.9	0.4 to 1.4	1.9	0.8 to 2.9
All Other QF Positive Serologies	4437	130	2.2	1.3 to 3.1	4.5	2.7 to 6.4

2890  
 2891 Abbreviations:  
 2892 N = total sample; % = prevalence; 95%CI = 95th% confidence interval; CPS = US Census Current  
 2893 Population Survey (US adult population); QF = Q Fever; IFA = antibody Immunofluorescence  
 2894 Assay; Phase II = initial acute disease QF IgG antibodies.  
 2895  
 2896 Notes:  
 2897 Phase II QF antibodies  $\geq$  1:128 is US Centers for Disease Control & Prevention definition of  
 2898 laboratory supportive evidence of acute Q Fever infection; Selective Acute QF Supportive  
 2899 infection definition is Coxiella (Phase II antibody  $\geq$ 1:128; Phase II IgG IFA  $\geq$  4x Phase I IgG IFA;  
 2900 and Phase I IgG IFA < 1:800). Total 2003 to 2004 US adult population is 205,284,670 people.  
 2901

M Dillon and  
C Dillon

Particle Model for  
Airborne Disease Transmission

2902 **Comparison to Prior Work**

2903 Prior studies suggest that the Q Fever prevalence estimates derived above may be plausible.  
2904 First, the overall US population Coxiella infection rate of 3.1% is similar to that reported in  
2905 major European outbreak studies that used IFA testing. Second, a small-scale CDC methodology  
2906 study examined the 2000 to 2011 Q Fever mortality case underreporting using Capture-  
2907 Recapture Analysis. Reported Q Fever cases in the US National Death Index (n = 25) were  
2908 compared to the CDC reported Q Fever case fatalities (n = 9). While strongly limited by small  
2909 sample sizes, this study estimated a total of 129 fatal Q Fever cases (95% CI: 62 to 1,250 cases)  
2910 occurred nationally over this time period [259]. Third, the CDC also performed a separate  
2911 Coxiella seroprevalence study using data from US commercial medical laboratories from tests  
2912 ordered by medical providers to evaluate symptomatic patients. While this latter survey was  
2913 not nationally representative, 16% (2,039) of the 12,821 specimens tested were positive for  
2914 Coxiella [255]. Finally, serological analysis of stored sera from population-based epidemiology  
2915 studies and medical diagnostic laboratory testing shows Coxiella burnetti infection prevalence  
2916 rates in other countries is similar to those seen in the United States (Netherlands 2.4%;  
2917 Australia 5.6%) [260], [261].

2918